<!DOCTYPE html>
<html xmlns="http://www.w3.org/1999/xhtml">
<head>
<meta name="generator" content=
"HTML Tidy for HTML5 for Mac OS X version 5.4.0" />
<title>cbbt_10q.htm</title>
<!--Document Created by EDGARMaster-->
</head>
<body spellcheck="true" style=
"text-align:justify;font:10pt TIMES NEW ROMAN;margin:0px 7%">
<p style="MARGIN: 0px"></p>
<table style="FONT-SIZE: 1px" cellspacing="0" cellpadding="0"
width="100%" border="0">
<tr>
<td>
<div style=
"HEIGHT: 4px; WIDTH: 100%; BACKGROUND: #000000; MARGIN: 0px 0px 2px"
name="hrule"></div>
<div style="HEIGHT: 2px; WIDTH: 100%; BACKGROUND: #000000" name=
"hrule"></div>
</td>
</tr>
</table>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px" align="center"><b><font size="3">UNITED
STATES</font></b></p>
<p style="MARGIN: 0px" align="center"><b><font size="3">SECURITIES
AND EXCHANGE COMMISSION</font></b></p>
<p style="MARGIN: 0px" align="center"><b><font size="3">Washington,
D.C. 20549</font></b></p>
<p style="MARGIN: 0px" align="center">&nbsp;</p>
<p style="MARGIN: 0px" align="center"><b><font size="5">FORM
10-Q</font></b></p>
<p style="MARGIN: 0px" align="center">&nbsp;</p>
<p style="MARGIN: 0px" align="center"><font style=
"FONT-FAMILY: Wingdings">x</font> QUARTERLY REPORT PURSUANT TO
SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</p>
<p style="MARGIN: 0px" align="center">&nbsp;</p>
<p style="MARGIN: 0px" align="center"><b>For the quarterly period
ended <u>March 31, 2018</u></b></p>
<p style="MARGIN: 0px" align="center">&nbsp;</p>
<p style="MARGIN: 0px" align="center"><font style=
"FONT-FAMILY: Wingdings">¨</font> TRANSITION REPORT PURSUANT TO
SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</p>
<p style="MARGIN: 0px" align="center">&nbsp;</p>
<p style="MARGIN: 0px" align="center">For the transition period
from ____ to ____</p>
<p style="MARGIN: 0px" align="center">&nbsp;</p>
<p style="MARGIN: 0px" align="center"></p>
<table style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN"
cellspacing="0" cols="1" cellpadding="0" width="55%" align="center"
border="0">
<tr>
<td style="BORDER-BOTTOM: black 1px solid">
<p style="MARGIN: 0px" align="center"><font size="5"><b>CEREBAIN
BIOTECH CORP.</b></font></p>
</td>
</tr>
<tr>
<td>
<p style="MARGIN: 0px" align="center">(Exact name of registrant as
specified in its charter)</p>
</td>
</tr>
</table>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px" align="center"></p>
<table style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN"
cellspacing="0" cellpadding="0" width="85%" align="center" border=
"0">
<tr>
<td style="BORDER-BOTTOM: black 1px solid" valign="top" width=
"30%">
<p style="MARGIN: 0px" align="center"><b>Nevada</b></p>
</td>
<td width="5%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: black 1px solid" valign="top" width=
"30%">
<p style="MARGIN: 0px" align="center"><b>000-54381</b></p>
</td>
<td width="5%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: black 1px solid" valign="top" width=
"30%">
<p style="MARGIN: 0px" align="center"><b>26-1974399</b></p>
</td>
</tr>
<tr>
<td valign="top">
<p style="MARGIN: 0px" align="center">(State or other
jurisdiction</p>
<p style="MARGIN: 0px" align="center">of incorporation or
organization)</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top">
<p style="MARGIN: 0px" align="center">(Commission</p>
<p style="MARGIN: 0px" align="center">File Number)</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top">
<p style="MARGIN: 0px" align="center">(I.R.S. Employer</p>
<p style="MARGIN: 0px" align="center">Identification No.)</p>
</td>
</tr>
</table>
<p style="MARGIN: 0px" align="center">&nbsp;</p>
<p style="MARGIN: 0px"></p>
<table style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN"
cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td valign="top" width="78%" colspan="3">
<p style="MARGIN: 0px" align="center"><b>600 Anton Blvd., Suite
1100</b></p>
<p style="MARGIN: 0px" align="center"><b><u>Costa Mesa, CA
92626</u></b></p>
</td>
</tr>
<tr>
<td valign="top" width="78%" colspan="3">
<p style="MARGIN: 0px" align="center">(Address of principal
executive offices)</p>
</td>
</tr>
<tr>
<td valign="top" width="78%" colspan="3">
<p style="MARGIN: 0px" align="center">&nbsp;</p>
</td>
</tr>
<tr>
<td valign="top" width="78%" colspan="3">
<p style="MARGIN: 0px" align="center">
<b><u>714-371-4109</u></b></p>
</td>
</tr>
<tr>
<td valign="top" width="78%" colspan="3">
<p style="MARGIN: 0px" align="center">(Registrant’s telephone
number, including area code)</p>
</td>
</tr>
<tr>
<td valign="top" width="78%" colspan="3">
<p align="center">&nbsp;</p>
</td>
</tr>
<tr>
<td valign="top" width="78%" colspan="3">
<p style="MARGIN: 0px" align="center">
__________________________________&nbsp;</p>
</td>
</tr>
<tr>
<td valign="top" width="78%" colspan="3">
<p style="MARGIN: 0px" align="center">(Former address, if changed
since last report)</p>
</td>
</tr>
<tr>
<td valign="top" width="78%" colspan="3">
<p align="center">&nbsp;</p>
</td>
</tr>
<tr>
<td valign="top" width="78%" colspan="3">
<p style="MARGIN: 0px" align="center">
___________________________________&nbsp;</p>
</td>
</tr>
<tr>
<td valign="top" width="78%" colspan="3">
<p style="MARGIN: 0px" align="center">(Former fiscal year, if
changed since last report)</p>
</td>
</tr>
</table>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px">Indicate by check mark whether the
registrant (1) has filed all reports required to be filed by
Section 13 or 15(d) of the Securities Exchange Act of 1934 during
the preceding 12 months (or for such shorter period that the
registrant was required to file such reports), and (2) has been
subject to such filing requirements for the past 90 days.
Yes&nbsp;<font style="FONT-FAMILY: Wingdings">x</font> No
<font style="FONT-FAMILY: Wingdings">¨</font></p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">Indicate by check mark
whether the registrant has submitted electronically and posted on
its corporate Web site, if any, every Interactive Data File
required to be submitted and posted pursuant to Rule 405 of
regulation S-T (§232.405 of this chapter) during the preceding 12
months (or for such shorter period that the registrant was required
to submit and post such files). Yes&nbsp;<font style=
"FONT-FAMILY: Wingdings">x</font> No <font style=
"FONT-FAMILY: Wingdings">¨</font></p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">Indicate by check mark
whether the registrant is a large accelerated filer, an accelerated
filer, a non-accelerated filer, or a smaller reporting company. See
the definitions of "large accelerated filer," "accelerated filer"
and "smaller reporting company" in Rule 12b-2 of the Exchange
Act.</p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"></p>
<table style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN"
cellspacing="0" cols="3" cellpadding="0" width="85%" align="center"
border="0">
<tr>
<td width="30%">
<p style="MARGIN: 0px">Large accelerated filer</p>
</td>
<td width="20%">
<p style="MARGIN: 0px"><font style=
"FONT-FAMILY: Wingdings">¨</font></p>
</td>
<td width="30%">
<p style="MARGIN: 0px">Accelerated filer</p>
</td>
<td width="20%">
<p style="MARGIN: 0px"><font style=
"FONT-FAMILY: Wingdings">¨</font></p>
</td>
</tr>
<tr>
<td>
<p style="MARGIN: 0px">Non-accelerated filer</p>
</td>
<td>
<p style="MARGIN: 0px"><font style=
"FONT-FAMILY: Wingdings">¨</font></p>
</td>
<td>
<p style="MARGIN: 0px">Smaller reporting company</p>
</td>
<td><font style="FONT-FAMILY: Wingdings">x</font></td>
</tr>
<tr>
<td colspan="2">
<p style="MARGIN: 0px">(Do not check if a smaller reporting
company)&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">Emerging growth company</p>
</td>
<td>
<p style="MARGIN: 0px"><font style=
"FONT-FAMILY: Wingdings">¨</font></p>
</td>
</tr>
</table>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">If an emerging growth
company, indicate by check mark if the registrant has elected not
to use the extended transition period for complying with any new or
revised financial accounting standards provided pursuant to Section
13(a) of the Exchange Act. <font style=
"FONT-FAMILY: Wingdings">¨</font></p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">Indicate by check mark
whether the registrant is a shell company (as defined in Rule 12b-2
of the Exchange Act). Yes&nbsp;<font style=
"FONT-FAMILY: Wingdings">¨</font> No <font style=
"FONT-FAMILY: Wingdings">x</font></p>
<p style="MARGIN: 0px" align="center">&nbsp;</p>
<p style="MARGIN: 0px" align="center">APPLICABLE ONLY TO ISSUERS
INVOLVED IN BANKRUPTCY PROCEEDINGS</p>
<p style="MARGIN: 0px" align="center">DURING THE PRECEDING FIVE
YEARS</p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px">Indicate by check mark whether the
registrant filed all documents and reports required to be filed by
Section 12, 13 or 15(d) of the Exchange Act after the distribution
of securities under a plan confirmed by a court.
Yes&nbsp;<font style="FONT-FAMILY: Wingdings">¨</font> No
<font style="FONT-FAMILY: Wingdings">¨</font></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px" align="center">APPLICABLE ONLY TO CORPORATE
ISSUERS</p>
<p style="MARGIN: 0px" align="center">&nbsp;</p>
<p style="MARGIN: 0px">Indicate the number of shares outstanding of
each of the issuer's classes of stock, as of the latest practicable
date.</p>
<p style="MARGIN: 0px">&nbsp;</p>
<table style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN"
cellspacing="0" cellpadding="0" width="85%" align="center" border=
"0">
<tr height="15">
<td valign="top" width="45%">
<p style="MARGIN: 0px" align="center">Class of Securities</p>
</td>
<td width="10%">
<p style="MARGIN: 0px" align="center">&nbsp;</p>
</td>
<td valign="top" width="45%">
<p style="MARGIN: 0px" align="center">Shares Outstanding at May 14,
2018</p>
</td>
</tr>
<tr height="15">
<td valign="top">
<p style="MARGIN: 0px" align="center">Common Stock, $0.001 par
value</p>
</td>
<td>
<p style="MARGIN: 0px" align="center">&nbsp;</p>
</td>
<td valign="top">
<p style="MARGIN: 0px" align="center">9,039,347</p>
</td>
</tr>
</table>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px"></p>
<table style="FONT-SIZE: 1px" cellspacing="0" cellpadding="0"
width="100%" border="0">
<tr>
<td>
<div style=
"HEIGHT: 2px; WIDTH: 100%; BACKGROUND: #000000; MARGIN: 0px 0px 2px"
name="hrule"></div>
<div style="HEIGHT: 4px; WIDTH: 100%; BACKGROUND: #000000" name=
"hrule"></div>
</td>
</tr>
</table>
<p style="MARGIN: 0px"></p>
<table class="pagebreak" style="FONT: 10pt TIMES NEW ROMAN"
cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td class="hpbhr">&nbsp;</td>
</tr>
<tr>
<td>&nbsp;</td>
</tr>
<tr>
<td>
<div style=
"WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div>
&nbsp;</td>
</tr>
<tr>
<td>&nbsp;</td>
</tr>
</table>
<p style="MARGIN: 0px" align="center"><b>CEREBAIN BIOTECH
CORP.</b></p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="center"><b><u><a name="TOC" id=
"TOC">TABLE OF CONTENTS</a></u></b></p>
<p style="MARGIN: 0px">&nbsp;</p>
<table style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN"
cellspacing="0" cellpadding="0" width="100%" border="0">
<tr height="15">
<td colspan="2"></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: black 1px solid">
<p style="MARGIN: 0px" align="center"><b>PAGE</b></p>
</td>
<td valign="top"></td>
</tr>
<tr height="15">
<td colspan="2">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr height="15">
<td colspan="2">
<p style="MARGIN: 0px"><b><a href=
"#PART%201%20-%20FINANCIAL%20INFORMATION">PART I – FINANCIAL
INFORMATION</a></b></p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr height="15">
<td width="9%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top"></td>
<td width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top" width="9%">
<p style="MARGIN: 0px" align="center">&nbsp;</p>
</td>
<td width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr height="15" bgcolor="#CCEEFF">
<td>
<p style="MARGIN: 0px"><a href=
"#ITEM%201.%20FINANCIAL%20STATEMENTS">ITEM 1.</a></p>
</td>
<td valign="top">
<p style="MARGIN: 0px"><a href=
"#ITEM%201.%20FINANCIAL%20STATEMENTS">FINANCIAL STATEMENTS</a></p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top">
<p style="MARGIN: 0px" align="center">3</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr height="15" bgcolor="#FFFFFF">
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top"></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top">
<p style="MARGIN: 0px" align="center">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr height="15" bgcolor="#CCEEFF">
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top">
<p style="MARGIN: 0px"><a href="#BS">UNAUDITED CONDENSED
CONSOLIDATED BALANCE SHEETS</a></p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top">
<p style="MARGIN: 0px" align="center">3</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr height="15" bgcolor="#FFFFFF">
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top"></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top">
<p style="MARGIN: 0px" align="center">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr height="15" bgcolor="#CCEEFF">
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top">
<p style="MARGIN: 0px"><a href="#SO">UNAUDITED CONDENSED
CONSOLIDATED STATEMENTS OF OPERATIONS</a></p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top">
<p style="MARGIN: 0px" align="center">4</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr height="15" bgcolor="#FFFFFF">
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top"></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top">
<p style="MARGIN: 0px" align="center">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr height="15" bgcolor="#CCEEFF">
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top">
<p style="MARGIN: 0px"><a href="#CF">UNAUDITED CONDENSED
CONSOLIDATED STATEMENTS OF CASH FLOWS</a></p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top">
<p style="MARGIN: 0px" align="center">5</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr height="15" bgcolor="#FFFFFF">
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top"></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top">
<p style="MARGIN: 0px" align="center">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr height="15" bgcolor="#CCEEFF">
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top">
<p style="MARGIN: 0px"><a href="#NOTES">NOTES TO THE UNAUDITED
CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</a></p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top">
<p style="MARGIN: 0px" align="center">6</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr height="15" bgcolor="#FFFFFF">
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top"></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top">
<p style="MARGIN: 0px" align="center">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr height="15" bgcolor="#CCEEFF">
<td>
<p style="MARGIN: 0px"><a href=
"#ITEM%202.%20MANAGEMENT%E2%80%99S%20DISCUSSION%20AND%20ANALYSIS%20OF%20FINANCIAL%20CONDITION%20AND%20RESULTS%20OF%20OPERATIONS">
ITEM 2.</a></p>
</td>
<td valign="top">
<p style="MARGIN: 0px"><a href=
"#ITEM%202.%20MANAGEMENT%E2%80%99S%20DISCUSSION%20AND%20ANALYSIS%20OF%20FINANCIAL%20CONDITION%20AND%20RESULTS%20OF%20OPERATIONS">
MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND
RESULTS OF OPERATIONS</a></p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top">
<p style="MARGIN: 0px" align="center">26</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr height="15" bgcolor="#FFFFFF">
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top"></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top">
<p style="MARGIN: 0px" align="center">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr height="15" bgcolor="#CCEEFF">
<td>
<p style="MARGIN: 0px"><a href=
"#ITEM%203.%20QUANTITATIVE%20AND%20QUALITATIVE%20DISCLOSURES%20ABOUT%20MARKET%20RISK">
ITEM 3.</a></p>
</td>
<td valign="top">
<p style="MARGIN: 0px"><a href=
"#ITEM%203.%20QUANTITATIVE%20AND%20QUALITATIVE%20DISCLOSURES%20ABOUT%20MARKET%20RISK">
QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</a></p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top">
<p style="MARGIN: 0px" align="center">36</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr height="15" bgcolor="#FFFFFF">
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top"></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top">
<p style="MARGIN: 0px" align="center">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr height="15" bgcolor="#CCEEFF">
<td>
<p style="MARGIN: 0px"><a href=
"#ITEM%204.%20CONTROLS%20AND%20PROCEDURES">ITEM 4.</a></p>
</td>
<td valign="top">
<p style="MARGIN: 0px"><a href=
"#ITEM%204.%20CONTROLS%20AND%20PROCEDURES">CONTROLS AND
PROCEDURES</a></p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top">
<p style="MARGIN: 0px" align="center">36</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr height="15" bgcolor="#FFFFFF">
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top"></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top">
<p style="MARGIN: 0px" align="center">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr height="15" bgcolor="#FFFFFF">
<td colspan="2">
<p style="MARGIN: 0px"><b><a href=
"#PART%20II.%20OTHER%20INFORMATION">PART II. OTHER
INFORMATION</a></b></p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top"></td>
</tr>
<tr height="15" bgcolor="#FFFFFF">
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top"></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top">
<p style="MARGIN: 0px" align="center">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr height="15" bgcolor="#CCEEFF">
<td>
<p style="MARGIN: 0px"><a href=
"#ITEM%201.%20LEGAL%20PROCEEDINGS">ITEM 1.</a></p>
</td>
<td valign="top">
<p style="MARGIN: 0px"><a href=
"#ITEM%201.%20LEGAL%20PROCEEDINGS">LEGAL PROCEEDINGS</a></p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top">
<p style="MARGIN: 0px" align="center">37</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr height="15" bgcolor="#FFFFFF">
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top"></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top">
<p style="MARGIN: 0px" align="center">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr height="15" bgcolor="#CCEEFF">
<td>
<p style="MARGIN: 0px"><a href="#ITEM%201A.%20RISK%20FACTORS">ITEM
1A.</a></p>
</td>
<td valign="top">
<p style="MARGIN: 0px"><a href="#ITEM%201A.%20RISK%20FACTORS">RISK
FACTORS</a></p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top">
<p style="MARGIN: 0px" align="center">38</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr height="15" bgcolor="#FFFFFF">
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top"></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top">
<p style="MARGIN: 0px" align="center">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr height="15" bgcolor="#CCEEFF">
<td>
<p style="MARGIN: 0px"><a href=
"#ITEM%202.%20UNREGISTERED%20SALES%20OF%20EQUITY%20SECURITIES%20AND%20USE%20OF%20PROCEEDS">
ITEM 2.</a></p>
</td>
<td valign="top">
<p style="MARGIN: 0px"><a href=
"#ITEM%202.%20UNREGISTERED%20SALES%20OF%20EQUITY%20SECURITIES%20AND%20USE%20OF%20PROCEEDS">
UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS</a></p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top">
<p style="MARGIN: 0px" align="center">38</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr height="15" bgcolor="#FFFFFF">
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top"></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top">
<p style="MARGIN: 0px" align="center">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr height="15" bgcolor="#CCEEFF">
<td>
<p style="MARGIN: 0px"><a href=
"#ITEM%203.%20DEFAULTS%20UPON%20SENIOR%20SECURITIES">ITEM
3.</a></p>
</td>
<td valign="top">
<p style="MARGIN: 0px"><a href=
"#ITEM%203.%20DEFAULTS%20UPON%20SENIOR%20SECURITIES">DEFAULTS UPON
SENIOR SECURITIES</a></p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top">
<p style="MARGIN: 0px" align="center">40</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr height="15" bgcolor="#FFFFFF">
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top"></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top">
<p style="MARGIN: 0px" align="center">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr height="15" bgcolor="#CCEEFF">
<td>
<p style="MARGIN: 0px"><a href=
"#ITEM%204.%20MINING%20SAFETY%20DISCLOSURES">ITEM 4.</a></p>
</td>
<td valign="top">
<p style="MARGIN: 0px"><a href=
"#ITEM%204.%20MINING%20SAFETY%20DISCLOSURES">MINING SAFETY
DISCLOSURES</a></p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top">
<p style="MARGIN: 0px" align="center">40</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr height="15" bgcolor="#FFFFFF">
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top"></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top">
<p style="MARGIN: 0px" align="center">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr height="15" bgcolor="#CCEEFF">
<td>
<p style="MARGIN: 0px"><a href=
"#ITEM%205.%20OTHER%20INFORMATION">ITEM 5.</a></p>
</td>
<td valign="top">
<p style="MARGIN: 0px"><a href=
"#ITEM%205.%20OTHER%20INFORMATION">OTHER INFORMATION</a></p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top">
<p style="MARGIN: 0px" align="center">40</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr height="15" bgcolor="#FFFFFF">
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top"></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top">
<p style="MARGIN: 0px" align="center">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr height="15" bgcolor="#CCEEFF">
<td>
<p style="MARGIN: 0px"><a href="#ITEM%206.%20EXHIBITS">ITEM
6.</a></p>
</td>
<td valign="top">
<p style="MARGIN: 0px"><a href=
"#ITEM%206.%20EXHIBITS">EXHIBITS</a></p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top">
<p style="MARGIN: 0px" align="center">41</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr height="15" bgcolor="#FFFFFF">
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top">
<p style="MARGIN: 0px" align="center">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr height="15" bgcolor="#CCEEFF">
<td colspan="2">
<p style="MARGIN: 0px"><a href="#SIGNATURES">SIGNATURES</a></p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top">
<p style="MARGIN: 0px" align="center">44</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
</table>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px"></p>
<table id="pagebreak00efca3e-3550-4d6f-9e6d-5b0845c7ee72" class=
"pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0"
cellpadding="0" width="100%" border="0">
<tr>
<td class="hpbhr">&nbsp;</td>
</tr>
<tr>
<td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center">
2</td>
</tr>
<tr>
<td>
<div style=
"WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div>
&nbsp;</td>
</tr>
<tr>
<td>&nbsp;</td>
</tr>
</table>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px" align="left"><b><a name=
"PART 1 - FINANCIAL INFORMATION">PART&nbsp;I - FINANCIAL
INFORMATION</a></b></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 0in" align="left"><b><a name=
"ITEM 1. FINANCIAL STATEMENTS">ITEM 1. FINANCIAL
STATEMENTS</a></b></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">The unaudited condensed
consolidated financial statements of registrant for the three-month
and nine-month periods ended March 31, 2018 and 2017 follow. The
unaudited condensed consolidated financial statements reflect all
adjustments which are, in the opinion of management, necessary to a
fair statement of the results for the interim periods presented.
All such adjustments are of a normal and recurring nature.</p>
<p style="MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0in" align=
"center">&nbsp;</p>
<p style="MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0in" align=
"center"><b>CEREBAIN BIOTECH CORP. AND SUBSIDIARY</b></p>
<p style="MARGIN: 0px; TEXT-INDENT: 0in" align="center"><b><a name=
"BS" id="BS">CONDENSED CONSOLIDATED BALANCE SHEETS</a></b></p>
<p style="MARGIN: 0px">&nbsp;</p>
<table style=
"WIDTH: 100%; TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN"
cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="hdcell" valign="bottom" colspan="2" align="center">
<p style="MARGIN: 0px" align="center"><b>March 31,</b></p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px"><b>&nbsp;</b></p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px"><b>&nbsp;</b></p>
</td>
<td id="hdcell" valign="bottom" colspan="2" align="center">
<p style="MARGIN: 0px" align="center"><b>June 30,</b></p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px"><b>&nbsp;</b></p>
</td>
</tr>
<tr>
<td valign="bottom">
<p style="MARGIN: 0px"><b>&nbsp;</b></p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px"><b>&nbsp;</b></p>
</td>
<td id="hdcell" style="BORDER-BOTTOM: black 1px solid" valign=
"bottom" colspan="2" align="center">
<p style="MARGIN: 0px; TEXT-INDENT: 1.4pt" align="center">
<b>2018</b></p>
</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom">
<p style="MARGIN: 0px"><b>&nbsp;</b></p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px"><b>&nbsp;</b></p>
</td>
<td id="hdcell" style="BORDER-BOTTOM: black 1px solid" valign=
"bottom" colspan="2" align="center">
<p style="MARGIN: 0px; TEXT-INDENT: 1.4pt" align="center">
<b>2017</b></p>
</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="hdcell" valign="bottom" width="9%" colspan="2" align=
"center">
<p style="MARGIN: 0px; TEXT-INDENT: 1.4pt" align="center">
(unaudited)</p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="hdcell" valign="bottom" width="9%" colspan="2" align=
"center">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr>
<td valign="top" colspan="9">
<p style="MARGIN: 0px 0px 0px 16.6pt; TEXT-INDENT: 0px" align=
"center"><b>ASSETS</b></p>
</td>
</tr>
<tr>
<td valign="top">
<p style="MARGIN: 0px" align="justify">Current assets:</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" colspan="2" align=
"right">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" colspan="2" align=
"right">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#CCEEFF">
<td valign="top">
<p style="MARGIN: 0px 0px 0px 15px">Cash and cash equivalents</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">$</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
30,064</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">$</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
11,345</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#FFFFFF">
<td valign="top">
<p style="MARGIN: 0px 0px 0px 15px">Prepaid expenses</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: black 1px solid" valign="bottom" width=
"1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" style="BORDER-BOTTOM: black 1px solid" valign=
"bottom" width="9%" align="right">95,396</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: black 1px solid" valign="bottom" width=
"1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" style="BORDER-BOTTOM: black 1px solid" valign=
"bottom" width="9%" align="right">225,517</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#CCEEFF">
<td valign="top">
<p style="MARGIN: 0px">Total current assets</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: black 1px solid" valign="bottom" width=
"1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" style="BORDER-BOTTOM: black 1px solid" valign=
"bottom" width="9%" align="right">125,460</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: black 1px solid" valign="bottom" width=
"1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" style="BORDER-BOTTOM: black 1px solid" valign=
"bottom" width="9%" align="right">236,862</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#FFFFFF">
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#CCEEFF">
<td valign="top">
<p style="MARGIN: 0px">Total assets</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: black 3px double" valign="bottom" width=
"1%">$</td>
<td id="ffcell" style="BORDER-BOTTOM: black 3px double" valign=
"bottom" width="9%" align="right">125,460</td>
<td style="PADDING-BOTTOM: 3px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: black 3px double" valign="bottom" width=
"1%">$</td>
<td id="ffcell" style="BORDER-BOTTOM: black 3px double" valign=
"bottom" width="9%" align="right">236,862</td>
<td style="PADDING-BOTTOM: 3px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#FFFFFF">
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#FFFFFF">
<td valign="top" colspan="9">
<p style="MARGIN: 0px" align="center"><b>LIABILITIES AND
STOCKHOLDERS’ DEFICIT</b></p>
</td>
</tr>
<tr bgcolor="#FFFFFF">
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#FFFFFF">
<td valign="top">
<p style="MARGIN: 0px">Current liabilities:</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#CCEEFF">
<td valign="top">
<p style="MARGIN: 0px 0px 0px 15px">Accounts payable</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">$</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
1,030,237</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">$</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
926,131</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#FFFFFF">
<td valign="top">
<p style="MARGIN: 0px 0px 0px 15px">Related party payables</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
325,000</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
260,608</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#CCEEFF">
<td valign="top">
<p style="MARGIN: 0px 0px 0px 15px">Accrued payroll</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
160,995</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
115,810</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#FFFFFF">
<td valign="top">
<p style="MARGIN: 0px 0px 0px 15px">Payroll taxes payable</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
70,244</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
59,234</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#CCEEFF">
<td valign="top">
<p style="MARGIN: 0px 0px 0px 15px">Convertible notes to
stockholders, current portion</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
360,000</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
100,000</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#FFFFFF">
<td valign="top">
<p style="MARGIN: 0px 0px 0px 15px">Short term notes payable to
stockholders</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
364,000</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
289,000</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#CCEEFF">
<td valign="top">
<p style="MARGIN: 0px 0px 0px 15px">Short term convertible notes
payable, net of debt discount of approximately $261,250 and $0,
respectively</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
23,750</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">-</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#FFFFFF">
<td valign="top">
<p style="MARGIN: 0px 0px 0px 15px">Derivative liabilities</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
320,000</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">-</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#CCEEFF">
<td valign="top">
<p style="MARGIN: 0px 0px 0px 15px">Warrant liabilities</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: black 1px solid" valign="bottom" width=
"1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" style="BORDER-BOTTOM: black 1px solid" valign=
"bottom" width="9%" align="right">96,903</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: black 1px solid" valign="bottom" width=
"1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" style="BORDER-BOTTOM: black 1px solid" valign=
"bottom" width="9%" align="right">-</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#FFFFFF">
<td valign="top">
<p style="MARGIN: 0px">Total current liabilities</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
2,751,129</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
1,750,783</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#CCEEFF">
<td>
<p style="MARGIN: 0px 0px 0px 15px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#FFFFFF">
<td valign="top">
<p style="MARGIN: 0px">Long term liabilities:</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#CCEEFF">
<td valign="top">
<p style="MARGIN: 0px 0px 0px 15px">Convertible notes to
stockholders, net of current portion and net of debt discount of
approximately $7,049 and $12,053, respectively</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: black 1px solid" valign="bottom" width=
"1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" style="BORDER-BOTTOM: black 1px solid" valign=
"bottom" width="9%" align="right">2,569,063</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: black 1px solid" valign="bottom" width=
"1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" style="BORDER-BOTTOM: black 1px solid" valign=
"bottom" width="9%" align="right">2,739,059</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#FFFFFF">
<td valign="top">
<p style="MARGIN: 0px">Total long-term liabilities</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: black 1px solid" valign="bottom" width=
"1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" style="BORDER-BOTTOM: black 1px solid" valign=
"bottom" width="9%" align="right">2,569,063</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: black 1px solid" valign="bottom" width=
"1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" style="BORDER-BOTTOM: black 1px solid" valign=
"bottom" width="9%" align="right">2,739,059</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#CCEEFF">
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#FFFFFF">
<td valign="top">
<p style="MARGIN: 0px">Total liabilities</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
5,320,192</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
4,489,842</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#CCEEFF">
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#FFFFFF">
<td valign="top">
<p style="MARGIN: 0px">Commitments and contingencies (Note 4)</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#CCEEFF">
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#FFFFFF">
<td valign="top">
<p style="MARGIN: 0px">Stockholders’ deficit</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#CCEEFF">
<td valign="top">
<p style="MARGIN: 0px 0px 0px 15px">Preferred stock ($0.001 par
value: 1,000,000 shares authorized; none issued and
outstanding)</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">-</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">-</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#FFFFFF">
<td valign="top">
<p style="MARGIN: 0px 0px 0px 15px">Common stock ($0.001 par value:
249,000,000 shares authorized;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#FFFFFF">
<td valign="top">
<p style="MARGIN: 0px 0px 0px 15px">9,039,347 and 7,880,347 shares
issued and outstanding at March 31, 2018 and June 30, 2017,
respectively)</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">9,039</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">7,880</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#CCEEFF">
<td valign="top">
<p style="MARGIN: 0px 0px 0px 15px">Additional paid in capital</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
26,826,015</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
23,269,861</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#FFFFFF">
<td valign="top">
<p style="MARGIN: 0px 0px 0px 15px">Accumulated deficit</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: black 1px solid" valign="bottom" width=
"1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" style="BORDER-BOTTOM: black 1px solid" valign=
"bottom" width="9%" align="right">(32,029,786</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">)</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: black 1px solid" valign="bottom" width=
"1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" style="BORDER-BOTTOM: black 1px solid" valign=
"bottom" width="9%" align="right">(27,530,721</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">)</td>
</tr>
<tr bgcolor="#CCEEFF">
<td valign="top">
<p style="MARGIN: 0px">Total stockholders’ deficit</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: black 1px solid" valign="bottom" width=
"1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" style="BORDER-BOTTOM: black 1px solid" valign=
"bottom" width="9%" align="right">(5,194,732</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">)</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: black 1px solid" valign="bottom" width=
"1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" style="BORDER-BOTTOM: black 1px solid" valign=
"bottom" width="9%" align="right">(4,252,980</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">)</td>
</tr>
<tr bgcolor="#FFFFFF">
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#CCEEFF">
<td valign="top">
<p style="MARGIN: 0px">Total liabilities and stockholders’
deficit</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: black 3px double" valign="bottom" width=
"1%">$</td>
<td id="ffcell" style="BORDER-BOTTOM: black 3px double" valign=
"bottom" width="9%" align="right">125,460</td>
<td style="PADDING-BOTTOM: 3px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: black 3px double" valign="bottom" width=
"1%">$</td>
<td id="ffcell" style="BORDER-BOTTOM: black 3px double" valign=
"bottom" width="9%" align="right">236,862</td>
<td style="PADDING-BOTTOM: 3px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
</table>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px" align="center">See accompanying notes to
unaudited condensed consolidated financial statements</p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px"></p>
<table id="pagebreak7757bcde-fed0-4727-90ec-7c5a8d5ad50a" class=
"pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0"
cellpadding="0" width="100%" border="0">
<tr>
<td class="hpbhr">&nbsp;</td>
</tr>
<tr>
<td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center">
3</td>
</tr>
<tr>
<td>
<div style=
"WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div>
&nbsp;</td>
</tr>
<tr>
<td><i><a href="#TOC">Table of Contents</a></i></td>
</tr>
</table>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0in" align=
"center"><b>CEREBAIN BIOTECH CORP. AND SUBSIDIARY</b></p>
<p style="MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0in" align=
"center"><b><a name="SO" id="SO">UNAUDITED CONDENSED CONSOLIDATED
STATEMENTS OF OPERATIONS</a></b></p>
<p style="MARGIN: 0px">&nbsp;</p>
<table style=
"WIDTH: 100%; TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN"
cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="hdcell" valign="bottom" colspan="6" align="center">
<p style="MARGIN: 0px" align="center"><b>For the Nine Months
Ended</b></p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="hdcell" valign="bottom" colspan="6" align="center">
<p style="MARGIN: 0px"><b>For the Three Months Ended</b></p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="hdcell" style="BORDER-BOTTOM: black 1px solid" valign=
"bottom" colspan="6" align="center">
<p style="MARGIN: 0px 0px 0px 0.25in" align="center"><b>March
31,</b></p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="hdcell" style="BORDER-BOTTOM: black 1px solid" valign=
"bottom" colspan="6" align="center">
<p style="MARGIN: 0px"><b>March 31,</b></p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="hdcell" style="BORDER-BOTTOM: black 1px solid" valign=
"bottom" width="9%" colspan="2" align="center"><b>2018</b></td>
<td style="PADDING-BOTTOM: 1px" valign="bottom">
<p style="MARGIN: 0px"><b>&nbsp;</b></p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px"><b>&nbsp;</b></p>
</td>
<td id="hdcell" style="BORDER-BOTTOM: black 1px solid" valign=
"bottom" width="9%" colspan="2" align="center"><b>2017</b></td>
<td style="PADDING-BOTTOM: 1px" valign="bottom">
<p style="MARGIN: 0px"><b>&nbsp;</b></p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px"><b>&nbsp;</b></p>
</td>
<td id="hdcell" style="BORDER-BOTTOM: black 1px solid" valign=
"bottom" width="9%" colspan="2" align="center"><b>2018</b></td>
<td style="PADDING-BOTTOM: 1px" valign="bottom">
<p style="MARGIN: 0px"><b>&nbsp;</b></p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="hdcell" style="BORDER-BOTTOM: black 1px solid" valign=
"bottom" width="9%" colspan="2" align="center">
<p style="MARGIN: 0px 0px 0px 0.25in" align="center">
<b>2017</b></p>
</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" colspan="2" align=
"right">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" colspan="2" align=
"right">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" colspan="2" align=
"right">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" colspan="2" align=
"right">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr>
<td valign="top">
<p style="MARGIN: 0px">Operating Expenses</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" colspan="2" align=
"right">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" colspan="2" align=
"right">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" colspan="2" align=
"right">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" colspan="2" align=
"right">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#CCEEFF">
<td valign="top">
<p style="MARGIN: 0px 0px 0px 7.3pt">Selling, general and
administrative expenses</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">$</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
790,175</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">$</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
1,267,759</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">$</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
313,716</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">$</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
439,052</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#FFFFFF">
<td valign="top">
<p style="MARGIN: 0px 0px 0px 8.1pt">Research and development
costs</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
205,030</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
190,369</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
80,402</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
58,902</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#CCEEFF">
<td valign="top">
<p style="MARGIN: 0px 0px 0px 7.3pt">Patent Royalty Expense</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
75,000</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
75,000</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
25,000</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
25,000</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#FFFFFF">
<td valign="top">
<p style="MARGIN: 0px 0px 0px 7.3pt">Marketing expenses</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: black 1px solid" valign="bottom" width=
"1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" style="BORDER-BOTTOM: black 1px solid" valign=
"bottom" width="9%" align="right">8,642</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: black 1px solid" valign="bottom" width=
"1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" style="BORDER-BOTTOM: black 1px solid" valign=
"bottom" width="9%" align="right">9,782</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: black 1px solid" valign="bottom" width=
"1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" style="BORDER-BOTTOM: black 1px solid" valign=
"bottom" width="9%" align="right">2,440</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: black 1px solid" valign="bottom" width=
"1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" style="BORDER-BOTTOM: black 1px solid" valign=
"bottom" width="9%" align="right">1,630</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#CCEEFF">
<td valign="top">
<p style="MARGIN: 0px">Total operating expenses</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: black 1px solid" valign="bottom" width=
"1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" style="BORDER-BOTTOM: black 1px solid" valign=
"bottom" width="9%" align="right">1,078,847</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: black 1px solid" valign="bottom" width=
"1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" style="BORDER-BOTTOM: black 1px solid" valign=
"bottom" width="9%" align="right">1,542,910</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: black 1px solid" valign="bottom" width=
"1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" style="BORDER-BOTTOM: black 1px solid" valign=
"bottom" width="9%" align="right">421,558</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: black 1px solid" valign="bottom" width=
"1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" style="BORDER-BOTTOM: black 1px solid" valign=
"bottom" width="9%" align="right">524,584</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#FFFFFF">
<td valign="top">
<p style="MARGIN: 0px">Other (income) expense</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#CCEEFF">
<td valign="top">
<p style="MARGIN: 0px 0px 0px 8.1pt">Accretion of debt discount</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
28,754</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
11,500</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
25,418</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">1,944</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#FFFFFF">
<td valign="top">
<p style="MARGIN: 0px 0px 0px 8.1pt">Loss from extinguishment of
debt</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
3,102,134</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
13,778,649</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">-</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">-</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#CCEEFF">
<td valign="top">
<p style="MARGIN: 0px 0px 0px 8.1pt">Interest expense</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
298,716</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
116,476</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
217,012</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
40,226</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#FFFFFF">
<td valign="top">
<p style="MARGIN: 0px 0px 0px 8.1pt">Change in fair value of
derivative liabilities</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
(10,000</td>
<td valign="bottom" width="1%">)</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">-</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
(10,000</td>
<td valign="bottom" width="1%">)</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">-</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#CCEEFF">
<td valign="top">
<p style="MARGIN: 0px 0px 0px 8.1pt">Change in fair value of
warrant liabilities</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: black 1px solid" valign="bottom" width=
"1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" style="BORDER-BOTTOM: black 1px solid" valign=
"bottom" width="9%" align="right">614</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: black 1px solid" valign="bottom" width=
"1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" style="BORDER-BOTTOM: black 1px solid" valign=
"bottom" width="9%" align="right">-</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: black 1px solid" valign="bottom" width=
"1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" style="BORDER-BOTTOM: black 1px solid" valign=
"bottom" width="9%" align="right">614</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: black 1px solid" valign="bottom" width=
"1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" style="BORDER-BOTTOM: black 1px solid" valign=
"bottom" width="9%" align="right">-</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#FFFFFF">
<td valign="top">
<p style="MARGIN: 0px">Total other expense, net</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: black 1px solid" valign="bottom" width=
"1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" style="BORDER-BOTTOM: black 1px solid" valign=
"bottom" width="9%" align="right">3,420,218</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: black 1px solid" valign="bottom" width=
"1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" style="BORDER-BOTTOM: black 1px solid" valign=
"bottom" width="9%" align="right">13,906,625</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: black 1px solid" valign="bottom" width=
"1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" style="BORDER-BOTTOM: black 1px solid" valign=
"bottom" width="9%" align="right">233,044</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: black 1px solid" valign="bottom" width=
"1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" style="BORDER-BOTTOM: black 1px solid" valign=
"bottom" width="9%" align="right">42,170</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#CCEEFF">
<td valign="top">
<p style="MARGIN: 0px">Net loss</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: black 3px double" valign="bottom" width=
"1%">$</td>
<td id="ffcell" style="BORDER-BOTTOM: black 3px double" valign=
"bottom" width="9%" align="right">(4,499,065</td>
<td style="PADDING-BOTTOM: 3px" valign="bottom" width="1%">)</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: black 3px double" valign="bottom" width=
"1%">$</td>
<td id="ffcell" style="BORDER-BOTTOM: black 3px double" valign=
"bottom" width="9%" align="right">(15,449,535</td>
<td style="PADDING-BOTTOM: 3px" valign="bottom" width="1%">)</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: black 3px double" valign="bottom" width=
"1%">$</td>
<td id="ffcell" style="BORDER-BOTTOM: black 3px double" valign=
"bottom" width="9%" align="right">(654,602</td>
<td style="PADDING-BOTTOM: 3px" valign="bottom" width="1%">)</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: black 3px double" valign="bottom" width=
"1%">$</td>
<td id="ffcell" style="BORDER-BOTTOM: black 3px double" valign=
"bottom" width="9%" align="right">(566,754</td>
<td style="PADDING-BOTTOM: 3px" valign="bottom" width="1%">)</td>
</tr>
<tr bgcolor="#FFFFFF">
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#CCEEFF">
<td valign="top">
<p style="MARGIN: 0px">Loss per share:</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#FFFFFF">
<td valign="top">
<p style="MARGIN: 0px">Basic and diluted loss per share</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: black 3px double" valign="bottom" width=
"1%">$</td>
<td id="ffcell" style="BORDER-BOTTOM: black 3px double" valign=
"bottom" width="9%" align="right">(0.54</td>
<td style="PADDING-BOTTOM: 3px" valign="bottom" width="1%">)</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: black 3px double" valign="bottom" width=
"1%">$</td>
<td id="ffcell" style="BORDER-BOTTOM: black 3px double" valign=
"bottom" width="9%" align="right">(2.08</td>
<td style="PADDING-BOTTOM: 3px" valign="bottom" width="1%">)</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: black 3px double" valign="bottom" width=
"1%">$</td>
<td id="ffcell" style="BORDER-BOTTOM: black 3px double" valign=
"bottom" width="9%" align="right">(0.07</td>
<td style="PADDING-BOTTOM: 3px" valign="bottom" width="1%">)</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: black 3px double" valign="bottom" width=
"1%">$</td>
<td id="ffcell" style="BORDER-BOTTOM: black 3px double" valign=
"bottom" width="9%" align="right">(0.07</td>
<td style="PADDING-BOTTOM: 3px" valign="bottom" width="1%">)</td>
</tr>
<tr bgcolor="#CCEEFF">
<td valign="top">
<p style="MARGIN: 0px">Basic and diluted weighted average shares
outstanding</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: black 3px double" valign="bottom" width=
"1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" style="BORDER-BOTTOM: black 3px double" valign=
"bottom" width="9%" align="right">8,365,059</td>
<td style="PADDING-BOTTOM: 3px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: black 3px double" valign="bottom" width=
"1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" style="BORDER-BOTTOM: black 3px double" valign=
"bottom" width="9%" align="right">7,421,427</td>
<td style="PADDING-BOTTOM: 3px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: black 3px double" valign="bottom" width=
"1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" style="BORDER-BOTTOM: black 3px double" valign=
"bottom" width="9%" align="right">8,755,125</td>
<td style="PADDING-BOTTOM: 3px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: black 3px double" valign="bottom" width=
"1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" style="BORDER-BOTTOM: black 3px double" valign=
"bottom" width="9%" align="right">7,605,236</td>
<td style="PADDING-BOTTOM: 3px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
</table>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px" align="center">See accompanying notes to
unaudited condensed consolidated financial statements</p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px"></p>
<table id="pagebreakfc129fcb-c930-4071-825c-7f05955b601d" class=
"pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0"
cellpadding="0" width="100%" border="0">
<tr>
<td class="hpbhr">&nbsp;</td>
</tr>
<tr>
<td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center">
4</td>
</tr>
<tr>
<td>
<div style=
"WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div>
&nbsp;</td>
</tr>
<tr>
<td><i><a href="#TOC">Table of Contents</a></i></td>
</tr>
</table>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0in" align=
"center"><b>CEREBAIN BIOTECH CORP. AND SUBSIDIARY</b></p>
<p style="MARGIN: 0px" align="center"><b><a name="CF" id=
"CF">UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH
FLOWS</a></b></p>
<p style="MARGIN: 0px">&nbsp;</p>
<table style=
"WIDTH: 100%; TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN"
cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="hdcell" valign="bottom" colspan="6" align="center">
<p style="MARGIN: 0px" align="center"><b>For the Nine Months
Ended</b></p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="hdcell" style="BORDER-BOTTOM: black 1px solid" valign=
"bottom" colspan="6" align="center">
<p style="MARGIN: 0px 0px 0px 0.25in" align="center"><b>March
31,</b></p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="hdcell" style="BORDER-BOTTOM: black 1px solid" valign=
"bottom" width="9%" colspan="2" align="center">
<p style="MARGIN: 0px 0px 0px 0.25in" align="center">
<b>2018</b></p>
</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="hdcell" style="BORDER-BOTTOM: black 1px solid" valign=
"bottom" width="9%" colspan="2" align="center">
<p style="MARGIN: 0px 0px 0px 0.25in" align="center">
<b>2017</b></p>
</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr>
<td valign="top">
<p style="MARGIN: 0px">Cash flows from operating activities:</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" colspan="2" align=
"right">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" colspan="2" align=
"right">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#CCEEFF">
<td valign="top">
<p style="MARGIN: 0px 0px 0px 15px">Net loss</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">$</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
(4,499,065</td>
<td valign="bottom" width="1%">)</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">$</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
(15,449,535</td>
<td valign="bottom" width="1%">)</td>
</tr>
<tr bgcolor="#FFFFFF">
<td valign="top">
<p style="MARGIN: 0px">Adjustments to reconcile net loss to net
cash used in operating activities:</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#CCEEFF">
<td valign="top">
<p style="MARGIN: 0px 0px 0px 15px">Accretion of debt discount</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
28,754</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
11,500</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#FFFFFF">
<td valign="top">
<p style="MARGIN: 0px 0px 0px 15px">Initial fair value of
derivative liabilities included as interest expense</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
173,039</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">-</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#CCEEFF">
<td valign="top">
<p style="MARGIN: 0px 0px 0px 15px">Change in derivative
liabilities</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
(10,000</td>
<td valign="bottom" width="1%">)</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">-</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#FFFFFF">
<td valign="top">
<p style="MARGIN: 0px 0px 0px 15px">Change in warrant
liabilities</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">614</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">-</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#CCEEFF">
<td valign="top">
<p style="MARGIN: 0px 0px 0px 15px">Loss from extinguishment of
debt</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
3,102,134</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
13,778,649</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#FFFFFF">
<td valign="top">
<p style="MARGIN: 0px 0px 0px 15px">Stock based compensation</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
115,179</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
263,792</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#CCEEFF">
<td valign="top">
<p style="MARGIN: 0px 0px 0px 15px">Amortization of stock based
prepaid consulting compensation</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
186,447</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
578,511</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#FFFFFF">
<td valign="top">
<p style="MARGIN: 0px 0px 0px 15px">Stock compensation for legal
services</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
15,000</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">-</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#CCEEFF">
<td valign="top">
<p style="MARGIN: 0px">Changes in operating assets and
liabilities:</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#FFFFFF">
<td valign="top">
<p style="MARGIN: 0px 0px 0px 15px">Prepaid expenses</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
(21,326</td>
<td valign="bottom" width="1%">)</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
(46,372</td>
<td valign="bottom" width="1%">)</td>
</tr>
<tr bgcolor="#CCEEFF">
<td valign="top">
<p style="MARGIN: 0px 0px 0px 15px">Accounts payable</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
104,106</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
253,829</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#FFFFFF">
<td valign="top">
<p style="MARGIN: 0px 0px 0px 15px">Related party payables</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
64,392</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
163,898</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#CCEEFF">
<td valign="top">
<p style="MARGIN: 0px 0px 0px 15px">Accrued payroll and taxes</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: black 1px solid" valign="bottom" width=
"1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" style="BORDER-BOTTOM: black 1px solid" valign=
"bottom" width="9%" align="right">56,195</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: black 1px solid" valign="bottom" width=
"1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" style="BORDER-BOTTOM: black 1px solid" valign=
"bottom" width="9%" align="right">-</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#FFFFFF">
<td valign="top">
<p style="MARGIN: 0px">Net cash used in operating activities</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: black 1px solid" valign="bottom" width=
"1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" style="BORDER-BOTTOM: black 1px solid" valign=
"bottom" width="9%" align="right">(684,531</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">)</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: black 1px solid" valign="bottom" width=
"1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" style="BORDER-BOTTOM: black 1px solid" valign=
"bottom" width="9%" align="right">(445,728</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">)</td>
</tr>
<tr bgcolor="#CCEEFF">
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#FFFFFF">
<td valign="top">
<p style="MARGIN: 0px">Cash flows from financing activities:</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#CCEEFF">
<td valign="top">
<p style="MARGIN: 0px 0px 0px 15px">Proceeds from exercise of
warrants</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">-</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
31,000</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#FFFFFF">
<td valign="top">
<p style="MARGIN: 0px 0px 0px 15px">Proceeds from issuance of
common stock and warrants</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
290,000</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
50,000</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#CCEEFF">
<td valign="top">
<p style="MARGIN: 0px 0px 0px 15px">Proceeds from short term notes
to stockholders</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
175,000</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">-</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#FFFFFF">
<td valign="top">
<p style="MARGIN: 0px 0px 0px 15px">Proceeds from convertible
notes</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">-</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
345,000</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#CCEEFF">
<td valign="top">
<p style="MARGIN: 0px 0px 0px 15px">Proceeds from short term
convertible notes, net</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
253,250</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">-</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#FFFFFF">
<td valign="top">
<p style="MARGIN: 0px 0px 0px 15px">Repayment of convertible
notes</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: black 1px solid" valign="bottom" width=
"1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" style="BORDER-BOTTOM: black 1px solid" valign=
"bottom" width="9%" align="right">(15,000</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">)</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: black 1px solid" valign="bottom" width=
"1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" style="BORDER-BOTTOM: black 1px solid" valign=
"bottom" width="9%" align="right">-</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#CCEEFF">
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#FFFFFF">
<td valign="top">
<p style="MARGIN: 0px">Net cash flows provided by financing
activities:</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: black 1px solid" valign="bottom" width=
"1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" style="BORDER-BOTTOM: black 1px solid" valign=
"bottom" width="9%" align="right">703,250</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: black 1px solid" valign="bottom" width=
"1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" style="BORDER-BOTTOM: black 1px solid" valign=
"bottom" width="9%" align="right">426,000</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#CCEEFF">
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#FFFFFF">
<td valign="top">
<p style="MARGIN: 0px">Net change in cash and cash equivalents</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
18,719</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
(19,728</td>
<td valign="bottom" width="1%">)</td>
</tr>
<tr bgcolor="#CCEEFF">
<td valign="top">
<p style="MARGIN: 0px">Cash and cash equivalents- beginning of
period</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: black 1px solid" valign="bottom" width=
"1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" style="BORDER-BOTTOM: black 1px solid" valign=
"bottom" width="9%" align="right">11,345</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: black 1px solid" valign="bottom" width=
"1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" style="BORDER-BOTTOM: black 1px solid" valign=
"bottom" width="9%" align="right">20,245</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#FFFFFF">
<td valign="top">
<p style="MARGIN: 0px">Cash and cash equivalents- end of period</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: black 3px double" valign="bottom" width=
"1%">$</td>
<td id="ffcell" style="BORDER-BOTTOM: black 3px double" valign=
"bottom" width="9%" align="right">30,064</td>
<td style="PADDING-BOTTOM: 3px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: black 3px double" valign="bottom" width=
"1%">$</td>
<td id="ffcell" style="BORDER-BOTTOM: black 3px double" valign=
"bottom" width="9%" align="right">517</td>
<td style="PADDING-BOTTOM: 3px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#CCEEFF">
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#FFFFFF">
<td valign="top">
<p style="MARGIN: 0px"><b>Supplemental disclosure of non-cash
activities:</b></p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#CCEEFF">
<td valign="top">
<p style="MARGIN: 0px">Cash paid during the period for:</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#FFFFFF">
<td valign="top">
<p style="MARGIN: 0px 0px 0px 15px">Interest</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: black 3px double" valign="bottom" width=
"1%">$</td>
<td id="ffcell" style="BORDER-BOTTOM: black 3px double" valign=
"bottom" width="9%" align="right">-</td>
<td style="PADDING-BOTTOM: 3px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: black 3px double" valign="bottom" width=
"1%">$</td>
<td id="ffcell" style="BORDER-BOTTOM: black 3px double" valign=
"bottom" width="9%" align="right">-</td>
<td style="PADDING-BOTTOM: 3px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#CCEEFF">
<td valign="top">
<p style="MARGIN: 0px 0px 0px 15px">Income tax</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: black 3px double" valign="bottom" width=
"1%">$</td>
<td id="ffcell" style="BORDER-BOTTOM: black 3px double" valign=
"bottom" width="9%" align="right">-</td>
<td style="PADDING-BOTTOM: 3px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: black 3px double" valign="bottom" width=
"1%">$</td>
<td id="ffcell" style="BORDER-BOTTOM: black 3px double" valign=
"bottom" width="9%" align="right">-</td>
<td style="PADDING-BOTTOM: 3px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr height="15" bgcolor="#FFFFFF">
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
</table>
<table style=
"WIDTH: 100%; TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN"
cellspacing="0" cellpadding="0" width="100%" border="0">
<tr bgcolor="#CCEEFF">
<td>
<p style="MARGIN: 0px">Supplemental disclosure on non-cash
investing and financing activities:</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#FFFFFF">
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#CCEEFF">
<td valign="top">
<p style="MARGIN: 0px">Debt discount associated with convertible
notes payable – beneficial conversion feature</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: 3px double" valign="bottom" width="1%">
$</td>
<td id="ffcell" style="BORDER-BOTTOM: 3px double" valign="bottom"
width="9%" align="right">-</td>
<td style="PADDING-BOTTOM: 3px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: 3px double" valign="bottom" width="1%">
$</td>
<td id="ffcell" style="BORDER-BOTTOM: 3px double" valign="bottom"
width="9%" align="right">4,500</td>
<td style="PADDING-BOTTOM: 3px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#FFFFFF">
<td valign="top">
<p style="MARGIN: 0px">Debt discount associated with convertible
notes payable – warrant feature</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: 3px double" valign="bottom" width="1%">
$</td>
<td id="ffcell" style="BORDER-BOTTOM: 3px double" valign="bottom"
width="9%" align="right">-</td>
<td style="PADDING-BOTTOM: 3px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: 3px double" valign="bottom" width="1%">
$</td>
<td id="ffcell" style="BORDER-BOTTOM: 3px double" valign="bottom"
width="9%" align="right">15,500</td>
<td style="PADDING-BOTTOM: 3px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#CCEEFF">
<td valign="top">
<p style="MARGIN: 0px">Stock issued for prepaid services</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: 3px double" valign="bottom" width="1%">
$</td>
<td id="ffcell" style="BORDER-BOTTOM: 3px double" valign="bottom"
width="9%" align="right">35,000</td>
<td style="PADDING-BOTTOM: 3px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: 3px double" valign="bottom" width="1%">
$</td>
<td id="ffcell" style="BORDER-BOTTOM: 3px double" valign="bottom"
width="9%" align="right">288,400</td>
<td style="PADDING-BOTTOM: 3px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#FFFFFF">
<td valign="top">
<p style="MARGIN: 0px">Warrants issued for prepaid services</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: 3px double" valign="bottom" width="1%">
$</td>
<td id="ffcell" style="BORDER-BOTTOM: 3px double" valign="bottom"
width="9%" align="right">-</td>
<td style="PADDING-BOTTOM: 3px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: 3px double" valign="bottom" width="1%">
$</td>
<td id="ffcell" style="BORDER-BOTTOM: 3px double" valign="bottom"
width="9%" align="right">170,808</td>
<td style="PADDING-BOTTOM: 3px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#CCEEFF">
<td valign="top">
<p style="MARGIN: 0px">Conversion of convertible notes payable into
stock</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: 3px double" valign="bottom" width="1%">
$</td>
<td id="ffcell" style="BORDER-BOTTOM: 3px double" valign="bottom"
width="9%" align="right">-</td>
<td style="PADDING-BOTTOM: 3px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: 3px double" valign="bottom" width="1%">
$</td>
<td id="ffcell" style="BORDER-BOTTOM: 3px double" valign="bottom"
width="9%" align="right">12,400</td>
<td style="PADDING-BOTTOM: 3px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#FFFFFF">
<td valign="top">
<p style="MARGIN: 0px">Embedded derivative recorded as debt
discount</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: 3px double" valign="bottom" width="1%">
$</td>
<td id="ffcell" style="BORDER-BOTTOM: 3px double" valign="bottom"
width="9%" align="right">156,961</td>
<td style="PADDING-BOTTOM: 3px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: 3px double" valign="bottom" width="1%">
$</td>
<td id="ffcell" style="BORDER-BOTTOM: 3px double" valign="bottom"
width="9%" align="right">-</td>
<td style="PADDING-BOTTOM: 3px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#CCEEFF">
<td valign="top">
<p style="MARGIN: 0px">Derivative warrant liability recorded as
debt discount</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: 3px double" valign="bottom" width="1%">
$</td>
<td id="ffcell" style="BORDER-BOTTOM: 3px double" valign="bottom"
width="9%" align="right">96,289</td>
<td style="PADDING-BOTTOM: 3px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: 3px double" valign="bottom" width="1%">
$</td>
<td id="ffcell" style="BORDER-BOTTOM: 3px double" valign="bottom"
width="9%" align="right">-</td>
<td style="PADDING-BOTTOM: 3px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#FFFFFF">
<td valign="top">
<p style="MARGIN: 0px">Debt issuance cost recorded as debt
discount</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: 3px double" valign="bottom" width="1%">
$</td>
<td id="ffcell" style="BORDER-BOTTOM: 3px double" valign="bottom"
width="9%" align="right">18,650</td>
<td style="PADDING-BOTTOM: 3px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: 3px double" valign="bottom" width="1%">
$</td>
<td id="ffcell" style="BORDER-BOTTOM: 3px double" valign="bottom"
width="9%" align="right">-</td>
<td style="PADDING-BOTTOM: 3px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
</table>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px" align="center">See accompanying notes to
unaudited condensed consolidated financial statements</p>
<p style="MARGIN: 0px">&nbsp;</p>
<table id="pagebreaka363e657-0917-45b9-93ef-cfe93728fb7b" class=
"pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0"
cellpadding="0" width="100%" border="0">
<tr>
<td class="hpbhr">&nbsp;</td>
</tr>
<tr>
<td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center">
5</td>
</tr>
<tr>
<td>
<div style=
"WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div>
&nbsp;</td>
</tr>
<tr>
<td><i><a href="#TOC">Table of Contents</a></i></td>
</tr>
</table>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0in" align=
"center"><b>CEREBAIN BIOTECH CORP. AND SUBSIDIARY</b></p>
<p style="MARGIN: 0px" align="center"><b><a name="NOTES" id=
"NOTES">NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL
STATEMENTS</a></b></p>
<p style="MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0in" align=
"center"><b>FOR THE THREE AND NINE MONTH PERIODS ENDED MARCH 31,
2018 AND 2017</b></p>
<p style="MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0in" align=
"center">&nbsp;</p>
NOTE 1 – ORGANIZATION AND PRINCIPAL ACTIVITIES
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px"><b>Description of Business</b></p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">Cerebain Biotech Corp.
(Formerly Discount Dental Materials, Inc.) (“Cerebain Biotech”),
was incorporated on December 18, 2007 under the laws of Nevada. The
Company is a smaller reporting biomedical company and through its
wholly owned subsidiary, Cerebain Operating, Inc. (Formerly
Cerebain Biotech Corp.), the Company’s business revolves around the
discovery of products for the treatment of Alzheimer’s disease
utilizing Omentum. The Company plans to produce products that will
include both a medical device solution as well as a synthetic drug
solution.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">Cerebain Operating, Inc. was
incorporated on February 22, 2010, in the State of Nevada.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">The accompanying (a)
condensed balance sheet at June 30, 2017 has been derived from
audited statements and (b) unaudited interim condensed financial
statements as of March 31, 2018 and for the nine-month and
three-month periods ended March 31, 2018 and 2017 have been
prepared in accordance with accounting principles generally
accepted in the United States for interim financial information on
the same basis as the annual financial statements and in the
opinion of management, reflect all adjustments, which include only
normal recurring adjustments, necessary to present fairly the
Company's financial position, results of operations and cash flows
for the periods shown. The results of operations for such periods
are not necessarily indicative of the results expected for a full
year or for any future period. They do not include all of the
information and footnotes required by generally accepted accounting
principles for complete financial statements. Therefore, these
financial statements should be read in conjunction with the
Company's audited consolidated financial statements and notes
thereto for the year ended June 30, 2017 included on Form 10-K
filed with the Securities and Exchange Commission on September 15,
2017.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"><b>NOTE 2 – BASIS OF
PRESENTATION</b></p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">The Company operates in one
segment in accordance with accounting guidance Financial Accounting
Standards Board (“FASB”) Accounting Standards Codification (“ASC”)
Topic 280, <i>Segment Reporting</i>. The Company’s Principal
Executive Officer has been identified as the chief operating
decision maker as defined by FASB ASC Topic 280.</p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"><b><i>Going
Concern</i></b></p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">The accompanying unaudited
condensed consolidated financial statements have been prepared
assuming the Company will continue as a going concern, which
contemplates, among other things, the realization of assets and
satisfaction of liabilities in the normal course of business. The
Company had an accumulated deficit of approximately $32,000,000 and
$27,500,000 at March 31, 2018 and June 30, 2017, respectively, and
had a net loss of approximately $4,500,000 and $15,500,000 for the
nine-month periods ended March 31, 2018 and 2017, respectively, and
net cash used in operating activities of approximately $685,000 and
$446,000 for the nine-month periods ended March 31, 2018 and 2017,
respectively, with no revenue earned since inception, limited cash
of approximately $30,000 and $11,000 at March 31, 2018 and June 30,
2017, respectively, and a lack of operational history. These
matters raise substantial doubt about the Company’s ability to
continue as a going concern.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">While the Company is
attempting to commence operations and generate revenues, the
Company’s cash position may not be significant enough to support
the Company’s daily operations. Management intends to raise
additional funds by way of a public or private offering. Management
believes that the actions presently being taken to further
implement its business plan and generate revenues provide the
opportunity for the Company to continue as a going concern. While
the Company believes in the viability of its strategy to generate
revenues and in its ability to raise additional funds, there can be
no assurances to that effect. The ability of the Company to
continue as a going concern is dependent upon the Company’s ability
to further implement its business plan and generate revenues.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px"></p>
<table id="pagebreak21b42f2a-6f3c-435f-8b47-c9505abb685d" class=
"pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0"
cellpadding="0" width="100%" border="0">
<tr>
<td class="hpbhr">&nbsp;</td>
</tr>
<tr>
<td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center">
6</td>
</tr>
<tr>
<td>
<div style=
"WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div>
&nbsp;</td>
</tr>
<tr>
<td><i><a href="#TOC">Table of Contents</a></i></td>
</tr>
</table>
<p style="MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0in" align=
"center">&nbsp;</p>
<p style="MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0in" align=
"center"><b>CEREBAIN BIOTECH CORP. AND SUBSIDIARY</b></p>
<p style="MARGIN: 0px" align="center"><b>NOTES TO THE UNAUDITED
CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</b></p>
<p style="MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0in" align=
"center"><b>FOR THE THREE AND NINE MONTH PERIODS ENDED MARCH 31,
2018 AND 2017</b></p>
&nbsp;
<p style="MARGIN: 0px" align="justify">The financial statements do
not include any adjustments that might be necessary if the Company
is unable to continue as a going concern.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"><b>NOTE 3 – SUMMARY OF
SIGNIFICANT ACCOUNTING POLICIES</b></p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">This summary of significant
accounting policies of the Company is presented to assist in
understanding the Company’s condensed consolidated financial
statements. The condensed consolidated financial statements and
notes are representations of the Company’s management, which is
responsible for their integrity and objectivity. These accounting
policies conform to accounting principles generally accepted in the
United States and have been consistently applied in the preparation
of the condensed consolidated financial statements.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px"><b>Use of Estimates</b></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">The preparation of these
condensed consolidated financial statements in accordance with
accounting principles generally accepted in the United States of
America requires management to make estimates and assumptions that
affect the reported amounts of assets and liabilities and
disclosures of contingent assets and liabilities at the dates of
the condensed consolidated financial statements and the reported
amounts of net sales and expenses during the reported periods.
Actual results may differ from those estimates and such differences
may be material to the condensed consolidated financial statements.
The more significant estimates and assumptions by management
include among others: useful lives and residual values of
long-lived assets, the valuation of equity instruments, the
valuation of warrants and options, the valuation of derivative
liabilities, and the valuation of warrant liabilities.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px"><b>Principles of Consolidation</b></p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">The accompanying condensed
consolidated financial statements include the accounts of Cerebain
Biotech Corp. and its wholly-owned subsidiary, Cerebain Operating,
Inc. (collectively referred to as the “Company”). There are no
material intercompany transactions.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px"><b>Advertising Costs</b></p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">Advertising costs are
recorded as general and administrative expenses when they are
incurred. Advertising costs charged to operations were
approximately $8,600 and $9,800 for the nine-month periods ended
March 31, 2018 and 2017, respectively and approximately $2,400 and
$1,600 for the three-month periods ended March 31, 2018 and 2017,
respectively.</p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px"><b>Research and Development</b></p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">The Company expenses the
cost of research and development as incurred. Research and
development costs charged to operations were approximately $205,000
and $190,000 for the nine-month periods ended March 31, 2018 and
2017, respectively, and approximately $80,400 and $59,000 for the
three-month periods ended March 31, 2018 and 2018, respectively,
and are included in research and development costs in the
accompanying condensed consolidated statements of operations (See
Note 4).</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px"><b>Debt</b></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">The Company issues debt that
may have separate warrants, conversion features, or no
equity-linked attributes.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"></p>
<table id="pagebreak34bb5c88-58da-4e17-84a7-9ab31610aae2" class=
"pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0"
cellpadding="0" width="100%" border="0">
<tr>
<td class="hpbhr">&nbsp;</td>
</tr>
<tr>
<td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center">
7</td>
</tr>
<tr>
<td>
<div style=
"WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div>
&nbsp;</td>
</tr>
<tr>
<td><i><a href="#TOC">Table of Contents</a></i></td>
</tr>
</table>
<p style="MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0in" align=
"center">&nbsp;</p>
<p style="MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0in" align=
"center"><b>CEREBAIN BIOTECH CORP. AND SUBSIDIARY</b></p>
<p style="MARGIN: 0px" align="center"><b>NOTES TO THE UNAUDITED
CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</b></p>
<p style="MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0in" align=
"center"><b>FOR THE THREE AND NINE MONTH PERIODS ENDED MARCH 31,
2018 AND 2017</b></p>
&nbsp;
<p style="MARGIN: 0px" align="justify"><b><i>Debt with
warrants</i></b></p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">In accordance with ASC Topic
470-20-25, when the Company issues debt with warrants, the Company
treats the warrants as a debt discount, recorded as a
contra-liability against the debt, and amortizes the balance over
the life of the underlying debt as amortization of debt discount
expense in the consolidated statements of operations. The offset to
the contra-liability is recorded as additional paid in capital in
the Company’s consolidated balance sheets if the warrants are not
treated as a derivative. The Company determines the value of the
warrants using the Black-Scholes Option Pricing Model (
“Black-Scholes”) using the stock price on the date of issuance, the
risk-free interest rate associated with the life of the debt, and
the volatility of the stock. If the debt is retired early, the
associated debt discount is then recognized immediately as
amortization of debt discount expense in the consolidated
statements of operations. The debt is treated as conventional
debt.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"><b><i>Convertible debt –
derivative treatment</i></b></p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">When the Company issues debt
with a conversion feature, we must first assess whether the
conversion feature meets the requirements to be treated as a
derivative, as follows: a) one or more underlyings, typically the
price of our common stock; b) one or more notional amounts or
payment provisions or both, generally the number of shares upon
conversion; c) no initial net investment, which typically excludes
the amount borrowed; and d) net settlement provisions, which in the
case of convertible debt generally means the stock received upon
conversion can be readily sold for cash. An embedded equity-linked
component that meets the definition of a derivative does not have
to be separated from the host instrument if the component qualifies
for the scope exception for certain contracts involving an issuer’s
own equity. The scope exception applies if the contract is both a)
indexed to its own stock; and b) classified in shareholders’ equity
in its statement of financial position.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">If the conversion feature
within convertible debt meets the requirements to be treated as a
derivative, we estimate the fair value of the convertible debt
derivative using the Monte Carlo Method upon the date of issuance.
If the fair value of the convertible debt derivative is higher than
the face value of the convertible debt, the excess is immediately
recognized as interest expense. Otherwise, the fair value of the
convertible debt derivative is recorded as a liability with an
offsetting amount recorded as a debt discount, which offsets the
carrying amount of the debt. The convertible debt derivative is
revalued at the end of each reporting period and any change in fair
value is recorded as a gain or loss in the statement of operations.
The debt discount is amortized through interest expense over the
life of the debt.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"><b><i>Convertible debt –
beneficial conversion feature</i></b></p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">If the conversion feature is
not treated as a derivative, the Company assesses whether it is a
beneficial conversion feature (“BCF”). A BCF exists if the
conversion price of the convertible debt instrument is less than
the stock price on the commitment date. This typically occurs when
the conversion price is less than the fair value of the stock on
the date the instrument was issued. The value of a BCF is equal to
the intrinsic value of the feature, the difference between the
conversion price and the common stock into which it is convertible
and is recorded as additional paid in capital and as a debt
discount in the consolidated balance sheets. The Company amortizes
the balance over the life of the underlying debt as amortization of
debt discount expense in the consolidated statements of operations.
If the debt is retired early, the associated debt discount is then
recognized immediately as amortization of debt discount expense in
the consolidated statements of operations.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">If the conversion feature
does not qualify for either the derivative treatment or as a BCF,
the convertible debt is treated as traditional debt.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"></p>
<table id="pagebreakea2ac19b-d44b-4e1b-bc21-72eef60e908a" class=
"pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0"
cellpadding="0" width="100%" border="0">
<tr>
<td class="hpbhr">&nbsp;</td>
</tr>
<tr>
<td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center">
8</td>
</tr>
<tr>
<td>
<div style=
"WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div>
&nbsp;</td>
</tr>
<tr>
<td><i><a href="#TOC">Table of Contents</a></i></td>
</tr>
</table>
<p style="MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0in" align=
"center">&nbsp;</p>
<p style="MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0in" align=
"center"><b>CEREBAIN BIOTECH CORP. AND SUBSIDIARY</b></p>
<p style="MARGIN: 0px" align="center"><b>NOTES TO THE UNAUDITED
CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</b></p>
<p style="MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0in" align=
"center"><b>FOR THE THREE AND NINE MONTH PERIODS ENDED MARCH 31,
2018 AND 2017</b></p>
&nbsp;
<p style="MARGIN: 0px" align="justify"><b><i>Debt Modifications and
Extinguishments</i></b></p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">When the Company modifies or
extinguishes debt, it does so in accordance with ASC Topic
470-50-40, which requires modification to debt instruments to be
evaluated to assess whether the modifications are considered 
“substantial modifications”. A substantial modification of terms
shall be accounted for like an extinguishment. Based on the
guidance relied upon and the analysis performed, if the Company
believes the embedded conversion feature has no fair value on the
date of issuance (measurement date) and the embedded conversion
feature has no beneficial conversion feature, the embedded
conversion feature does not meet the criteria in ASC 470-50-40-10
or 470-20-25 and the issuance of the convertible note payable is
considered a modification, and not an extinguishment that would
require the recognition of a gain or loss. If the Company
determines the change in terms meet the criteria for substantial
modification under ASC 470 it will treat the modification as
extinguishment and recognize a loss from debt extinguishment.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px"><b>Fair Value of Financial
Instruments</b></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">The Company applies the
provisions of accounting guidance, FASB Topic ASC 825 that requires
all entities to disclose the fair value of financial instruments,
both assets and liabilities recognized and not recognized on the
balance sheet, for which it is practicable to estimate fair value,
and defines fair value of a financial instrument as the amount at
which the instrument could be exchanged in a current transaction
between willing parties. As of March 31, 2018 and June 30, 2017,
the fair value of cash, accounts payable, related party payables,
and notes payable to stockholders approximated carrying value due
to the short maturity of the instruments, quoted market prices or
interest rates which fluctuate with market rates.</p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px"><b>Fair Value Measurements</b></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">FASB ASC Topic 825 
“Financial Instruments,” requires disclosure about fair value of
financial instruments.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">The FASB ASC Topic 820,
<i>Fair Value Measurement</i>, clarifies the definition of fair
value for financial reporting, establishes a framework for
measuring fair value and requires additional disclosures about the
use of fair value measurements.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">The inputs or methodologies
used for valuing securities are not necessarily an indication of
the risk associated with investing in these securities. These
inputs are summarized in the three broad levels listed below.</p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px"></p>
<table style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN"
cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td width="4%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top" width="4%"><font style=
"FONT-FAMILY: Symbol">·</font></td>
<td valign="top">Level 1 – observable market inputs that are
unadjusted quoted prices for identical assets or liabilities in
active markets.</td>
</tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top"><font style="FONT-FAMILY: Symbol">·</font></td>
<td valign="top">Level 2 – other significant observable inputs
(including quoted prices for similar securities, interest rates,
credit risk, etc.).</td>
</tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top"><font style="FONT-FAMILY: Symbol">·</font></td>
<td valign="top">Level 3 – significant unobservable inputs
(including the Company’s own assumptions in determining the fair
value of investments).</td>
</tr>
</table>
&nbsp;
<p style="MARGIN: 0px" align="justify">The carrying value of
financial assets and liabilities recorded at fair value is measured
on a recurring or nonrecurring basis. Financial assets and
liabilities measured on a non-recurring basis are those that are
adjusted to fair value when a significant event occurs. The Company
had no financial assets or liabilities carried and measured on a
nonrecurring basis during the reporting periods. Financial assets
and liabilities measured on a recurring basis are those that are
adjusted to fair value each time a financial statement is prepared.
The warrant and derivative liabilities are recognized at fair value
on a recurring basis at March 31, 2018 and are Level 3
measurements. There have been no transfers between levels.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px"><b>Concentrations, Risks, and
Uncertainties</b></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">The Company is a startup
company subject to the substantial business risks and uncertainties
inherent to such an entity, including the potential risk of
business failure.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px"></p>
<table id="pagebreak89b013ad-d4b7-4e11-9e1b-ed86dc7632d7" class=
"pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0"
cellpadding="0" width="100%" border="0">
<tr>
<td class="hpbhr">&nbsp;</td>
</tr>
<tr>
<td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center">
9</td>
</tr>
<tr>
<td>
<div style=
"WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div>
&nbsp;</td>
</tr>
<tr>
<td><i><a href="#TOC">Table of Contents</a></i></td>
</tr>
</table>
<p style="MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0in" align=
"center"><b>&nbsp;</b></p>
<p style="MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0in" align=
"center"><b>CEREBAIN BIOTECH CORP. AND SUBSIDIARY</b></p>
<p style="MARGIN: 0px" align="center"><b>NOTES TO THE UNAUDITED
CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</b></p>
<p style="MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0in" align=
"center"><b>FOR THE THREE AND NINE MONTH PERIODS ENDED MARCH 31,
2018 AND 2017</b></p>
&nbsp;
<p style="MARGIN: 0px"><b>Basic and Diluted Earnings Per
Share</b></p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">Basic earnings (loss) per
common share is computed by dividing net earnings applicable to
common stockholders by the weighted-average number of common shares
outstanding during the period. Diluted earnings (loss) per common
share is determined using the weighted-average number of common
shares outstanding during the period, adjusted for the dilutive
effect of common stock equivalents, using the treasury stock
method, consisting of shares that might be issued upon exercise of
common stock warrants and conversion of convertible notes. In
periods where losses are reported, the weighted-average number of
common stock outstanding excludes common shares equivalents,
because their inclusion would be anti-dilutive.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">Basic earnings per share are
based on the weighted-average number of shares of common stock
outstanding. Diluted earnings per share is based on the
weighted-average number of shares of common stock outstanding
adjusted for the effects of common stock that may be issued as a
result of the following types of potentially dilutive
instruments:</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"></p>
<table style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN"
cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td width="4%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top" width="4%"><font style=
"FONT-FAMILY: Symbol">·</font></td>
<td valign="top">Warrants,</td>
</tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top"><font style="FONT-FAMILY: Symbol">·</font></td>
<td valign="top">Convertible notes,</td>
</tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top"><font style="FONT-FAMILY: Symbol">·</font></td>
<td valign="top">Employee stock options, and</td>
</tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top"><font style="FONT-FAMILY: Symbol">·</font></td>
<td valign="top">Other equity awards, which include long-term
incentive awards.</td>
</tr>
</table>
&nbsp;
<p style="MARGIN: 0px" align="justify">The FASB ASC Topic 260, 
“<i>Earnings Per Share”</i>, requires the Company to include
additional shares in the computation of earnings per share,
assuming dilution. The additional shares included in diluted
earnings per share represents the number of shares that would be
issued if all of the Company’s outstanding dilutive instruments
were converted into common stock.</p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">Diluted earnings per share
are based on the assumption that all dilutive options were
converted or exercised. Dilution is computed by applying the
treasury stock method. Under this method, options, warrants, and
convertible notes are assumed to be exercised at the time of
issuance, and as if funds obtained thereby were used to purchase
common stock at the average market price during the period.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">Basic and diluted earnings
(loss) per share are the same since the Company had net losses for
all periods presented and including the additional potential common
shares would have an anti-dilutive effect.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"><b>Recent Accounting
Pronouncements</b></p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">The Company has evaluated
new accounting pronouncements that have been issued and are not yet
effective for the Company and determined that there are no such
pronouncements expected to have a significant impact on the Company’
s future financial statements.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px"><b>NOTE 4</b> <b>–</b> <b>COMMITMENTS AND
CONTINGENCIES</b></p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"><b>Commitments</b></p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">In September 2012, the
Company entered into an agreement with Sonos Models, Inc. (“Sonos”)
to build up to three medical device prototypes to be used for
testing. In April 2014, the Company entered into an addendum to the
agreement with Sonos, which included a commitment by the Company to
pay Sonos up to One Million Dollars ($1,000,000) cash, excluding
stock-based compensation, for research and development costs. These
costs will be recognized in research and development expense as
costs are incurred (See Note 3). To date, Sonos has been issued
325,000 restricted shares of the Company’s stock and the Company
has paid approximately $320,000, of which $165,000 has been
incurred towards the Company’s monetary commitment.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"></p>
<table id="pagebreakfc321481-1abd-4eaa-8d54-8f7c48383257" class=
"pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0"
cellpadding="0" width="100%" border="0">
<tr>
<td class="hpbhr">&nbsp;</td>
</tr>
<tr>
<td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center">
10</td>
</tr>
<tr>
<td>
<div style=
"WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div>
&nbsp;</td>
</tr>
<tr>
<td><i><a href="#TOC">Table of Contents</a></i></td>
</tr>
</table>
<p style="MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0in" align=
"center"><b>&nbsp;</b></p>
<p style="MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0in" align=
"center"><b>CEREBAIN BIOTECH CORP. AND SUBSIDIARY</b></p>
<p style="MARGIN: 0px" align="center"><b>NOTES TO THE UNAUDITED
CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</b></p>
<p style="MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0in" align=
"center"><b>FOR THE THREE AND NINE MONTH PERIODS ENDED MARCH 31,
2018 AND 2017</b></p>
&nbsp;
<p style="MARGIN: 0px" align="justify">To date, the results of the
research suggest the Company has three options for implantable
devices with a bias towards having them as non-invasive as
possible. The options are comprised of two electro-stim types that
have a multitude of variable test parameters that can be changed
and modified externally as the testing facility conducts clinical
trials on each patient. It is theorized that if a patient’s
response to the Omentum stimulation is successful, the clinical
facility should be able to perform various tests for the purpose of
setting “markers” for the patient and then perform the standardized
cognitive testing for Alzheimer’s patient with the intent of
developing a testing matrix. It is the Company’s objective to test
various methods and modalities with the aim of developing an
enormous matrix of input to direct us to the best solution.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"><b>Consulting
Agreements</b></p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">Between December 2016 and
March 2018, the Company entered into service and consulting
agreements with various vendors to provide assistance to the
Company in several areas including the marketing of its biomedical
products upon the availability of the device, capital markets and
marketing strategies, research and development, advertising
services and assistance in the introduction of the Company to
medical device testing organization and to facilitate access to
doctors in numerous countries, including Poland, Uzbekistan and
China. They were compensated an approximate aggregate 1,935,000
shares of the Company’s fully vested and non-forfeitable common
stock. These contracts are for twelve to thirty-six months and may
be renewed or extended for any period as may be agreed by the
parties. As of March 31, 2018, the Company has extended some of the
contracts for additional periods. Any of the parties may terminate
their respective agreement by providing thirty (30) days written
notice of such termination. The Company has recognized $30,000 in
accounts payable which is in arrears with one contractual
obligation and is in discussions with the consultant to renegotiate
the terms of the contract. As these contracts are for a period of
up to twelve months to thirty-six months, the Company recorded the
original approximate $2,670,000 as the value of the shares issued
to prepaid expense and is amortizing the expense associated with
these issuances over a twelve to thirty-six-month period. For the
nine-month periods ended March 31, 2018 and 2017, the Company
amortized from prepaid expenses to selling, general and
administrative expenses approximately $123,000 and $472,000,
respectively, and for the three-month periods ended March 31, 2018
and 2017 approximately $20,000 and $192,000, respectively. The
unamortized prepaid expenses of these contracts are approximately
$6,000 and included in prepaid expenses on the consolidated balance
sheets at March 31, 2018 compared to $215,000 for the nine-month
period ended March 31, 2017.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">In January 2016, the Company
entered into a consulting agreement with an individual to provide
business consulting services for a period of thirty-six months.
Compensation was issuance of 75,000 shares of the Company’s stock
and fully vested and non-forfeitable options to acquire up to
300,000 shares of the Company’s common stock, at an exercise price
of $0.33 per share. Fair Market Value of these options totaled
approximately $83,500 and is being recognized ratably over the
service period in selling, general and administrative expense. The
options were valued using the Black-Scholes value option pricing
model with the following inputs: volatility of 210%; risk-free
interest rate of 1.07%; expected term of 3 years; and 0% dividend
yield. For the nine-month periods ended March 31, 2018 and 2017,
the Company amortized from prepaid expenses to selling, general and
administrative expenses approximately $21,000 and $21,000,
respectively, and for the three-month periods ended March 31, 2018
and 2017, approximately $7,000 and $7,000, respectively. The
unamortized prepaid expense of this contract is approximately
$28,000 and included in prepaid expenses on the consolidated
balance sheets at March 31, 2018.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"></p>
<table id="pagebreaka0fc85d1-39c5-4ff7-9277-b7d92bcc72a6" class=
"pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0"
cellpadding="0" width="100%" border="0">
<tr>
<td class="hpbhr">&nbsp;</td>
</tr>
<tr>
<td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center">
11</td>
</tr>
<tr>
<td>
<div style=
"WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div>
&nbsp;</td>
</tr>
<tr>
<td><i><a href="#TOC">Table of Contents</a></i></td>
</tr>
</table>
<p style="MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0in" align=
"center">&nbsp;</p>
<p style="MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0in" align=
"center"><b>CEREBAIN BIOTECH CORP. AND SUBSIDIARY</b></p>
<p style="MARGIN: 0px" align="center"><b>NOTES TO THE UNAUDITED
CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</b></p>
<p style="MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0in" align=
"center"><b>FOR THE THREE AND NINE MONTH PERIODS ENDED MARCH 31,
2018 AND 2017</b></p>
&nbsp;
<p style="MARGIN: 0px" align="justify">In October 2016, the Company
entered into a consulting agreement with an individual to provide
business consulting services for a period of twelve months.
Compensation was issuance of 300,000 shares of the Company’s stock
(See Note 7) and fully vested and non-forfeitable warrants to
acquire up to 300,000 shares of the Company’s common stock, at an
exercise price of $0.40 per share. Fair Market Value of these
warrants totaled approximately $171,000, and is to be recognized
ratably over the service period in selling, general and
administrative expense. The warrants were valued using the
Black-Scholes value option pricing model with the following inputs:
volatility of 205%; risk-free interest rate of 0.63%; expected term
of 1 year(s); and 0% dividend yield. For the nine-month periods
ended March 31, 2018 and 2017, the Company amortized from prepaid
expenses to selling, general and administrative expenses
approximately $43,000 and $85,000, respectively, and for the
three-month periods ended March 31, 2018 and 2017, approximately $0
and $43,000, respectively. The prepaid expense of this contract has
been fully amortized as of March 31, 2018.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">As of March 31, 2018, future
maturities of prepaid expenses on value of shares issued for
consulting are as follows:</p>
<p style="MARGIN: 0px">&nbsp;</p>
<table style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN"
cellspacing="0" cellpadding="0" width="85%" align="center" border=
"0">
<tr>
<td valign="top">
<p style="MARGIN: 0px" align="justify">Fiscal year ended June
30,</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" colspan="2" align=
"right">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" colspan="2" align=
"right">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#CCEEFF">
<td valign="top">
<p style="MARGIN: 0px" align="justify">2018</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">$</td>
<td id="ffcell" valign="bottom" width="9%" align="right">8,835</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#FFFFFF">
<td valign="top">
<p style="MARGIN: 0px" align="justify">2019</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: black 1px solid" valign="bottom" width=
"1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" style="BORDER-BOTTOM: black 1px solid" valign=
"bottom" width="9%" align="right">25,235</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#CCEEFF">
<td valign="top">
<p style="MARGIN: 0px" align="justify">Total</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: black 3px double" valign="bottom" width=
"1%">$</td>
<td id="ffcell" style="BORDER-BOTTOM: black 3px double" valign=
"bottom" width="9%" align="right">34,070</td>
<td style="PADDING-BOTTOM: 3px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
</table>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"><b>Legal</b></p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">On July 21, 2016, the
Company was sued in the United States District Court for the
Eastern District of Pennsylvania (<i><u>Miriam Weber Miller v.
Cerebain Biotech Corp. and Eric Clemons</u></i>, Civil Action No.
16-3943) by Miriam Weber Miller, with Mr. Clemons named as an
individual defendant. According to the Complaint, the Plaintiff
alleged: (i) she was hired by the Company to perform public
relations, investor relations, corporate growth strategies, and was
to be an advisor to the Company’s Chief Executive Officer, (ii) she
performed services, and (iii) that she was not fully compensated
for those services. The Complaint claimed causes of action for
breach of contract, violation of the Pennsylvania wage payment and
collection law, and unjust enrichment, and sought damages of
approximately $400,000. On April 3, 2017, without admitting fault
or liability, and still denying the same, the Company made a
business decision to resolve the lawsuit and it is now settled,
effectively ending the litigation. In consideration for signing the
agreement, the Company agreed to pay Ms. Miller as follows:</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px 0px 0px 0in" align="justify">The Company paid
Ms. Miller the total gross amount of one hundred twenty thousand
dollars ($120,000) as follows:</p>
<p style="MARGIN: 0px 0px 0px 0in" align="justify">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 0px" align="justify"></p>
<table style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN"
cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td valign="top" width="4%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top" width="4%">a)</td>
<td valign="top">One payment of twenty thousand dollars ($20,000)
within thirty (30) days after March 29, 2017; and</td>
</tr>
<tr>
<td valign="top">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top">b)</td>
<td valign="top">Beginning within ninety (90) days after March 29,
2017, the Company made monthly payments of fifteen thousand dollars
($15,000) to Ms. Miller’s representative until such time that Ms.
Miller and her representative has received the gross amount of
$120,000.</td>
</tr>
</table>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">Upon all payments being made
pursuant to the terms set forth in the agreement, Ms. Miller has
agreed to knowingly and voluntarily release and discharge the
Company of and from all claims, demands, liabilities, obligations,
promises, controversies, compensation, wages, bonuses, commissions,
damages, rights, actions and causes of action known and unknown, at
law or in equity, which Ms. Miller has or may have against the
Company as of the date of execution of the settlement
agreement.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">The Company had recognized
an accrual in Accounts Payable for payment of the agreed upon
settlement, but no accrual has been made for additional legal
contingencies in the consolidated financial statements as of March
31, 2018. For the nine-month and three-month periods ended March
31, 2018, the Company paid Ms. Miller $85,000 and $0, respectively,
as agreed in the settlement agreement. As of March 31, 2018, the
terms of the settlement agreement have been met and Ms. Miller has
been paid in full.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"></p>
<table id="pagebreak6a8002ff-cd7e-43d7-9377-6b6f88b848f5" class=
"pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0"
cellpadding="0" width="100%" border="0">
<tr>
<td class="hpbhr">&nbsp;</td>
</tr>
<tr>
<td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center">
12</td>
</tr>
<tr>
<td>
<div style=
"WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div>
&nbsp;</td>
</tr>
<tr>
<td><i><a href="#TOC">Table of Contents</a></i></td>
</tr>
</table>
<p style="MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0in" align=
"center">&nbsp;</p>
<p style="MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0in" align=
"center"><b>CEREBAIN BIOTECH CORP. AND SUBSIDIARY</b></p>
<p style="MARGIN: 0px" align="center"><b>NOTES TO THE UNAUDITED
CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</b></p>
<p style="MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0in" align=
"center"><b>FOR THE THREE AND NINE MONTH PERIODS ENDED MARCH 31,
2018 AND 2017</b></p>
&nbsp;
<p style="MARGIN: 0px"><b>NOTE</b> <b>5</b> <b>– PATENT
RIGHTS</b></p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">On June 10, 2010, the
Company entered into a Patent License Agreement under which the
Company acquired the exclusive rights to certain intellectual
property related to using Omentum for treating dementia conditions.
Under the agreement, the Company has paid rights fees of $50,000 to
Dr. Saini, and the Company issued Dr. Saini 825,000 shares of the
Company’s common stock, valued at $6,600 (based on the fair market
value on the date of grant) restricted in accordance with Rule 144.
In addition, Dr. Saini will have the option to participate in the
sale of equity by the Company in the future, up to ten percent
(10%) of the money raised, in exchange for the applicable number of
his shares. To date, Dr. Saini has not participated in any sales of
equity.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">The Patent License agreement
provides for a royalty payment of six (6) percent of the value of
the net sales, as defined, generated from the sale of licensed
products. The agreement also provides for yearly minimum royalty
payments of $50,000 for the fourth (June 2014), fifth (June 2015),
and sixth (June 2016) anniversary of the date of the agreement, and
a yearly minimum royalty payment of $100,000 for each year
thereafter during the term of the agreement. The Company has
accrued the minimum patent royalty expense associated with the
patent rights in accounts payable and is currently in arrears and
in discussions to renegotiate the terms of the agreement. The term
of the agreement shall continue until the patent in the
intellectual property expires, unless terminated sooner under the
provisions of the agreement, as defined.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">The patent will have an
estimated useful life of 20 years based on the term of the patent.
Amortization of the patent will begin when the patent is issued by
the United States Patent and Trademark Office and put in use.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">Legal fees pertaining to the
patent are recorded as general and administrative expenses when
they are incurred. Legal fees charged to operations were
approximately $4,000 and $5,100 for the nine-month periods ended
March 31, 2018 and 2017, respectively, and approximately $2,400 and
$1,300 for the three-month periods ended March 31, 2018 and 2017,
respectively.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">The Company recognized a
patent royalty expense of approximately $75,000 for the nine-month
period ended March 31, 2018 compared to $75,000 for the nine-month
period ended March 31, 2017 and approximately $25,000 for the
three-month period ended March 31, 2018 compared to $25,000 for the
three-month period ended March 31, 2017. The accrued payable of
$325,000 pertaining to the patent royalty expense at March 31, 2018
is included in related party payables.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px"><b>NOTE</b> <b>6</b> <b>– NOTES
PAYABLE</b></p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"><b>Short Term Notes Payable
to Stockholders</b></p>
<p style="MARGIN: 0px">&nbsp;</p>
<table style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN"
cellspacing="0" cellpadding="0" width="85%" align="center" border=
"0">
<tr>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="hdcell" style="BORDER-BOTTOM: black 1px solid" valign=
"bottom" colspan="6" align="center">
<p style="MARGIN: 0px" align="center"><b>Short Term Notes
Payable</b></p>
<p style="MARGIN: 0px" align="center"><b>to Stockholders</b></p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="hdcell" style="BORDER-BOTTOM: black 1px solid; MARGIN: 0px"
valign="bottom" width="9%" colspan="2" align="center">
<p style="MARGIN: 0px"><b>March31,</b></p>
<p style="MARGIN: 0px"><b>2018</b></p>
</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="hdcell" style="BORDER-BOTTOM: black 1px solid" valign=
"bottom" width="9%" colspan="2" align="center">
<p style="MARGIN: 0px" align="center"><b>June 30,</b></p>
<p style="MARGIN: 0px" align="center"><b>2017</b></p>
</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#CCEEFF">
<td valign="top">
<p style="MARGIN: 0px" align="justify">Short term notes payable
(A)</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: black 1px solid" valign="bottom" width=
"1%">$</td>
<td id="ffcell" style="BORDER-BOTTOM: black 1px solid" valign=
"bottom" width="9%" align="right">114,000</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: black 1px solid" valign="bottom" width=
"1%">$</td>
<td id="ffcell" style="BORDER-BOTTOM: black 1px solid" valign=
"bottom" width="9%" align="right">114,000</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#FFFFFF">
<td valign="top">
<p style="MARGIN: 0px" align="justify">Short term notes payable
(B)</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: black 1px solid" valign="bottom" width=
"1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" style="BORDER-BOTTOM: black 1px solid" valign=
"bottom" width="9%" align="right">250,000</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: black 1px solid" valign="bottom" width=
"1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" style="BORDER-BOTTOM: black 1px solid" valign=
"bottom" width="9%" align="right">175,000</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#CCEEFF">
<td valign="top">
<p style="MARGIN: 0px" align="justify">Net total</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: black 3px double" valign="bottom" width=
"1%">$</td>
<td id="ffcell" style="BORDER-BOTTOM: black 3px double" valign=
"bottom" width="9%" align="right">364,000</td>
<td style="PADDING-BOTTOM: 3px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: black 3px double" valign="bottom" width=
"1%">$</td>
<td id="ffcell" style="BORDER-BOTTOM: black 3px double" valign=
"bottom" width="9%" align="right">289,000</td>
<td style="PADDING-BOTTOM: 3px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
</table>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px"><u>Short Term Notes Payable to
Stockholders</u></p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"></p>
<table style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN"
cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td valign="top" width="4%">(A)</td>
<td valign="top">In 2012, the Company issued a short term note
payable to a non-affiliate stockholder. The note was scheduled to
mature on December 31, 2013 and accrued interest at seven and
one-half (7.5) percent per annum. In February 2016, the noteholder
provided the Company with an additional $1,000. As of March 31,
2018, the outstanding balance was $114,000. The Company is
currently in default and is in discussions with the noteholder to
restructure the terms of the note.</td>
</tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr>
<td valign="top">(B)</td>
<td valign="top">In 2017, the Company issued short term notes
payable to a non-affiliate stockholder. The notes were scheduled to
mature on June 30, 2017 and accrued no interest. In addition, the
Company issued to the noteholder 50,000 shares of the Company’s
common stock. In connection with the issuance of the 50,000 shares
of stock, the Company recorded the approximate $26,000 value of the
shares issued as debt discount cost. The expense has been fully
amortized at June 30, 2017. The Company used a recent sale of stock
to an independent third party for cash to determine the fair market
value of the transaction. As of June 30, 2017, the outstanding
principal balance was $175,000. On August 29, 2017, the Company
issued a $250,000 amended and consolidated note payable. The
amended and consolidated note payable is a consolidation of the
$175,000 notes payable and an additional $75,000. The amended and
consolidated promissory note was scheduled to mature on December
31, 2017 and accrues no interest. In addition, the Company issued
to the noteholder 200,000 shares of the Company’s common stock (see
Note 7). In connection with the issuance of the 200,000 shares of
stock, the Company recorded the approximate $30,000 value of the
shares issued as loss on extinguishment of debt. The Company is
currently in default and is in discussions with the noteholder to
restructure the terms of the note.</td>
</tr>
</table>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"></p>
<table id="pagebreakd86a0b2f-70bb-4d47-aece-de2b7fdf3b9b" class=
"pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0"
cellpadding="0" width="100%" border="0">
<tr>
<td class="hpbhr">&nbsp;</td>
</tr>
<tr>
<td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center">
13</td>
</tr>
<tr>
<td>
<div style=
"WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div>
&nbsp;</td>
</tr>
<tr>
<td><i><a href="#TOC">Table of Contents</a></i></td>
</tr>
</table>
<p style="MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0in" align=
"center">&nbsp;</p>
<p style="MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0in" align=
"center"><b>CEREBAIN BIOTECH CORP. AND SUBSIDIARY</b></p>
<p style="MARGIN: 0px" align="center"><b>NOTES TO THE UNAUDITED
CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</b></p>
<p style="MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0in" align=
"center"><b>FOR THE THREE AND NINE MONTH PERIODS ENDED MARCH 31,
2018 AND 2017</b></p>
&nbsp;
<p style="MARGIN: 0px"><u>Short Term Convertible Notes
Payable</u></p>
<p style="MARGIN: 0px">&nbsp;</p>
<table style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN"
cellspacing="0" cellpadding="0" width="85%" align="center" border=
"0">
<tr>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="hdcell" style="BORDER-BOTTOM: black 1px solid" valign=
"bottom" colspan="6" align="center">
<p style="MARGIN: 0px" align="center"><b>Short Term
Convertible</b></p>
<p style="MARGIN: 0px" align="center"><b>Notes Payable</b></p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="hdcell" style="BORDER-BOTTOM: 1px solid; MARGIN: 0px"
valign="bottom" width="9%" colspan="2" align="center">
<p style="MARGIN: 0px"><b>March31,</b></p>
<p style="MARGIN: 0px"><b>2018</b></p>
</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="hdcell" style="BORDER-BOTTOM: 1px solid" valign="bottom"
width="9%" colspan="2" align="center">
<p style="MARGIN: 0px" align="center"><b>June 30,</b></p>
<p style="MARGIN: 0px" align="center"><b>2017</b></p>
</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#CCEEFF">
<td valign="top">
<p style="MARGIN: 0px" align="justify">Crown Bridge Partners</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">$</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
65,000</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">$</td>
<td id="ffcell" valign="bottom" width="9%" align="right">-</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#FFFFFF">
<td valign="top">
<p style="MARGIN: 0px" align="justify">Auctus Fund</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
110,000</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">-</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#CCEEFF">
<td valign="top">
<p style="MARGIN: 0px" align="justify">EMA Financial</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: 1px solid" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" style="BORDER-BOTTOM: 1px solid" valign="bottom"
width="9%" align="right">110,000</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: 1px solid" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" style="BORDER-BOTTOM: 1px solid" valign="bottom"
width="9%" align="right">-</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#FFFFFF">
<td valign="top">
<p style="MARGIN: 0px" align="justify">Subtotal</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: 1px solid" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" style="BORDER-BOTTOM: 1px solid" valign="bottom"
width="9%" align="right">285,000</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: 1px solid" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" style="BORDER-BOTTOM: 1px solid" valign="bottom"
width="9%" align="right">-</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#CCEEFF">
<td valign="top">
<p style="MARGIN: 0px 0px 0px 15px" align="justify">Debt
discount</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: 1px solid" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" style="BORDER-BOTTOM: 1px solid" valign="bottom"
width="9%" align="right">(261,250</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">)</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: 1px solid" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" style="BORDER-BOTTOM: 1px solid" valign="bottom"
width="9%" align="right">-</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#FFFFFF">
<td valign="top">
<p style="MARGIN: 0px" align="justify">Net total</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: 3px double" valign="bottom" width="1%">
$</td>
<td id="ffcell" style="BORDER-BOTTOM: 3px double" valign="bottom"
width="9%" align="right">23,750</td>
<td style="PADDING-BOTTOM: 3px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: 3px double" valign="bottom" width="1%">
$</td>
<td id="ffcell" style="BORDER-BOTTOM: 3px double" valign="bottom"
width="9%" align="right">-</td>
<td style="PADDING-BOTTOM: 3px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
</table>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"><u>Crown Bridge
Partners</u></p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">On March 2, 2018, the
Company held an initial closing under a Securities Purchase
Agreement (the “Crown SPA”) and corresponding Convertible
Promissory Note (the “Crown Note”) with Crown Bridge Partners, LLC
(“Crown”), dated February 14, 2018. Under the Crown SPA and the
Crown Note, Crown agreed to loan the Company up to One Hundred
Thirty Thousand Dollars ($130,000) in tranches. The Crown Note has
an original issuance discount of $13,000, meaning the maximum
amount the Company can borrow under the Crown Note is $117,000. The
initial tranche on March 2, 2018 was $65,000, with the Company
receiving $58,500 and the remaining $6,500 being retained by Crown
as the portion of the prorated original issuance discount. The
Crown Note bears interest at Ten Percent (10%) per annum and
matures twelve (12) months from the date of each tranche, with the
initial tranche of $65,000 maturing on March 2, 2019. Under the
terms of the Crown Note, Crown has the right, at any time to
convert all or part of the amounts due to it under the Crown Note
into shares of the Company’s common stock. The conversion price is
55% of the lesser of (a) the lowest traded price or (b) the lowest
closing bid price, of the Company’s common stock on the twenty-five
trading days prior to the conversion date. However, Crown may not
convert the amounts due under the Note into shares of the Company’s
common stock if such conversion would cause it to own more than
4.99% of the Company’s then-outstanding common stock, which
limitation may be waived by Crown upon 61 days-notice. In the event
the Company defaults under the terms of the Crown Note, the Company
owes 150% of the principal amount then due under the Note, plus any
unpaid interest, immediately. The Company may prepay the amounts
loaned to the Company under the Crown Note as follows: (i) during
the initial 60-day period after each tranche, at 125% multiplied by
the amount the Company is prepaying, (ii) during the 61st through
120 days after each tranche, at 135% multiplied by the amount the
Company is prepaying, and (iii) during the 121st through 180th day
after each tranche, at 150% multiplied by the amount the Company is
prepaying. Any prepayments are subject to Crown’s written
acceptance of such prepayment. After 180 days from each tranche the
Company cannot prepay that tranche in cash.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"></p>
<table id="pagebreak269a4210-3256-455f-bee4-bdeb529cbea7" class=
"pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0"
cellpadding="0" width="100%" border="0">
<tr>
<td class="hpbhr">&nbsp;</td>
</tr>
<tr>
<td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center">
14</td>
</tr>
<tr>
<td>
<div style=
"WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div>
&nbsp;</td>
</tr>
<tr>
<td><i><a href="#TOC">Table of Contents</a></i></td>
</tr>
</table>
<p style="MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0in" align=
"center">&nbsp;</p>
<p style="MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0in" align=
"center"><b>CEREBAIN BIOTECH CORP. AND SUBSIDIARY</b></p>
<p style="MARGIN: 0px" align="center"><b>NOTES TO THE UNAUDITED
CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</b></p>
<p style="MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0in" align=
"center"><b>FOR THE THREE AND NINE MONTH PERIODS ENDED MARCH 31,
2018 AND 2017</b></p>
&nbsp;
<p style="MARGIN: 0px" align="justify">While this Note is
outstanding, if the Company enters into a Section 3(a)(9)
transaction, as defined by the Securities Act, (including but not
limited to the issuance of new promissory notes or of a replacement
promissory note), or Section 3(a)(10) transaction, as defined by
the Securities Act, in which any 3rd party has the right to convert
monies owed to that 3rd party (or receive shares pursuant to a
settlement or otherwise) at a discount to market greater than the
Variable Conversion Price in effect at that time (prior to all
other applicable adjustments in the Note), then the Variable
Conversion Price shall be automatically adjusted to such greater
discount percentage (prior to all applicable adjustments in this
Note) until this Note is no longer outstanding. Each time, while
this Note is outstanding, the Company enters into a Section 3(a)(9)
transaction, as defined by the Securities Act, (including but not
limited to the issuance of new promissory notes or of a replacement
promissory note), or Section 3(a)(10) transaction, as defined by
the Securities Act, in which any 3rd party has a look back period
greater than the look back period in effect under the Note at that
time, then the Holder’s look back period shall automatically be
adjusted to such greater number of days until this Note is no
longer outstanding.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">In addition to issuing the
Crown Note, the Company agreed to issue Crown a warrant with each
funding tranche. Each warrant will be for the purchase of shares of
the Company’s common stock equal to 75% of the face value of the
tranche divided by $0.50. For example, the first tranche of funding
is for $65,000, the Company issued a warrant to purchase 97,500
shares of the Company’s common stock at an exercise price of $0.50
per share. The warrant contains a cashless exercise provision. Each
warrant expires five years after the date of issuance.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">In connection with the
warrants, if the Company, at any time from and after the Issuance
Date, shall sell or grant any option to purchase, or sell or grant
any right to reprice, or otherwise dispose of, sell or issue (or
announce any offer, sale, grant or any option to purchase or other
disposition of) any Common Stock or Common Stock Equivalents
entitling any person, firm, association or entity to acquire shares
of Common Stock at an effective price per share less than the
then-current Exercise Price (including but not limited to under the
Note), as adjusted hereunder (any such issuance being referred to
as a “<u>Dilutive Issuance</u>,” subject, however, to the provision
contained in the further definition of the term “Dilutive Issuance”
contained in the agreement, then (a) the Exercise Price shall be
adjusted to match the lowest price per share at which such Common
Stock was issued or may be acquired pursuant to such Common Stock
Equivalents in the Dilutive Issuance, and (b) the number of Warrant
Shares issuable upon the exercise of this Warrant shall be
increased to an amount equal to the number of Warrant Shares Holder
could purchase hereunder for the aggregate Exercise Price, as
reduced pursuant to the agreement, equal to the aggregate Exercise
Price payable immediately prior to such reduction in Exercise
Price. Additionally, following the occurrence of a Dilutive
Issuance, all references in this Warrant to “Warrant Shares” shall
be a reference to the Warrant Shares as increased pursuant to the
agreement, and all references in this Warrant to “Exercise Price”
shall be a reference to the Exercise Price as reduced pursuant to
the agreement, as the same may occur from time to time hereunder.
Subject to the anti-dilution provision, the Company adjusted Crown’
s warrant to purchase 243,750 shares of our common stock at an
exercise price of $0.20 per share as a result of the warrant issued
to Auctus Fund on March 8, 2018.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"><u>Auctus Fund</u></p>
<p style="MARGIN: 0px; TEXT-INDENT: 33.75pt" align="justify">
&nbsp;</p>
<p style="MARGIN: 0px" align="justify">On March 8, 2018, the
Company closed a Securities Purchase Agreement (the “Auctus SPA”)
and corresponding Convertible Promissory Note (the “Auctus Note”)
with Auctus Fund, LLC (“Auctus”), dated February 15, 2018. Under
the Auctus SPA and the Auctus Note, Auctus agreed to loan the
Company One Hundred Ten Thousand Dollars ($110,000). The Auctus
Note bears interest at Ten Percent (10%) per annum and matures on
November 15, 2018. Under the terms of the Auctus Note, Auctus has
the right, at any time to convert all or part of the amounts due to
it under the Auctus Note into shares of the Company’s common stock.
The conversion price is 55% multiplied by the lowest Trading Price
during the twenty-five trading days prior to the conversion date.
However, Auctus may not convert the amounts due under the Note into
shares of the Company’s common stock if such conversion would cause
it to own more than 4.99% of the Company’s then-outstanding common
stock, which limitation may be waived by Auctus upon 61
days-notice. In the event the Company defaults under the terms of
the Auctus Note, the Company owes 150% of the principal amount then
due under the Note, plus any unpaid interest, immediately. The
Company may prepay the amounts loaned to the Company under the
Auctus Note as follows: (i) during the initial 90-day period after
the issue date, at 135% multiplied by the amount the Company is
prepaying, and (ii) from the 91st through the 180th day after the
issue date, at 150% multiplied by the amount the Company is
prepaying. Any prepayments are subject to Auctus’ written
acceptance of such prepayment. After 180 days from the issue date
the Company cannot prepay the Auctus Note.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<table id="pagebreaka55e65f5-3587-426f-9331-e860b89c575a" class=
"pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0"
cellpadding="0" width="100%" border="0">
<tr>
<td class="hpbhr">&nbsp;</td>
</tr>
<tr>
<td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center">
15</td>
</tr>
<tr>
<td>
<div style=
"WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div>
&nbsp;</td>
</tr>
<tr>
<td><i><a href="#TOC">Table of Contents</a></i></td>
</tr>
</table>
<p style="MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0in" align=
"center">&nbsp;</p>
<p style="MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0in" align=
"center"><b>CEREBAIN BIOTECH CORP. AND SUBSIDIARY</b></p>
<p style="MARGIN: 0px" align="center"><b>NOTES TO THE UNAUDITED
CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</b></p>
<p style="MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0in" align=
"center"><b>FOR THE THREE AND NINE MONTH PERIODS ENDED MARCH 31,
2018 AND 2017</b></p>
&nbsp;
<p style="MARGIN: 0px" align="justify">While this Note is
outstanding, if the Company enters into a Section 3(a)(9)
transaction, as defined by the Securities Act, (including but not
limited to the issuance of new promissory notes or of a replacement
promissory note), or Section 3(a)(10) transaction, as defined by
the Securities Act, in which any 3rd party has the right to convert
monies owed to that 3rd party (or receive shares pursuant to a
settlement or otherwise) at a discount to market greater than the
Variable Conversion Price in effect at that time (prior to all
other applicable adjustments in the Note), then the Variable
Conversion Price shall be automatically adjusted to such greater
discount percentage (prior to all applicable adjustments in this
Note) until this Note is no longer outstanding. Each time, while
this Note is outstanding, the Company enters into a Section 3(a)(9)
transaction, as defined by the Securities Act, (including but not
limited to the issuance of new promissory notes or of a replacement
promissory note), or Section 3(a)(10) transaction, as defined by
the Securities Act, in which any 3rd party has a look back period
greater than the look back period in effect under the Note at that
time, then the Holder’s look back period shall automatically be
adjusted to such greater number of days until this Note is no
longer outstanding.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">In addition to issuing the
Auctus Note, the Company agreed to issue Auctus a warrant to
acquire 275,000 shares of the Company’s common stock at an exercise
price of $0.20 per share. The warrant contains a cashless exercise
provision and expires on the fifth anniversary of the warrant.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">In connection with the
warrants, if the Company, at any time from and after the Issuance
Date, shall sell or grant any option to purchase, or sell or grant
any right to reprice, or otherwise dispose of, sell or issue (or
announce any offer, sale, grant or any option to purchase or other
disposition of) any Common Stock or Common Stock Equivalents
entitling any person, firm, association or entity to acquire shares
of Common Stock at an effective price per share less than the
then-current Exercise Price (including but not limited to under the
Note), as adjusted hereunder (any such issuance being referred to
as a “<u>Dilutive Issuance</u>,” subject, however, to the proviso
contained in the further definition of the term “Dilutive Issuance”
contained in the agreement, then (a) the Exercise Price shall be
adjusted to match the lowest price per share at which such Common
Stock was issued or may be acquired pursuant to such Common Stock
Equivalents in the Dilutive Issuance, and (b) the number of Warrant
Shares issuable upon the exercise of this Warrant shall be
increased to an amount equal to the number of Warrant Shares Holder
could purchase hereunder for the aggregate Exercise Price, as
reduced pursuant to the agreement, equal to the aggregate Exercise
Price payable immediately prior to such reduction in Exercise
Price. Additionally, following the occurrence of a Dilutive
Issuance, all references in this Warrant to “Warrant Shares” shall
be a reference to the Warrant Shares as increased pursuant to the
agreement, and all references in this Warrant to “Exercise Price”
shall be a reference to the Exercise Price as reduced pursuant to
the agreement, as the same may occur from time to time
hereunder.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"><u>EMA Financial</u></p>
<p style="MARGIN: 0px; TEXT-INDENT: 33.75pt" align="justify">
&nbsp;</p>
<p style="MARGIN: 0px" align="justify">On March 8, 2018, the
Company closed a Securities Purchase Agreement (the “EMA SPA”) and
corresponding Convertible Promissory Note (the “EMA Note”) with EMA
Financial, LLC (“EMA”), dated February 12, 2018. Under the EMA SPA
and the EMA Note, EMA agreed to loan the Company One Hundred Ten
Thousand Dollars ($110,000). The EMA Note has an original issuance
discount of $6,600, meaning the amount the Company received at
funding was $103,400. The EMA Note bears interest at Ten Percent
(10%) per annum and matures on February 12, 2019. Under the terms
of the EMA Note, EMA has the right, at any time to convert all or
part of the amounts due to it under the EMA Note into shares of the
Company’s common stock. The conversion price is 55% multiplied by
the lowest Trading Price during the twenty trading days prior to
the conversion date. However, EMA may not convert the amounts due
under the Note into shares of the Company’s common stock if such
conversion would cause it to own more than 4.99% of the Company’s
then-outstanding common stock, which limitation may be waived by
EMA upon 61 days-notice. In the event the Company defaults under
the terms of the EMA Note, the Company owes 150% of the principal
amount then due under the Note, plus any unpaid interest,
immediately. The Company may prepay the amounts loaned to the
Company under the EMA Note as follows: (i) during the initial
90-day period after the issue date, at 135% multiplied by the
amount the Company is prepaying, and (ii) from the 91st through the
180th day after the issue date, at 150% multiplied by the amount
the Company is prepaying. Any prepayments are subject to EMA’s
written acceptance of such prepayment. After 180 days from the
issue date the Company cannot prepay the EMA Note.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<table id="pagebreak07f8f067-46fc-40b1-8c0f-d304953cafc2" class=
"pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0"
cellpadding="0" width="100%" border="0">
<tr>
<td class="hpbhr">&nbsp;</td>
</tr>
<tr>
<td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center">
16</td>
</tr>
<tr>
<td>
<div style=
"WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div>
&nbsp;</td>
</tr>
<tr>
<td><i><a href="#TOC">Table of Contents</a></i></td>
</tr>
</table>
<p style="MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0in" align=
"center">&nbsp;</p>
<p style="MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0in" align=
"center"><b>CEREBAIN BIOTECH CORP. AND SUBSIDIARY</b></p>
<p style="MARGIN: 0px" align="center"><b>NOTES TO THE UNAUDITED
CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</b></p>
<p style="MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0in" align=
"center"><b>FOR THE THREE AND NINE MONTH PERIODS ENDED MARCH 31,
2018 AND 2017</b></p>
&nbsp;
<p style="MARGIN: 0px" align="justify">While this Note is
outstanding, if the Company enters into a Section 3(a)(9)
transaction, as defined by the Securities Act, (including but not
limited to the issuance of new promissory notes or of a replacement
promissory note), or Section 3(a)(10) transaction, as defined by
the Securities Act, in which any 3rd party has the right to convert
monies owed to that 3rd party (or receive shares pursuant to a
settlement or otherwise) at a discount to market greater than the
Variable Conversion Price in effect at that time (prior to all
other applicable adjustments in the Note), then the Variable
Conversion Price shall be automatically adjusted to such greater
discount percentage (prior to all applicable adjustments in this
Note) until this Note is no longer outstanding. Each time, while
this Note is outstanding, the Company enters into a Section 3(a)(9)
transaction, as defined by the Securities Act, (including but not
limited to the issuance of new promissory notes or of a replacement
promissory note), or Section 3(a)(10) transaction, as defined by
the Securities Act, in which any 3rd party has a look back period
greater than the look back period in effect under the Note at that
time, then the Holder’s look back period shall automatically be
adjusted to such greater number of days until this Note is no
longer outstanding.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">In addition to issuing the
EMA Note, the Company agreed to issue EMA a warrant to acquire
137,500 shares of the Company’s common stock at an exercise price
of $0.40 per share. The warrant contains a cashless exercise
provision and expires on the fifth anniversary of the warrant.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">In connection with the
warrants, if the Company, at any time from and after the Issuance
Date, shall sell or grant any option to purchase, or sell or grant
any right to reprice, or otherwise dispose of, sell or issue (or
announce any offer, sale, grant or any option to purchase or other
disposition of) any Common Stock or Common Stock Equivalents
entitling any person, firm, association or entity to acquire shares
of Common Stock at an effective price per share less than the
then-current Exercise Price (including but not limited to under the
Note), as adjusted hereunder (any such issuance being referred to
as a “<u>Dilutive Issuance</u>,” subject, however, to the proviso
contained in the further definition of the term “Dilutive Issuance”
contained in the agreement, then (a) the Exercise Price shall be
adjusted to match the lowest price per share at which such Common
Stock was issued or may be acquired pursuant to such Common Stock
Equivalents in the Dilutive Issuance, and (b) the number of Warrant
Shares issuable upon the exercise of this Warrant shall be
increased to an amount equal to the number of Warrant Shares Holder
could purchase hereunder for the aggregate Exercise Price, as
reduced pursuant to the agreement, equal to the aggregate Exercise
Price payable immediately prior to such reduction in Exercise
Price. Additionally, following the occurrence of a Dilutive
Issuance, all references in this Warrant to “Warrant Shares” shall
be a reference to the Warrant Shares as increased pursuant to the
agreement, and all references in this Warrant to “Exercise Price”
shall be a reference to the Exercise Price as reduced pursuant to
the agreement, as the same may occur from time to time hereunder.
Subject to the anti-dilution provision and as a result of the
warrant issued to Auctus detailed above, the Company issued EMA an
amended and restated warrant to purchase 275,000 shares of our
common stock at an exercise price of $0.20 per share, which
replaced the original warrant issued to EMA.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"><u>Short Term Convertible
Notes Conversion</u></p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">The Company evaluated the
notes under the requirements of ASC 480 “Distinguishing Liabilities
From Equity” (ASC 480) and concluded that the notes do not fall
within the scope of ASC 480. The Company next evaluated the notes
under the requirements of ASC 815 “Derivatives and Hedging”. Due to
the existence of the anti-dilution provisions which reduces the
purchaser’s conversion price in the event of subsequent dilutive
issuances by the Company below the purchaser’s conversion price as
described above, the conversion features do not meet the definition
of “indexed to” the Company’s stock, and the scope exception to ASC
815’s derivative accounting provisions does not apply. The Company
also evaluated the embedded derivative criteria in ASC 815, and
concluded that the conversion features meet all the embedded
derivative criteria in ASC 815, and therefore, the conversion
features meet the definition of an embedded derivative that should
be separated from the notes and accounted for as a derivative
liabilities.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<table id="pagebreak6fa6b3b1-0be6-4c9b-90f9-7f777f375fe5" class=
"pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0"
cellpadding="0" width="100%" border="0">
<tr>
<td class="hpbhr">&nbsp;</td>
</tr>
<tr>
<td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center">
17</td>
</tr>
<tr>
<td>
<div style=
"WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div>
&nbsp;</td>
</tr>
<tr>
<td><i><a href="#TOC">Table of Contents</a></i></td>
</tr>
</table>
<p style="MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0in" align=
"center">&nbsp;</p>
<p style="MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0in" align=
"center"><b>CEREBAIN BIOTECH CORP. AND SUBSIDIARY</b></p>
<p style="MARGIN: 0px" align="center"><b>NOTES TO THE UNAUDITED
CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</b></p>
<p style="MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0in" align=
"center"><b>FOR THE THREE AND NINE MONTH PERIODS ENDED MARCH 31,
2018 AND 2017</b></p>
&nbsp;
<p style="MARGIN: 0px" align="justify">The embedded derivatives
were recorded as a derivative liabilities on the consolidated
Balance Sheet at its fair value of $330,000 at the date of
issuance. At each subsequent reporting date, the fair value of the
embedded derivative liabilities will be remeasured and changes in
the fair value will be recorded in the consolidated Statements of
Operations. At March 31, 2018, the embedded derivatives were
re-measured at fair value that was determined to be $320,000.
During the three and nine months ended March 31, 2018, the Company
recorded a gain on embedded derivative re-valuation of $10,000 and
$10,000, respectively.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">The fair value of the
embedded derivative liabilities are measured in accordance with ASC
820 “Fair Value Measurement”, using the “Monte Carlo Method”
modeling incorporating the following inputs:</p>
<p style="MARGIN: 0px">&nbsp;</p>
<table style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN"
cellspacing="0" cellpadding="0" width="85%" align="center" border=
"0">
<tr>
<td valign="bottom"></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="hdcell" valign="bottom" colspan="2" align="center">
<p style="MARGIN: 0px" align="center"><b>March 31,</b></p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="hdcell" valign="bottom" colspan="2" align="center">
<p style="MARGIN: 0px" align="center"><b>March 2,</b></p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr>
<td style="BORDER-BOTTOM: black 1px solid" valign="bottom">
<p style="MARGIN: 0px"><b>Crown Bridge Partners</b></p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="hdcell" style="BORDER-BOTTOM: 1px solid" valign="bottom"
width="9%" colspan="2" align="center">
<p style="MARGIN: 0px" align="center"><b>2018</b></p>
</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="hdcell" style="BORDER-BOTTOM: 1px solid" valign="bottom"
width="9%" colspan="2" align="center">
<p style="MARGIN: 0px" align="center"><b>2018</b></p>
</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" colspan="2" align=
"right">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" colspan="2" align=
"right">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#CCEEFF">
<td valign="top">
<p style="MARGIN: 0px">Expected dividend yield</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">0.00</td>
<td valign="bottom" width="1%">%</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">0.00</td>
<td valign="bottom" width="1%">%</td>
</tr>
<tr bgcolor="#FFFFFF">
<td valign="top">
<p style="MARGIN: 0px">Expected stock-price volatility</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">260.0</td>
<td valign="bottom" width="1%">%</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">255.0</td>
<td valign="bottom" width="1%">%</td>
</tr>
<tr bgcolor="#CCEEFF">
<td valign="top">
<p style="MARGIN: 0px">Risk-free interest rate</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">2.01</td>
<td valign="bottom" width="1%">%</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">2.06</td>
<td valign="bottom" width="1%">%</td>
</tr>
<tr bgcolor="#FFFFFF">
<td valign="top">
<p style="MARGIN: 0px">Stock price</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">$</td>
<td id="ffcell" valign="bottom" width="9%" align="right">0.15</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">$</td>
<td id="ffcell" valign="bottom" width="9%" align="right">0.18</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#CCEEFF">
<td valign="top">
<p style="MARGIN: 0px">Conversion price</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">$</td>
<td id="ffcell" valign="bottom" width="9%" align="right">0.05</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">$</td>
<td id="ffcell" valign="bottom" width="9%" align="right">0.06</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
</table>
<p style="MARGIN: 0px">&nbsp;</p>
<table style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN"
cellspacing="0" cellpadding="0" width="85%" align="center" border=
"0">
<tr>
<td valign="bottom"></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="hdcell" valign="bottom" colspan="2" align="center">
<p style="MARGIN: 0px" align="center"><b>March 31,</b></p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="hdcell" valign="bottom" colspan="2" align="center">
<p style="MARGIN: 0px" align="center"><b>March 8,</b></p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr>
<td style="BORDER-BOTTOM: black 1px solid" valign="bottom">
<p style="MARGIN: 0px"><b>Auctus Fund</b></p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="hdcell" style="BORDER-BOTTOM: 1px solid" valign="bottom"
width="9%" colspan="2" align="center">
<p style="MARGIN: 0px" align="center"><b>2018</b></p>
</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="hdcell" style="BORDER-BOTTOM: 1px solid" valign="bottom"
width="9%" colspan="2" align="center">
<p style="MARGIN: 0px" align="center"><b>2018</b></p>
</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" colspan="2" align=
"right">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" colspan="2" align=
"right">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#CCEEFF">
<td valign="top">
<p style="MARGIN: 0px">Expected dividend yield</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">0.00</td>
<td valign="bottom" width="1%">%</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">0.00</td>
<td valign="bottom" width="1%">%</td>
</tr>
<tr bgcolor="#FFFFFF">
<td valign="top">
<p style="MARGIN: 0px">Expected stock-price volatility</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">255.0</td>
<td valign="bottom" width="1%">%</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">275.0</td>
<td valign="bottom" width="1%">%</td>
</tr>
<tr bgcolor="#CCEEFF">
<td valign="top">
<p style="MARGIN: 0px">Risk-free interest rate</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">2.01</td>
<td valign="bottom" width="1%">%</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">1.97</td>
<td valign="bottom" width="1%">%</td>
</tr>
<tr bgcolor="#FFFFFF">
<td valign="top">
<p style="MARGIN: 0px">Stock price</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">$</td>
<td id="ffcell" valign="bottom" width="9%" align="right">0.15</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">$</td>
<td id="ffcell" valign="bottom" width="9%" align="right">0.16</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#CCEEFF">
<td valign="top">
<p style="MARGIN: 0px">Conversion price</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">$</td>
<td id="ffcell" valign="bottom" width="9%" align="right">0.05</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">$</td>
<td id="ffcell" valign="bottom" width="9%" align="right">0.05</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
</table>
<p style="MARGIN: 0px">&nbsp;</p>
<table style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN"
cellspacing="0" cellpadding="0" width="85%" align="center" border=
"0">
<tr>
<td valign="bottom"></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="hdcell" valign="bottom" colspan="2" align="center">
<p style="MARGIN: 0px" align="center"><b>March 31,</b></p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="hdcell" valign="bottom" colspan="2" align="center">
<p style="MARGIN: 0px" align="center"><b>March 8,</b></p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr>
<td style="BORDER-BOTTOM: black 1px solid" valign="bottom">
<p style="MARGIN: 0px"><b>EMA Financial</b></p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="hdcell" style="BORDER-BOTTOM: 1px solid" valign="bottom"
width="9%" colspan="2" align="center">
<p style="MARGIN: 0px" align="center"><b>2018</b></p>
</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="hdcell" style="BORDER-BOTTOM: 1px solid" valign="bottom"
width="9%" colspan="2" align="center">
<p style="MARGIN: 0px" align="center"><b>2018</b></p>
</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" colspan="2" align=
"right">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" colspan="2" align=
"right">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#CCEEFF">
<td valign="top">
<p style="MARGIN: 0px">Expected dividend yield</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">0.00</td>
<td valign="bottom" width="1%">%</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">0.00</td>
<td valign="bottom" width="1%">%</td>
</tr>
<tr bgcolor="#FFFFFF">
<td valign="top">
<p style="MARGIN: 0px">Expected stock-price volatility</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">270.0</td>
<td valign="bottom" width="1%">%</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">265.0</td>
<td valign="bottom" width="1%">%</td>
</tr>
<tr bgcolor="#CCEEFF">
<td valign="top">
<p style="MARGIN: 0px">Risk-free interest rate</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">2.01</td>
<td valign="bottom" width="1%">%</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">2.05</td>
<td valign="bottom" width="1%">%</td>
</tr>
<tr bgcolor="#FFFFFF">
<td valign="top">
<p style="MARGIN: 0px">Stock price</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">$</td>
<td id="ffcell" valign="bottom" width="9%" align="right">0.15</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">$</td>
<td id="ffcell" valign="bottom" width="9%" align="right">0.16</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#CCEEFF">
<td valign="top">
<p style="MARGIN: 0px">Conversion price</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">$</td>
<td id="ffcell" valign="bottom" width="9%" align="right">0.05</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">$</td>
<td id="ffcell" valign="bottom" width="9%" align="right">0.06</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
</table>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"><u>Short Term Convertible
Notes Warrants</u></p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">The Company evaluated the
Warrants under ASC 480 “Distinguishing Liabilities From Equity” and
ASC 815 “Derivatives and Hedging”. Due to the existence of the
antidilution provision, which reduces the Exercise Price and
Conversion Price in the event of subsequent issuances, the Warrants
are not indexed to our common stock, and the Company has determined
that the Warrants meet the definition of a derivative under ASC
815. Accordingly, the Warrants were recorded as derivative
liabilities in the consolidated Balance Sheet at their fair value
of $96,289 at the date of issuance. At each subsequent reporting
date, the fair value of the Warrants will be remeasured and changes
in the fair value will be reported in the consolidated Statements
of Operations. At March 31, 2018, the warrant liability was
re-measured at fair value that was determined to be $96,903. During
the three and nine months ended March 31, 2018, the Company
recorded a loss on warrant re-valuation of $614 and $614,
respectively.</p>
<p style="MARGIN: 0px">&nbsp;</p>
<table id="pagebreakf0e93c50-c187-4482-8fda-98092006a0dd" class=
"pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0"
cellpadding="0" width="100%" border="0">
<tr>
<td class="hpbhr">&nbsp;</td>
</tr>
<tr>
<td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center">
18</td>
</tr>
<tr>
<td>
<div style=
"WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div>
&nbsp;</td>
</tr>
<tr>
<td><i><a href="#TOC">Table of Contents</a></i></td>
</tr>
</table>
<p style="MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0in" align=
"center">&nbsp;</p>
<p style="MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0in" align=
"center"><b>CEREBAIN BIOTECH CORP. AND SUBSIDIARY</b></p>
<p style="MARGIN: 0px" align="center"><b>NOTES TO THE UNAUDITED
CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</b></p>
<p style="MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0in" align=
"center"><b>FOR THE THREE AND NINE MONTH PERIODS ENDED MARCH 31,
2018 AND 2017</b></p>
&nbsp;
<p style="MARGIN: 0px" align="justify">The fair value of the
Warrants is measured in accordance with ASC 820 “Fair Value
Measurement”, using “Monte Carlo simulation” modeling,
incorporating the following inputs:</p>
<p style="MARGIN: 0px">&nbsp;</p>
<table style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN"
cellspacing="0" cellpadding="0" width="85%" align="center" border=
"0">
<tr>
<td style="BORDER-BOTTOM: black 1px solid" valign="bottom">
<p style="MARGIN: 0px"><b>Crown Bridge Partners</b></p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="hdcell" style="BORDER-BOTTOM: 1px solid" valign="bottom"
width="9%" colspan="2" align="center">
<p style="MARGIN: 0px" align="center"><b>March 31,</b></p>
<p style="MARGIN: 0px" align="center"><b>2018</b></p>
</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="hdcell" style="BORDER-BOTTOM: 1px solid" valign="bottom"
width="9%" colspan="2" align="center">
<p style="MARGIN: 0px" align="center"><b>March 3,</b></p>
<p style="MARGIN: 0px" align="center"><b>2018</b></p>
</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" colspan="2" align=
"right">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" colspan="2" align=
"right">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#CCEEFF">
<td valign="top">
<p style="MARGIN: 0px">Expected dividend yield</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">0.00</td>
<td valign="bottom" width="1%">%</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">0.00</td>
<td valign="bottom" width="1%">%</td>
</tr>
<tr bgcolor="#FFFFFF">
<td valign="top">
<p style="MARGIN: 0px">Expected stock-price volatility</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">215.0</td>
<td valign="bottom" width="1%">%</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">215.0</td>
<td valign="bottom" width="1%">%</td>
</tr>
<tr bgcolor="#CCEEFF">
<td valign="top">
<p style="MARGIN: 0px">Risk-free interest rate</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">2.56</td>
<td valign="bottom" width="1%">%</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">2.63</td>
<td valign="bottom" width="1%">%</td>
</tr>
<tr bgcolor="#FFFFFF">
<td valign="top">
<p style="MARGIN: 0px">Stock price</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">$</td>
<td id="ffcell" valign="bottom" width="9%" align="right">0.15</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">$</td>
<td id="ffcell" valign="bottom" width="9%" align="right">0.18</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#CCEEFF">
<td valign="top">
<p style="MARGIN: 0px">Exercise price</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">$</td>
<td id="ffcell" valign="bottom" width="9%" align="right">0.20</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">$</td>
<td id="ffcell" valign="bottom" width="9%" align="right">0.50</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
</table>
<p style="MARGIN: 0px">&nbsp;</p>
<table style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN"
cellspacing="0" cellpadding="0" width="85%" align="center" border=
"0">
<tr>
<td style="BORDER-BOTTOM: black 1px solid" valign="bottom">
<p style="MARGIN: 0px"><b>Auctus Fund</b></p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="hdcell" style="BORDER-BOTTOM: 1px solid" valign="bottom"
width="9%" colspan="2" align="center">
<p style="MARGIN: 0px" align="center"><b>March 31,</b></p>
<p style="MARGIN: 0px" align="center"><b>2018</b></p>
</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="hdcell" style="BORDER-BOTTOM: 1px solid" valign="bottom"
width="9%" colspan="2" align="center">
<p style="MARGIN: 0px" align="center"><b>March 8,</b></p>
<p style="MARGIN: 0px" align="center"><b>2018</b></p>
</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" colspan="2" align=
"right">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" colspan="2" align=
"right">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#CCEEFF">
<td valign="top">
<p style="MARGIN: 0px">Expected dividend yield</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">0.00</td>
<td valign="bottom" width="1%">%</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">0.00</td>
<td valign="bottom" width="1%">%</td>
</tr>
<tr bgcolor="#FFFFFF">
<td valign="top">
<p style="MARGIN: 0px">Expected stock-price volatility</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">215.0</td>
<td valign="bottom" width="1%">%</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">215.0</td>
<td valign="bottom" width="1%">%</td>
</tr>
<tr bgcolor="#CCEEFF">
<td valign="top">
<p style="MARGIN: 0px">Risk-free interest rate</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">2.56</td>
<td valign="bottom" width="1%">%</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">2.63</td>
<td valign="bottom" width="1%">%</td>
</tr>
<tr bgcolor="#FFFFFF">
<td valign="top">
<p style="MARGIN: 0px">Stock price</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">$</td>
<td id="ffcell" valign="bottom" width="9%" align="right">0.15</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">$</td>
<td id="ffcell" valign="bottom" width="9%" align="right">0.16</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#CCEEFF">
<td valign="top">
<p style="MARGIN: 0px">Exercise price</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">$</td>
<td id="ffcell" valign="bottom" width="9%" align="right">0.20</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">$</td>
<td id="ffcell" valign="bottom" width="9%" align="right">0.20</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
</table>
<p style="MARGIN: 0px">&nbsp;</p>
<table style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN"
cellspacing="0" cellpadding="0" width="85%" align="center" border=
"0">
<tr bgcolor="#FFFFFF">
<td style="BORDER-BOTTOM: black 1px solid" valign="bottom">
<p style="MARGIN: 0px"><b>EMA Financial</b></p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="hdcell" style="BORDER-BOTTOM: 1px solid" valign="bottom"
width="9%" colspan="2" align="center">
<p style="MARGIN: 0px" align="center"><b>March 31,</b></p>
<p style="MARGIN: 0px" align="center"><b>2018</b></p>
</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="hdcell" style="BORDER-BOTTOM: 1px solid" valign="bottom"
width="9%" colspan="2" align="center">
<p style="MARGIN: 0px" align="center"><b>March 8,</b></p>
<p style="MARGIN: 0px" align="center"><b>2018</b></p>
</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#FFFFFF">
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" colspan="2" align=
"right">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" colspan="2" align=
"right">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#CCEEFF">
<td valign="top">
<p style="MARGIN: 0px">Expected dividend yield</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">0.00</td>
<td valign="bottom" width="1%">%</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">0.00</td>
<td valign="bottom" width="1%">%</td>
</tr>
<tr bgcolor="#FFFFFF">
<td valign="top">
<p style="MARGIN: 0px">Expected stock-price volatility</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">215.0</td>
<td valign="bottom" width="1%">%</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">215.0</td>
<td valign="bottom" width="1%">%</td>
</tr>
<tr bgcolor="#CCEEFF">
<td valign="top">
<p style="MARGIN: 0px">Risk-free interest rate</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">2.56</td>
<td valign="bottom" width="1%">%</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">2.63</td>
<td valign="bottom" width="1%">%</td>
</tr>
<tr bgcolor="#FFFFFF">
<td valign="top">
<p style="MARGIN: 0px">Stock price</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">$</td>
<td id="ffcell" valign="bottom" width="9%" align="right">0.15</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">$</td>
<td id="ffcell" valign="bottom" width="9%" align="right">0.16</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#CCEEFF">
<td valign="top">
<p style="MARGIN: 0px">Exercise price</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">$</td>
<td id="ffcell" valign="bottom" width="9%" align="right">0.20</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">$</td>
<td id="ffcell" valign="bottom" width="9%" align="right">0.40</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
</table>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"><u>Debt Discount</u></p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">The Company issued the notes
with warrants that require liability treatment under ASC 815. As
such, the proceeds of the notes were allocated, based on fair
values, as follows: original issue discount of approximately
$32,000, approximately $96,000 to the warrants granted, and
approximately $330,000 to the embedded derivative, resulting in a
debt discount to such notes of approximately $285,000 with the
remaining amount of approximately $173,000 expensed at inception of
the note. The debt discount is accreted to interest expense over
the term of the note.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">The Company recorded debt
discount accretion of approximately $24,000 and $0 to interest
expense for the three and nine months ended March 31, 2018,
respectively. The accretion of debt discount expense to be
recognized in future years is approximately $261,000.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px">Changes in the derivative and warrant
liabilities were as follows:</p>
<p style="MARGIN: 0px">&nbsp;</p>
<table style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN"
cellspacing="0" cellpadding="0" width="85%" align="center" border=
"0">
<tr>
<td valign="top">
<p style="MARGIN: 0px">Derivative liabilities:</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" colspan="2" align=
"right">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#CCEEFF">
<td valign="top">
<p style="MARGIN: 0px">March 2-8, 2018</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">$</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
330,000</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#FFFFFF">
<td valign="top">
<p style="MARGIN: 0px">Increase (decrease) in fair value</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: 1px solid" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" style="BORDER-BOTTOM: 1px solid" valign="bottom"
width="9%" align="right">(10,000</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">)</td>
</tr>
<tr bgcolor="#CCEEFF">
<td valign="top">
<p style="MARGIN: 0px">March 31, 2018</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: 3px double" valign="bottom" width="1%">
$</td>
<td id="ffcell" style="BORDER-BOTTOM: 3px double" valign="bottom"
width="9%" align="right">320,000</td>
<td style="PADDING-BOTTOM: 3px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#FFFFFF">
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#CCEEFF">
<td valign="top">
<p style="MARGIN: 0px">Warrant liabilities:</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#FFFFFF">
<td valign="top">
<p style="MARGIN: 0px">March 2-8, 2018</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">$</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
96,289</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#CCEEFF">
<td valign="top">
<p style="MARGIN: 0px">Increase in fair value</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: 1px solid" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" style="BORDER-BOTTOM: 1px solid" valign="bottom"
width="9%" align="right">614</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#FFFFFF">
<td valign="top">
<p style="MARGIN: 0px">March 31, 2018</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: 3px double" valign="bottom" width="1%">
$</td>
<td id="ffcell" style="BORDER-BOTTOM: 3px double" valign="bottom"
width="9%" align="right">96,903</td>
<td style="PADDING-BOTTOM: 3px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
</table>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<table id="pagebreakd2d2cce3-faf6-4c66-a32c-d001a7df9db6" class=
"pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0"
cellpadding="0" width="100%" border="0">
<tr>
<td class="hpbhr">&nbsp;</td>
</tr>
<tr>
<td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center">
19</td>
</tr>
<tr>
<td>
<div style=
"WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div>
&nbsp;</td>
</tr>
<tr>
<td><i><a href="#TOC">Table of Contents</a></i></td>
</tr>
</table>
<p style="MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0in" align=
"center">&nbsp;</p>
<p style="MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0in" align=
"center"><b>CEREBAIN BIOTECH CORP. AND SUBSIDIARY</b></p>
<p style="MARGIN: 0px" align="center"><b>NOTES TO THE UNAUDITED
CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</b></p>
<p style="MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0in" align=
"center"><b>FOR THE THREE AND NINE MONTH PERIODS ENDED MARCH 31,
2018 AND 2017</b></p>
&nbsp;
<p style="MARGIN: 0px" align="justify"><b>Convertible Notes to
Stockholders</b></p>
<p style="MARGIN: 0px">&nbsp;</p>
<table style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN"
cellspacing="0" cellpadding="0" width="85%" align="center" border=
"0">
<tr>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="hdcell" style="BORDER-BOTTOM: black 1px solid" valign=
"bottom" colspan="6" align="center">
<p style="MARGIN: 0px" align="center"><b>Convertible Notes
Payable</b></p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="hdcell" style="BORDER-BOTTOM: 1px solid; MARGIN: 0px"
valign="bottom" width="9%" colspan="2" align="center">
<p style="MARGIN: 0px"><b>March31,</b></p>
<p style="MARGIN: 0px"><b>2018</b></p>
</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="hdcell" style="BORDER-BOTTOM: 1px solid" valign="bottom"
width="9%" colspan="2" align="center">
<p style="MARGIN: 0px" align="center"><b>June 30,</b></p>
<p style="MARGIN: 0px" align="center"><b>2017</b></p>
</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#CCEEFF">
<td valign="top">
<p style="MARGIN: 0px" align="justify">Convertible notes payable
(A)</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">$</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
116,000</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">$</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
131,000</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#FFFFFF">
<td valign="top">
<p style="MARGIN: 0px" align="justify">Convertible note payable
(B)</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
260,000</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
260,000</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#CCEEFF">
<td valign="top">
<p style="MARGIN: 0px" align="justify">Convertible notes payable
(C)</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: 1px solid" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" style="BORDER-BOTTOM: 1px solid" valign="bottom"
width="9%" align="right">2,560,112</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: 1px solid" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" style="BORDER-BOTTOM: 1px solid" valign="bottom"
width="9%" align="right">2,460,112</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#FFFFFF">
<td valign="top">
<p style="MARGIN: 0px" align="justify">Subtotal</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: 1px solid" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" style="BORDER-BOTTOM: 1px solid" valign="bottom"
width="9%" align="right">2,936,112</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: 1px solid" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" style="BORDER-BOTTOM: 1px solid" valign="bottom"
width="9%" align="right">2,851,112</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#CCEEFF">
<td valign="top">
<p style="MARGIN: 0px 0px 0px 15px" align="justify">Debt
discount</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: 1px solid" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" style="BORDER-BOTTOM: 1px solid" valign="bottom"
width="9%" align="right">(7,049</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">)</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: 1px solid" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" style="BORDER-BOTTOM: 1px solid" valign="bottom"
width="9%" align="right">(12,053</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">)</td>
</tr>
<tr bgcolor="#FFFFFF">
<td valign="top">
<p style="MARGIN: 0px" align="justify">Net total</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: 3px double" valign="bottom" width="1%">
$</td>
<td id="ffcell" style="BORDER-BOTTOM: 3px double" valign="bottom"
width="9%" align="right">2,929,063</td>
<td style="PADDING-BOTTOM: 3px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: 3px double" valign="bottom" width="1%">
$</td>
<td id="ffcell" style="BORDER-BOTTOM: 3px double" valign="bottom"
width="9%" align="right">2,839,059</td>
<td style="PADDING-BOTTOM: 3px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
</table>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"><b><i>Convertible Notes
Payable (A)</i></b></p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">Between September 2013 and
December 2017, the Company entered into various unsecured
convertible promissory notes with non-affiliate stockholders for
principal amounts of approximately $7,500 to $30,000, totaling
approximately $157,000, offset by the conversion of convertible
notes payable to shares of the Company’s common stock of
approximately $26,000 and the repayment of one note totaling
$15,000, netting a balance of approximately $116,000. Under the
terms of these notes, maturity dates range from June 2015 and July
2019, interest rates range from 7.5% to 8.0% per annum, and are
convertible into shares of the Company’s common stock at rates that
range from $0.20 and $5.00 per share, but only if such conversion
would not cause the noteholders to own more than 9.9% of the
Company’s outstanding common stock and contains piggyback
registration rights. In addition, the Company granted to certain
noteholders a cashless option to purchase one (1) share of the
Company’s common stock, $.001 par value, at the exercise price of
$0.50 to $1.25 per share, for each share the noteholders are
entitled pursuant to the promissory notes. The options are fully
vested and shall expire from one to three years from date of
execution. For the period ended March 31, 2018, the Company is in
default approximately $47,500 on various notes. As a result, these
notes are included in the current portion of convertible notes
payable, and the Company is in discussions with the noteholders to
restructure the terms of the notes.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px">The Company determined that some of the
notes had a beneficial conversion feature of approximately
$38,000.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">The Company recognized an
accretion of debt discount expense of approximately $5,000 and
$11,500 for the nine-month periods ended March 31, 2018 and 2017,
respectively, and approximately $1,700 and $2,000 for the
three-month periods ended March 31, 2018 and 2017, respectively.
The accretion of debt discount expense to be recognized in future
years is approximately $7,000.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px"><b><i>Unsecured, Amended and Consolidated
Convertible Note Payable (B)</i></b></p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"><i>December 2014 Convertible
Note</i></p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">In December 2014, the
Company entered into an unsecured convertible promissory note with
a non-affiliate stockholder for a principal amount of $200,000. The
note payable accrued interest at 7.5% per annum and was convertible
into shares of the Company’s common stock at a conversion rates of
$1.00 per share, but only if such conversion would not cause the
noteholder to own more than 9.9% of the Company’s outstanding
common stock and contained piggyback registration rights. The note
payable was extinguished in December 2015.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">In December 2014, the
Company determined that the note had a beneficial conversion
feature of approximately $90,000.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"><i>December 2015 Convertible
Note</i></p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">In December 2015, the
Company entered into an unsecured amended and consolidated
convertible promissory note with a non-affiliate stockholder for a
principal amount of $260,000. In exchange, the Company extinguished
a $10,000 short term note payable, the $200,000 convertible note
payable issued in December 2014, and received cash of $50,000. The
amended and consolidated note payable matures in October 2019,
accrues interest at 7.5% per annum, and convertible into shares of
the Company’s common stock at a conversion rates of $0.20 per
share, but only if such conversion would not cause the noteholder
to own more than 9.9% of the Company’s outstanding common stock,
and contains piggyback registration rights. In addition, the
Company granted to the noteholder a cashless warrant to purchase
one (1) share of the Company’s common stock, $.001 par value, at
the exercise price of $0.50 per share, for each share the
noteholder is entitled pursuant to the promissory note. The options
are fully vested and shall expire three years from date of
execution.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<table id="pagebreakc4d6c8ce-6537-46e1-b43f-9a19e619f0bf" class=
"pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0"
cellpadding="0" width="100%" border="0">
<tr>
<td class="hpbhr">&nbsp;</td>
</tr>
<tr>
<td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center">
20</td>
</tr>
<tr>
<td>
<div style=
"WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div>
&nbsp;</td>
</tr>
<tr>
<td><i><a href="#TOC">Table of Contents</a></i></td>
</tr>
</table>
<p style="MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0in" align=
"center">&nbsp;</p>
<p style="MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0in" align=
"center"><b>CEREBAIN BIOTECH CORP. AND SUBSIDIARY</b></p>
<p style="MARGIN: 0px" align="center"><b>NOTES TO THE UNAUDITED
CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</b></p>
<p style="MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0in" align=
"center"><b>FOR THE THREE AND NINE MONTH PERIODS ENDED MARCH 31,
2018 AND 2017</b></p>
&nbsp;
<p style="MARGIN: 0px" align="justify">The Company determined the
estimated relative fair value discount of the warrants was
approximately $128,000 which was valued using the Black-Scholes
option pricing model with the following inputs: volatility of 240%;
risk-free interest rate of 1.05%; expected term of 3 years; and 0%
dividend yield.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">The Company determined that
the note had a beneficial conversion feature of approximately
$141,000.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"><b><i>Unsecured, Amended and
Consolidated Convertible Notes Payable (C)</i></b></p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"><i>January 2017 Convertible
Note</i></p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">In January 2017, the Company
entered into an unsecured amended and consolidated convertible
promissory note with a non-affiliate stockholder for a principal
amount of approximately $2,460,000. In exchange, the Company
modified the $2,410,112 convertible promissory note payable issued
in November 2016 and received cash of $50,000. The amended and
consolidated convertible note payable matures in January 2019,
accrues interest at 5% per annum, and is convertible into shares of
the Company’s common stock at a conversion rate of $0.15 per share,
but only if such conversion would not cause the noteholder to own
more than 9.9% of the Company’s outstanding common stock, and
contains piggyback registration rights. The note payable was
extinguished in October 2017.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">In connection with the
$2,460,000 convertible note payable, the Company determined the
embedded conversion feature does not meet the criteria in ASC
470-50-40-10 or 470-20-25, and the issuance of the convertible
promissory note payable is considered a modification, and not an
extinguishment that would require the recognition of a gain or
loss.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px"><i>October 2017 Convertible Note</i></p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">In October 2017, the Company
entered into an unsecured amended and consolidated convertible
promissory note with a non-affiliate stockholder for a principal
amount of approximately $2,560,000. In exchange, the Company
modified the $2,460,112 convertible promissory note payable issued
in January 2017 and received cash of $100,000. The amended and
consolidated convertible promissory note matures in October 2019,
accrues interest at 5% per annum and is convertible into shares of
the Company’s common stock at a conversion rate of $0.10 per share,
but only if such conversion would not cause the noteholder to own
more than 9.9% of the Company’s outstanding common stock, and
contains piggyback registration rights.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">In connection with the
$2,560,000 convertible note, the Company determined the embedded
conversion feature does meet the criteria in ASC 470-50-40-10 or
470-20-25, and the issuance of the convertible promissory note
payable is considered an extinguishment that would require the
recognition of a gain or loss. The Company recognized a loss from
extinguishment of debt of approximately $0 and $3.1 million for the
three-month and nine-month periods ended March 31, 2018,
respectively.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">The Company recognized
interest expense on all notes payable to stockholders of
approximately $126,000 and $116,000 for the nine-month periods
ended March 31, 2018 and 2017, respectively and approximately
$44,000 and $40,000 for the three-month periods ended March 31,
2018 and 2017, respectively. Accrued interest on all notes payable
to stockholders at March 31, 2018 and 2017 totaled approximately
$382,000 and $219,000, respectively, and is included in accounts
payable.</p>
<p style="MARGIN: 0px">&nbsp;</p>
<table id="pagebreakae03b409-aad8-432c-8da1-eeef3cd55fba" class=
"pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0"
cellpadding="0" width="100%" border="0">
<tr>
<td class="hpbhr">&nbsp;</td>
</tr>
<tr>
<td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center">
21</td>
</tr>
<tr>
<td>
<div style=
"WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div>
&nbsp;</td>
</tr>
<tr>
<td><i><a href="#TOC">Table of Contents</a></i></td>
</tr>
</table>
<p style="MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0in" align=
"center">&nbsp;</p>
<p style="MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0in" align=
"center"><b>CEREBAIN BIOTECH CORP. AND SUBSIDIARY</b></p>
<p style="MARGIN: 0px" align="center"><b>NOTES TO THE UNAUDITED
CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</b></p>
<p style="MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0in" align=
"center"><b>FOR THE THREE AND NINE MONTH PERIODS ENDED MARCH 31,
2018 AND 2017</b></p>
&nbsp;
<p style="MARGIN: 0px" align="justify">As of March 31, 2018, future
maturities of all notes payable are as follows:</p>
<p style="MARGIN: 0px">&nbsp;</p>
<table style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN"
cellspacing="0" cellpadding="0" width="85%" align="center" border=
"0">
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" colspan="2" align=
"right">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#CCEEFF">
<td valign="top">
<p style="MARGIN: 0px" align="justify">2018</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">$</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
724,000</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#FFFFFF">
<td valign="top">
<p style="MARGIN: 0px" align="justify">2019</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
2,845,112</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#CCEEFF">
<td valign="top">
<p style="MARGIN: 0px" align="justify">2020</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: black 1px solid" valign="bottom" width=
"1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" style="BORDER-BOTTOM: black 1px solid" valign=
"bottom" width="9%" align="right">16,000</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#FFFFFF">
<td valign="top">
<p style="MARGIN: 0px" align="justify">Total outstanding notes</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
3,585,112</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#CCEEFF">
<td valign="top">
<p style="MARGIN: 0px" align="justify">Debt Discount</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: 1px solid" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" style="BORDER-BOTTOM: 1px solid" valign="bottom"
width="9%" align="right">(268,299</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">)</td>
</tr>
<tr bgcolor="#FFFFFF">
<td valign="top">
<p style="MARGIN: 0px" align="justify">Net Notes Payable</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: 3px double" valign="bottom" width="1%">
$</td>
<td id="ffcell" style="BORDER-BOTTOM: 3px double" valign="bottom"
width="9%" align="right">3,316,813</td>
<td style="PADDING-BOTTOM: 3px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
</table>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px"><b>NOTE 7 – STOCK TRANSACTIONS</b></p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">For the nine-month period
ended March 31, 2018, the Company issued 144,000 shares of its
common stock to a non-affiliate investor at $1.25 per share in
exchange for $180,000. The investor had an existing stock purchase
agreement with the Company that allowed him to purchase up to
$2,000,000 worth of the Company’s common stock at $1.25 per share.
In addition to the 144,000 shares of the Company’s common stock,
the Company issued the investor a warrant to acquire 144,000 shares
of the Company’s common stock at $2.50 per share. The warrants have
been accounted for as an equity transaction under GAAP.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">For the nine-month period
ended March 31, 2018, the Company entered into stock purchase
agreements with a non-affiliate stockholder, under which the
Company issued 220,000 shares of its common stock, in exchange for
$110,000. In connection with the stock purchase agreement, the
Company issued 220,000 warrants at $1.00 per share. The warrants
have been accounted for as an equity transaction under GAAP.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">For the nine-month period
ended March 31, 2018, the Company issued 795,000 fully vested,
nonforfeitable shares of common stock to various individuals as
payment for legal services, consulting services, employee stock
award and financing fee per agreements dated between July 2017 and
March 2018. The aggregate fair market value of these shares was
approximately $138,000 as the fair market value of the stock was
between $0.15 and $0.20 per share. The Company used recent sales of
stock to determine the fair market value of these transactions.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">On May 15, 2017, the Company
issued a Private Placement Memorandum (“PPM”). The PPM authorizes
the sale of up to 400 units, with each Unit consisting of one
$10,000 Principal Amount Convertible Debenture and a warrant to
purchase one share of the Company’s common stock, at a price of
$1.25 per Unit. Each Unit includes a warrant to purchase 25,000
shares of the Company’s common stock, $.001 par value, at the
exercise price of $0.80 per share. The Debentures will be
convertible at Forty Cents ($0.40) per share. The Offering was to
terminate on June 30, 2017, unless extended one or more times by us
to a date not later than July 31, 2017. On August 18, 2017, by
unanimous written consent of the Company’s directors, the company
extended the offering through December 31, 2017. The Company
received no subscriptions and the offering closed effective
December 31, 2017.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px"><b>NOTE</b> <b>8</b> <b>– OPTIONS AND</b>
<b>WARRANTS</b></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"><u>Options</u></p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">For the nine-month period
ended March 31, 2018, the Company had 910,000 options outstanding
at a weighted average exercise price of $1.45 and a weighted
average contractual life of 7.69 years, with 682,000 options
exercisable at a weighted average exercise price of $1.64 and a
weighted average contractual life of 6.92 years. For the nine-month
periods ended March 31, 2018 and 2017, the Company recognized an
expense of approximately $48,000 and $285,000, respectively, and
for the three-month periods ended March 31, 2018 and 2017, the
Company recognized an expense of approximately $16,000 and $85,000,
respectively, which was recorded as compensation expense. The
compensation expected to be recognized in selling, general and
administrative expense in future years is approximately
$113,000.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<table id="pagebreakd71db6bd-32d7-4d51-bb0d-fc7b9631ed21" class=
"pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0"
cellpadding="0" width="100%" border="0">
<tr>
<td class="hpbhr">&nbsp;</td>
</tr>
<tr>
<td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center">
22</td>
</tr>
<tr>
<td>
<div style=
"WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div>
&nbsp;</td>
</tr>
<tr>
<td><i><a href="#TOC">Table of Contents</a></i></td>
</tr>
</table>
<p style="MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0in" align=
"center">&nbsp;</p>
<p style="MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0in" align=
"center"><b>CEREBAIN BIOTECH CORP. AND SUBSIDIARY</b></p>
<p style="MARGIN: 0px" align="center"><b>NOTES TO THE UNAUDITED
CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</b></p>
<p style="MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0in" align=
"center"><b>FOR THE THREE AND NINE MONTH PERIODS ENDED MARCH 31,
2018 AND 2017</b></p>
&nbsp;
<p style="MARGIN: 0px" align="justify"><u>Warrants</u></p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">For the nine-month period
ended March 31, 2018, the Company had approximately 3,200,000
warrants outstanding at an average exercise price of $0.78. For the
nine-month periods ended March 31, 2018 and 2017, the Company
recognized an accretion of debt discount related to warrants
expense of approximately $3,900 and $2,800, respectively, and for
the three-month periods ended March 31, 2018 and 2017, the Company
recognized an accretion of debt discount related to warrants
expense of approximately $1,300 and $1,300, respectively. The
approximate expense expected to be recognized in future years is
$5,900.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"><b>NOTE 9 – RELATED PARTY
TRANSACTIONS</b></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px"><b>Employment Agreements</b></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"><u>Eric Clemons</u></p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">On October 1, 2014, the
Company entered into an addendum to the employment agreement. The
addendum had no accounting impact on the prior agreement. Terms of
the addendum include included the following:</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"></p>
<table style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN"
cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td width="4%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top" width="4%"><font style=
"FONT-FAMILY: Symbol">·</font></td>
<td valign="top">Extension of employment until December 31, 2017.
The Company has entered into a new employment agreement with Mr.
Clemons.</td>
</tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top"><font style="FONT-FAMILY: Symbol">·</font></td>
<td valign="top">Annual salary of One Hundred Ninety-Five Thousand
Dollars ($195,000).</td>
</tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top"><font style="FONT-FAMILY: Symbol">·</font></td>
<td valign="top">Option to acquire up to 100,000 shares of the
Company’s common stock under the Company’s 2014 Omnibus Stock Grant
and Option Plan at an exercise price of $1.20 per share subject to
a vesting schedule. Fair Market Value of these options totaled
approximately $112,000 and is recognized ratably over the vesting
period in selling, general and administrative expense. The options
were valued using the Black-Scholes value option pricing model with
the following inputs: volatility of 262%; risk-free interest rate
of 1.69%; expected term of 5 years; and 0% dividend yield. As of
March 31, 2018, 80,000 options to purchase the Company’s common
stock have vested. The Company recognized selling, general and
administrative expense of approximately $16,500 for the nine-month
periods ended March 31, 2018 and 2017, respectively and
approximately $5,500 for the three-month periods ended March 31,
2018 and 2017, respectively. The compensation expected to be
recognized in selling, general and administrative expense in future
years is approximately $10,000.</td>
</tr>
</table>
<font face="Symbol">&nbsp;</font>
<p style="MARGIN: 0px" align="justify">On March 1, 2015, the
Company entered into an addendum to the employment agreement. The
addendum had no accounting impact on the prior agreements. Terms of
the addendum included a cash placement bonus equal to an amount up
to 10% of the aggregate purchase price paid by each purchaser of
the Company’s Securities and Convertible Debt, where the purchaser
of said Securities and Convertible Debt has been directly
introduced to the Company by Mr. Clemons. For the nine-month
periods ended March 31, 2018 and 2017, a cash placement bonus was
earned of approximately $0 and $27,000, respectively, and for the
three-month periods ended March 31, 2018 and 2017, a cash placement
bonus was earned of approximately $0, respectively, which was
recognized as a reduction of the proceeds from the sale of shares
of common stock and debt issuances and recorded as an expense.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">On September 29, 2016, the
Company issued Mr. Clemons an option to acquire up to 105,000
shares of the Company’s common stock under the Company’s 2014
Omnibus Stock Grant and Option Plan at an exercise price of $0.75
per share subject to a vesting schedule. Fair Market Value of these
options totaled approximately $78,000 and is recognized ratably
over the vesting period in selling, general and administrative
expense. The options were valued using the Black-Scholes value
option pricing model with the following inputs: volatility of 206%;
risk-free interest rate of 1.13%; expected term of 6 years; and 0%
dividend yield. As of March 31, 2018, 42,000 options to purchase
the Company’s common stock have vested. The Company recognized
selling, general and administrative expense of approximately
$12,000 and $27,000 for the nine-month periods ended March 31, 2018
and 2017, respectively, and approximately $4,000 for the
three-month periods ended March 31, 2018 and 2017, respectively.
The compensation expected to be recognized in selling, general and
administrative expense in future years is approximately
$35,000.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<table id="pagebreak33f73655-39f8-4c51-bfef-60c3588868e0" class=
"pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0"
cellpadding="0" width="100%" border="0">
<tr>
<td class="hpbhr">&nbsp;</td>
</tr>
<tr>
<td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center">
23</td>
</tr>
<tr>
<td>
<div style=
"WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div>
&nbsp;</td>
</tr>
<tr>
<td><i><a href="#TOC">Table of Contents</a></i></td>
</tr>
</table>
<p style="MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0in" align=
"center">&nbsp;</p>
<p style="MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0in" align=
"center"><b>CEREBAIN BIOTECH CORP. AND SUBSIDIARY</b></p>
<p style="MARGIN: 0px" align="center"><b>NOTES TO THE UNAUDITED
CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</b></p>
<p style="MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0in" align=
"center"><b>FOR THE THREE AND NINE MONTH PERIODS ENDED MARCH 31,
2018 AND 2017</b></p>
&nbsp;
<p style="MARGIN: 0px" align="justify">On February 1, 2018, the
Company entered into a new employment agreement with Eric Clemons,
an officer of the company. The new contract had no accounting
impact on the prior agreements. Terms of the agreement include the
following:</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"></p>
<table style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN"
cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td width="4%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top" width="4%"><font style=
"FONT-FAMILY: Symbol">·</font></td>
<td valign="top">Term of contract thirty-six months.</td>
</tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top"><font style="FONT-FAMILY: Symbol">·</font></td>
<td valign="top">Annual salary of Two Hundred Fourteen Thousand
Five Hundred Dollars ($214,500).</td>
</tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top"><font style="FONT-FAMILY: Symbol">·</font></td>
<td valign="top">Stock grant of 800,000 of the Company’s common
restricted shares for services provided to the Company. Stock grant
is subject to a vesting schedule, of which 160,000 shares of stock
were issued on February 1, 2018 (See Note 7). The aggregate fair
market value of these shares was approximately $144,000 as the fair
market value of the stock was $0.18 per share. The Company used
recent sales of stock to determine the fair market value of this
transaction. As of March 31, 2018, 160,000 shares have been issued.
The Company recognized selling, general and administrative expense
of approximately $34,000 and $0 for the nine-month periods ended
March 31, 2018 and 2017, respectively, and approximately $34,000
and $0 for the three-month periods ended March 31, 2018 and 2017,
respectively. The compensation expected to be recognized in
selling, general and administrative expense in future years is
approximately $110,000.</td>
</tr>
</table>
<font face="Symbol">&nbsp;</font>
<p style="MARGIN: 0px" align="justify">To date, employee and
employer payroll taxes have been accrued but have not been remitted
to taxing authorities by the Company for cash compensation paid. As
a result, the Company is liable such payroll taxes and any related
penalties and interest.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"><u>Wesley Tate</u></p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">On October 1, 2014, the
Company entered into an addendum to the employment agreement. The
addendum had no accounting impact on the prior agreements. Terms of
the agreement included the following:</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"></p>
<table style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN"
cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td width="4%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top" width="4%"><font style=
"FONT-FAMILY: Symbol">·</font></td>
<td valign="top">Extension of employment until June 15, 2017. The
Company entered into a new contract on October 1, 2015.</td>
</tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top"><font style="FONT-FAMILY: Symbol">·</font></td>
<td valign="top">Annual salary of One Hundred Fifty-Six Thousand
Dollars ($156,000).</td>
</tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top"><font style="FONT-FAMILY: Symbol">·</font></td>
<td valign="top">Option to acquire up to 50,000 shares of the
Company’s common stock under the Company’s 2014 Omnibus Stock Grant
and Option Plan at an exercise price of $1.20 per share subject to
a vesting schedule. Fair Market Value of these options totaled
approximately $56,000 and is recognized ratably over the vesting
period in selling, general and administrative expense. The options
were valued using the Black-Scholes value option pricing model with
the following inputs: volatility of 262%; risk-free interest rate
of 1.69%; expected term of 5 years; and 0% dividend yield. As of
March 31, 2018, 40,000 options to purchase the Company’s common
stock have vested. The Company recognized selling, general and
administrative expense of approximately $8,000 for the nine-month
periods ended March 31, 2018 and 2017, respectively and
approximately $2,700 for the three-month periods ended March 31,
2018 and 2017, respectively. The compensation expected to be
recognized in selling, general and administrative expense in future
years is approximately $5,000.</td>
</tr>
</table>
<font face="Symbol">&nbsp;</font>
<p style="MARGIN: 0px" align="justify">On September 29, 2016, the
Company issued Mr. Tate an option to acquire up to 105,000 shares
of the Company’s common stock under the Company’s 2014 Omnibus
Stock Grant and Option Plan at an exercise price of $0.75 per share
subject to a vesting schedule. Fair Market Value of these options
totaled approximately $78,000 and is recognized ratably over the
vesting period in selling, general and administrative expense. The
options were valued using the Black-Scholes value option pricing
model with the following inputs: volatility of 206%; risk-free
interest rate of 1.13%; expected term of 6 years; and 0% dividend
yield. As of March 31, 2018, 42,000 options to purchase the Company’
s common stock have vested. The Company recognized selling, general
and administrative expense of approximately $12,000 and $27,000 for
the nine-month periods ended March 31, 2018 and 2017, respectively,
and approximately $4,000 for the three-month periods ended March
31, 2018 and 2017, respectively. The compensation expected to be
recognized in selling, general and administrative expense in future
years is approximately $35,000.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<table id="pagebreak4b2475d6-0c1b-44f0-9f7c-2a84aeea7172" class=
"pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0"
cellpadding="0" width="100%" border="0">
<tr>
<td class="hpbhr">&nbsp;</td>
</tr>
<tr>
<td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center">
24</td>
</tr>
<tr>
<td>
<div style=
"WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div>
&nbsp;</td>
</tr>
<tr>
<td><i><a href="#TOC">Table of Contents</a></i></td>
</tr>
</table>
<p style="MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0in" align=
"center">&nbsp;</p>
<p style="MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0in" align=
"center"><b>CEREBAIN BIOTECH CORP. AND SUBSIDIARY</b></p>
<p style="MARGIN: 0px" align="center"><b>NOTES TO THE UNAUDITED
CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</b></p>
<p style="MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0in" align=
"center"><b>FOR THE THREE AND NINE MONTH PERIODS ENDED MARCH 31,
2018 AND 2017</b></p>
&nbsp;
<p style="MARGIN: 0px" align="justify">On February 1, 2018, the
Company entered into a new employment agreement with Wesley Tate,
an officer of the company. The new contract had no accounting
impact on the prior agreements. Terms of the agreement include the
following:</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"></p>
<table style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN"
cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td width="4%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top" width="4%"><font style=
"FONT-FAMILY: Symbol">·</font></td>
<td valign="top">Term of contract thirty-six months.</td>
</tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top"><font style="FONT-FAMILY: Symbol">·</font></td>
<td valign="top">Annual salary of One Hundred Eighty-Seven Thousand
Two Hundred Dollars ($187,200).</td>
</tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top"><font style="FONT-FAMILY: Symbol">·</font></td>
<td valign="top">Stock grant of 800,000 of the Company’s common
restricted shares for services provided to the Company. Stock grant
is subject to a vesting schedule of which 160,000 shares of stock
were issued on February 1, 2018 (See Note 7). The aggregate fair
market value of these shares was approximately $144,000 as the fair
market value of the stock was $0.18 per share. The Company used
recent sales of stock to determine the fair market value of this
transaction. As of March 31, 2018, 160,000 shares have been issued.
The Company recognized selling, general and administrative expense
of approximately $34,000 and $0 for the nine-month periods ended
March 31, 2018 and 2017, respectively, and approximately $34,000
and $0 for the three-month periods ended March 31, 2018 and 2017,
respectively. The compensation expected to be recognized in
selling, general and administrative expense in future years is
approximately $110,000.</td>
</tr>
</table>
<font face="Symbol">&nbsp;</font>
<p style="MARGIN: 0px" align="justify">To date, employee and
employer payroll taxes have been accrued but have not been remitted
to taxing authorities by the Company for cash compensation paid. As
a result, the Company is liable such payroll taxes and any related
penalties and interest.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"><b>NOTE</b> <b>10 – EARNINGS
PER SHARE</b></p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">FASB ASC Topic 260,
<i>Earnings Per Share</i>, requires a reconciliation of the
numerator and denominator of the basic and diluted earnings (loss)
per share (EPS) computations.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">The total number of
potential additional dilutive options and warrants outstanding was
approximately 4.0 million and 2.6 million for the nine-month
periods ended March 31, 2018 and 2017, respectively. In addition,
the convertible notes convert at an exercise price of between $0.10
and $5.00 per share of common stock representing approximately 30
million shares. The options, warrants and shares underlying the
convertible note were considered for the dilutive calculation but
in periods where losses are reported, the weighted-average number
of common stock outstanding excludes common stock equivalents,
because their inclusion would be anti-dilutive.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px">The following table sets forth the
computation of basic and diluted net income per share:</p>
<p style="MARGIN: 0px">&nbsp;</p>
<table style=
"WIDTH: 100%; TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN"
cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="hdcell" style="BORDER-BOTTOM: 1px solid" valign="bottom"
colspan="6" align="center">
<p style="MARGIN: 0px 0px 0px 0.25in" align="center"><b>For The
Nine Months ended</b></p>
<p style="MARGIN: 0px" align="center"><b>March 31,</b></p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="hdcell" style="BORDER-BOTTOM: 1px solid" valign="bottom"
colspan="6" align="center">
<p style="MARGIN: 0px 0px 0px 0.25in" align="center"><b>For The
Three Months ended</b></p>
<p style="MARGIN: 0px" align="center"><b>March 31,</b></p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="hdcell" style="BORDER-BOTTOM: black 1px solid" valign=
"bottom" width="9%" colspan="2" align="center">
<p style="MARGIN: 0px" align="center"><b>2018</b></p>
</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="hdcell" style="BORDER-BOTTOM: black 1px solid" valign=
"bottom" width="9%" colspan="2" align="center">
<p style="MARGIN: 0px" align="center"><b>2017</b></p>
</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="hdcell" style="BORDER-BOTTOM: black 1px solid" valign=
"bottom" width="9%" colspan="2" align="center">
<p style="MARGIN: 0px" align="center"><b>2018</b></p>
</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="hdcell" style="BORDER-BOTTOM: black 1px solid" valign=
"bottom" width="9%" colspan="2" align="center">
<p style="MARGIN: 0px" align="center"><b>2017</b></p>
</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" colspan="2" align=
"right">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" colspan="2" align=
"right">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" colspan="2" align=
"right">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" colspan="2" align=
"right">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" colspan="2" align=
"right">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" colspan="2" align=
"right">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" colspan="2" align=
"right">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" colspan="2" align=
"right">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#CCEEFF">
<td valign="top">
<p style="MARGIN: 0px">Net loss attributable to the common
stockholders</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: 3px double" valign="bottom" width="1%">
$</td>
<td id="ffcell" style="BORDER-BOTTOM: 3px double" valign="bottom"
width="9%" align="right">(4,499,065</td>
<td style="PADDING-BOTTOM: 3px" valign="bottom" width="1%">)</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: 3px double" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" style="BORDER-BOTTOM: 3px double" valign="bottom"
width="9%" align="right">(15,449,535</td>
<td style="PADDING-BOTTOM: 3px" valign="bottom" width="1%">)</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: 3px double" valign="bottom" width="1%">
$</td>
<td id="ffcell" style="BORDER-BOTTOM: 3px double" valign="bottom"
width="9%" align="right">(654,602</td>
<td style="PADDING-BOTTOM: 3px" valign="bottom" width="1%">)</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: 3px double" valign="bottom" width="1%">
$</td>
<td id="ffcell" style="BORDER-BOTTOM: 3px double" valign="bottom"
width="9%" align="right">(566,754</td>
<td style="PADDING-BOTTOM: 3px" valign="bottom" width="1%">)</td>
</tr>
<tr bgcolor="#FFFFFF">
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#CCEEFF">
<td valign="top">
<p style="MARGIN: 0px">Basic weighted average outstanding shares of
common stock</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
8,365,059</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
7,421,427</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
8,755,125</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
7,605,236</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#FFFFFF">
<td valign="top">
<p style="MARGIN: 0px">Dilutive effect of options and warrants</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: 1px solid" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" style="BORDER-BOTTOM: 1px solid" valign="bottom"
width="9%" align="right">-</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: 1px solid" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" style="BORDER-BOTTOM: 1px solid" valign="bottom"
width="9%" align="right">-</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: 1px solid" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" style="BORDER-BOTTOM: 1px solid" valign="bottom"
width="9%" align="right">-</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: 1px solid" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" style="BORDER-BOTTOM: 1px solid" valign="bottom"
width="9%" align="right">-</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#CCEEFF">
<td valign="top">
<p style="MARGIN: 0px">Diluted weighted average common stock and
common stock equivalents</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: 1px solid" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" style="BORDER-BOTTOM: 1px solid" valign="bottom"
width="9%" align="right">8,365,059</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: 1px solid" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" style="BORDER-BOTTOM: 1px solid" valign="bottom"
width="9%" align="right">7,421,427</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: 1px solid" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" style="BORDER-BOTTOM: 1px solid" valign="bottom"
width="9%" align="right">8,755,125</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: 1px solid" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" style="BORDER-BOTTOM: 1px solid" valign="bottom"
width="9%" align="right">7,605,236</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#FFFFFF">
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#CCEEFF">
<td valign="top">
<p style="MARGIN: 0px">Earnings (loss) per share:</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#FFFFFF">
<td valign="top">
<p style="MARGIN: 0px">Basic and diluted</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: 3px double" valign="bottom" width="1%">
$</td>
<td id="ffcell" style="BORDER-BOTTOM: 3px double" valign="bottom"
width="9%" align="right">(0.54</td>
<td style="PADDING-BOTTOM: 3px" valign="bottom" width="1%">)</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: 3px double" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" style="BORDER-BOTTOM: 3px double" valign="bottom"
width="9%" align="right">(2.08</td>
<td style="PADDING-BOTTOM: 3px" valign="bottom" width="1%">)</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: 3px double" valign="bottom" width="1%">
$</td>
<td id="ffcell" style="BORDER-BOTTOM: 3px double" valign="bottom"
width="9%" align="right">(0.07</td>
<td style="PADDING-BOTTOM: 3px" valign="bottom" width="1%">)</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: 3px double" valign="bottom" width="1%">
$</td>
<td id="ffcell" style="BORDER-BOTTOM: 3px double" valign="bottom"
width="9%" align="right">(0.07</td>
<td style="PADDING-BOTTOM: 3px" valign="bottom" width="1%">)</td>
</tr>
</table>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px"><b>NOTE 11</b> <b>–</b> <b>SUBSEQUENT
EVENTS</b></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px">There have been no events which are required
to be reported under this Note.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<table id="pagebreak44b7cbd0-3ed6-4ce2-9401-b312f8ca7c27" class=
"pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0"
cellpadding="0" width="100%" border="0">
<tr>
<td class="hpbhr">&nbsp;</td>
</tr>
<tr>
<td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center">
25</td>
</tr>
<tr>
<td>
<div style=
"WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div>
&nbsp;</td>
</tr>
<tr>
<td><i><a href="#TOC">Table of Contents</a></i></td>
</tr>
</table>
<p style="MARGIN: 0px">&nbsp;&nbsp;</p>
<p style="MARGIN: 0px"><a name=
"ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS">
<b>ITEM 2.</b> <b>MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL
CONDITION AND RESULTS OF OPERATIONS</b></a></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px">DISCLAIMER REGARDING FORWARD LOOKING
STATEMENTS</p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">Certain statements in this
Form 10-Q, which are not statements of historical fact, are what
are known as "forward-looking statements," which are basically
statements about the future. For that reason, these statements
involve risk and uncertainty since no one can accurately predict
the future. Words such as "plans," "intends," "hopes," "seeks,"
"anticipates," "expects," and the like, often identify such forward
looking statements, but are not the only indication that a
statement is a forward-looking statement. Such forward-looking
statements include statements concerning our plans and objectives
with respect to our present and future operations, and statements
which express or imply that such present and future operations will
or may produce revenues, income or profits. These and other factors
may cause our actual results to differ materially from any
forward-looking statement. We caution you not to place undue
reliance on these forward-looking statements. Although we base
these forward-looking statements on our expectations, assumptions,
and projections about future events, actual events and results may
differ materially, and our expectations, assumptions, and
projections may prove to be inaccurate. The forward-looking
statements speak only as of the date hereof, and we expressly
disclaim any obligation to publicly release the results of any
revisions to these forward-looking statements to reflect events or
circumstances after the date of this filing.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px"><b>Business Overview</b></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">We were incorporated on
December 18, 2007, in the State of Nevada. We are a smaller
reporting biomedical company and through our wholly owned
subsidiary, Cerebain Operating, Inc. (“Cerebain”), our business
involves the discovery of products for the treatment of Alzheimer’s
disease utilizing Omentum. Under our current plan, our products
will include both a medical device solution as well as a synthetic
drug solution.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">In accordance with our
current business plan, the testing, research and development of
both a medical device solution as well as a synthetic drug solution
are underway, and we have contracted with certain third-party
companies to research, develop, and test certain products that
could be used to treat dementia utilizing Omentum. We have also
contracted with various individuals to facilitate the introduction
of the company to medical device testing organizations in overseas
locations including Poland, China and Uzbekistan for the purpose of
testing our medicinal treatments utilizing Omentum. Our management
anticipates that we may form subsidiaries and joint ventures to
develop different drugs based on the intellectual property.
Although we have contracted with a firm to research, develop and
test products that could be used to treat dementia utilizing
Omentum, in order to fully execute on that agreement, as well as
hire one or more firms to research, develop and test medicinal
treatments utilizing Omentum, we will need to raise additional
funds. There can be no assurance we will be successful in raising
the necessary funds. There can also be no assurance that further
research and development will validate and support the results of
our preliminary research and studies, or that the necessary
regulatory approvals will be obtained or that we will be able to
develop commercially viable products on the basis of our
technologies.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"><b>Description of Patent
License Agreement</b></p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">On June 10, 2010, our
subsidiary, Cerebain Operating, Inc., entered into a Patent License
Agreement under which it acquired the exclusive rights to certain
intellectual property related to using Omentum for treating
dementia conditions. Under the agreement we paid rights fees of
$50,000 to Dr. Saini and issued him 825,000 shares of our common
stock, valued at $6,600 (based on the fair market value on the date
of grant) restricted in accordance with Rule 144. In addition, Dr.
Saini has the option to participate in the sale of equity by us in
the future, up to ten percent (10%) of the money raised, in
exchange for the applicable number of his shares.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">In addition, the Patent
License agreement provides for a royalty payment of six (6) percent
of the value of the net sales, as defined, generated from the sale
of licensed products. The agreement also provides for yearly
minimum royalty payments of $50,000 for the fourth (June 2014),
fifth (June 2015), and sixth (June 2016) anniversary of the date of
the agreement, and a yearly minimum royalty payment of $100,000 for
each year thereafter during the term of the agreement. We have
recognized costs associated with the patent rights for $325,000 in
accounts payable for the patent rights and are currently in arrears
and in discussions to renegotiate the terms of the agreement. The
term of the agreement shall continue until the patent in the
intellectual property expires, unless terminated sooner under the
provisions of the agreement, as defined.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<table id="pagebreak9c933fe7-1083-4025-b521-f44faae4715d" class=
"pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0"
cellpadding="0" width="100%" border="0">
<tr>
<td class="hpbhr">&nbsp;</td>
</tr>
<tr>
<td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center">
26</td>
</tr>
<tr>
<td>
<div style=
"WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div>
&nbsp;</td>
</tr>
<tr>
<td><i><a href="#TOC">Table of Contents</a></i></td>
</tr>
</table>
<p style="MARGIN: 0px">&nbsp;&nbsp;</p>
<p style="MARGIN: 0px" align="justify">The patent will have an
estimated useful life of 20 years based on the term of the patent.
Amortization of the patent will begin when the patent is issued by
the United States Patent and Trademark Office and put in use.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">Legal fees pertaining to the
patent are recorded as general and administrative expenses when
they are incurred. Legal fees charged to operations were
approximately $4,000 and $5,100 for the nine-month periods ended
March 31, 2018 and 2017, respectively, and approximately $2,400 and
$1,300 for the three-month periods ended March 31, 2018 and 2017,
respectively.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">We recognized a patent
royalty expense of approximately $75,000 for the nine-month period
ended March 31, 2018 compared to $75,000 for the nine-month period
ended March 31, 2017 and approximately $25,000 for the three-month
period ended March 31, 2018 compared to $25,000 for the three-month
period ended March 31, 2017. The accrued payable of $325,000
pertaining to the patent royalty expense at March 31, 2018 is
included in related party payables.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"><b>Overview of Dementia and
Alzheimer’s Disease</b></p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">Dementia (taken from Latin,
originally meaning "madness") is generally referred to as a serious
loss and/or decline of human brain function. The areas of brain
function affected by dementia include memory, attention, language,
problem solving and emotion. Dementia is generally considered as a
progressive and non-reversible condition. Alzheimer’s disease is
the most common form of dementia. Alzheimer’s disease is an
age-related, non-reversible brain disorder that develops over a
period of years. Initially, people experience memory loss and
confusion, which may be mistaken for the kinds of memory changes
that are sometimes associated with normal aging. However, the
symptoms of Alzheimer’s disease gradually lead to behavior and
personality changes, a decline in cognitive abilities such as
decision making and language skills, and problems recognizing
family and friends. Alzheimer’s disease ultimately leads to a
severe loss of mental functions. These losses are related to the
worsening breakdown of the connections between certain neurons in
the brain responsible for memory and learning. Neurons can’t
survive when they lose their connections to other neurons. As
neurons die throughout the brain, the affected regions begin to
atrophy, or shrink. By the final stage of Alzheimer’s disease,
damage is widespread and brain tissue has shrunk significantly.</p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px"><u>Causes</u></p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">Many scientists generally
accept that one or more of the following mechanisms are responsible
for dementia:</p>
<p style="MARGIN: 0px; TEXT-INDENT: 0.5in" align="justify">
&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 0.5in" align="justify">1)
accumulation of toxic materials in brain cells, which leads to
death of the cells;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 0.5in" align="justify">2)
reduction of certain biological factors (e.g. Acetylcholine or ACh)
in a brain; and</p>
<p style="MARGIN: 0px; TEXT-INDENT: 0.5in" align="justify">3) loss
or reduction of blood flow in the brain.</p>
<p style="MARGIN: 0px; TEXT-INDENT: 0.5in" align="justify">
&nbsp;</p>
<p style="MARGIN: 0px" align="justify">Neurodegenerative diseases,
such as Alzheimer's disease and Parkinson's disease, are the most
common causes of dementia. Dementia can also be due to a stroke. In
most circumstances, the changes in the brain that are causing
dementia cannot be controlled or reversed.</p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px"><u>Statistics</u></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0in"><font face=
"Wingdings">§</font> <i>Affected population worldwide</i></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">According to the Alzheimer’s
Association 2017 Alzheimer’s Disease Facts and Figures, an
estimated 5.5 million Americans have Alzheimer's disease, including
approximately 200,000 individuals younger than age 65 who have
younger-onset Alzheimer's. By 2050, it is estimated that up to 16
million Americans will have the disease. Almost two-thirds, 3.3
million, of American seniors living with Alzheimer's are women. By
2025, it is estimated that 20 states will see a 35 percent or
greater growth in the number of people with Alzheimer’s. Someone in
the United States develops Alzheimer’s every 66 seconds. In 2050,
it is predicted that someone in the United States will develop the
disease every 33 seconds.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"></p>
<table id="pagebreakad5403b2-8da0-46bd-9f9f-e216f7371d45" class=
"pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0"
cellpadding="0" width="100%" border="0">
<tr>
<td class="hpbhr">&nbsp;</td>
</tr>
<tr>
<td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center">
27</td>
</tr>
<tr>
<td>
<div style=
"WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div>
&nbsp;</td>
</tr>
<tr>
<td><i><a href="#TOC">Table of Contents</a></i></td>
</tr>
</table>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">In addition, the Alzheimer’s
Association stated Alzheimer’s disease is the 6<sup>th</sup>
leading cause of death in the United States and the 5<sup>th</sup>
leading cause of death for those aged 65 and older. In 2013, over
84,000 Americans officially died from Alzheimer’s; in 2016, an
estimated 700,000 people will die with Alzheimer’s, meaning they
will die after having developed the disease. Deaths from Alzheimer
increased 71 percent from 2000 to 2013, while deaths from other
major diseases (including heart disease, stroke, breast and
prostate cancer, and HIVAIDS) decreased. Alzheimer’s is the only
cause of death among the top 10 in America that cannot be
prevented, cured, or even slowed.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">According to the 2015 World
Alzheimer Report, in 2015 about 46.8 million people had dementia
worldwide. The report stated that this figure is likely to nearly
double every 20 years, to nearly 74.7 million in 2030 and 131.5
million in 2050. For 2015, they estimate over 9.9 million new cases
of dementia each year worldwide, implying one new case every 3.2
seconds. The regional distribution of new dementia cases is 4.9
million (49% of the total) in Asia, 2.5 million (25%) in Europe,
1.7 million (18%) in the Americas, and 0.8 million (8%) in
Africa.</p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0in"><font face=
"Wingdings">§</font> <i>Cost</i></p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">According to the Alzheimer’s
Association 2017 Alzheimer’s Disease Facts and Figures, unpaid
caregivers are primarily immediate family members, but they may be
other relatives and friends. In 2015, 15.9 million family and
friends provided an estimated 18.1 billion hours of unpaid care, a
contribution to the nation valued at over $221.3 billion. Nearly
half of care contributors cut back on their own expenses (including
food, transportation and medical care) to pay for dementia-related
care of a family member or friend. Care contributors are 28 percent
more likely than other adults to eat less or go hungry because they
cannot afford to pay for food. One in five care contributors cut
back on their own doctor visits because of their care
responsibilities. And, among caregivers, 74 percent report they are
“somewhat” to “very” concerned about maintaining their own health
since becoming a caregiver. On average care contributors lose over
$15,000 in annual income as a result of reducing or quitting work
to meet the demand of caregiving.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">According to the 2015 World
Alzheimer Report, the global cost of care for dementia will likely
exceed $818 billion in 2015, or 1.09 percent of the world's gross
domestic product (GDP). These costs include those attributed to
informal care from family member or others, direct social care from
professional care givers, and direct medical bills. About 70% of
these costs occur in Western Europe and North America. Such costs
will continue to increase dramatically as the affected population
of dementia increases.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0in"><font face=
"Wingdings">§</font> <i>Cost to Nation</i></p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">According to the Alzheimer’s
Association 2017 Alzheimer’s Disease Facts and Figures, Alzheimer’s
disease is the most expensive condition in the nation. In 2017, the
direct costs to American society of caring for those with
Alzheimer's will total an estimated $236 billion, with just under
half of the costs borne by Medicare. Nearly one in every five
Medicare dollars is spent on people with Alzheimer’s and other
dementias. In 2050, it is estimated it will be one in every three
dollars. The average per-person Medicare spending for those with
Alzheimer's and other dementias is three times higher than for
those without these conditions. The average per-person Medicaid
spending for seniors with Alzheimer's and other dementias is 19
times higher than average per-person Medicaid spending for all
other seniors. Unless something is done, in 2050, Alzheimer’s will
cost over $1.1 trillion (in 2016 dollars). Costs to Medicare will
increase over 365 percent to $589 billion.</p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px"><b>Current Approaches to Treating
Dementia</b></p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">Currently, there is no cure
for dementia. There are a number of prescription drugs that target
those with Alzheimer’s and dementia, however those drugs primarily
relieve some of the disease mechanisms and are often used early in
the course of the disease; however, their effects in long-term
progression of the disease condition are still unclear. A majority
of management of dementia generally focuses on providing emotional
and physical support to a patient during the progression of the
disease from caregivers or in facilities. While such support is
important and necessary to a patient, it is irrelevant to treatment
of the disease. Accordingly, an effective method of treatment which
may be able to delay the progression of the disease and/or recover
damaged brain cells does not presently exist and remains a great
need.</p>
<p style="MARGIN: 0px">&nbsp;</p>
<table id="pagebreak29882576-e475-416e-90a6-292f272f3028" class=
"pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0"
cellpadding="0" width="100%" border="0">
<tr>
<td class="hpbhr">&nbsp;</td>
</tr>
<tr>
<td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center">
28</td>
</tr>
<tr>
<td>
<div style=
"WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div>
&nbsp;</td>
</tr>
<tr>
<td><i><a href="#TOC">Table of Contents</a></i></td>
</tr>
</table>
<p style="MARGIN: 0px">&nbsp;&nbsp;</p>
<p style="MARGIN: 0px"><b>Omentum and its Use in Treating
Dementia</b></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"><u>Omentum Overview</u></p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">The Omentum is a layer of
tissue lying over internal organs (e.g. the intestines) like a
blanket. Omentum has the ability to generate biological agents that
nourish nerves and help them grow. When such agents identified from
the Omentum were tested, they were shown to provoke the growth of
new brain cells in areas of the brain affected by Alzheimer's
disease. The Omentum tissue can also increase the level of
Acetylcholine (ACh) whose reduction is considered as a main cause
of brain cell death. Some scientists believe that the ability of
the Omentum to provide this important factor (ACh) may be a key to
successfully treating dementia. Additionally, the Omentum has been
shown to be angiogenic (i.e. to promote new blood vessel growth) in
areas of the body lacking blood flow.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"><u>Use of Omentum in
Treating Dementia</u></p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">Historically, doctors have
utilized Omentum to treat dementia using a procedure called omental
transposition. This approach involves a surgical procedure in which
the Omentum is surgically lengthened into the brain through the
chest, neck and behind the ear. The Omentum is then laid directly
on the underlying brain. According to studies conducted by a team
in the University of Nevada, School of Medicine, omental
transposition not only arrested Alzheimer's disease, but also
reversed it, resulting in the patient’s neurologic function being
improved. Despite the promising results, this surgical procedure
has not been popular because it is very invasive and therefore
often causes unwanted complications to a patient, especially in the
elderly. Accordingly, a less invasive procedure or a pharmaceutical
approach in treatment of dementia remains a significant need.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px"><b>Research and Development</b></p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">In an effort to develop a
less invasive procedure in the treatment of dementia, on May 16,
2012, we signed an agreement with medical device product
development company Sonos Models, Inc. (“Sonos”) to assess our
options for a medical device solution (“Initial Feasibility Study”
).</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">We completed the Initial
Feasibility Study and, as a result of the findings, entered into an
agreement with Sonos in September 2012 to build up to three medical
device prototypes to be used for testing. In April 2014, we entered
into an addendum to the agreement with Sonos, which included a
commitment by us to pay Sonos up to One Million Dollars
($1,000,000) cash, excluding stock-based compensation, for research
and development costs. These costs will be recognized in research
and development expense as costs are incurred.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">To date, the results of the
research suggest we have three options for implantable devices with
a bias towards having them as non-invasive as possible. The options
are comprised of two electro-stim types that have a multitude of
variable test parameters that can be changed and modified
externally as the testing facility conducts clinical trials on each
patient. It is theorized that if a patient’s response to the
Omentum stimulation is successful, the clinical facility should be
able to perform various tests for the purpose of setting “markers”
for the patient and then perform the standardized cognitive testing
for Alzheimer’s patient with the intent of developing a testing
matrix. It is our objective to test various methods and modalities
with the aim of developing an enormous matrix of input to direct us
to the best solution. Our goal is to be less invasive, as small as
possible and as simple as possible to reach the broadest patient
base. We intend to “Shape and Innovate History” as we visualize and
create a solution for this debilitating disease.</p>
<p style="MARGIN: 0px">&nbsp;</p>
<table id="pagebreak1608dc5b-e285-4e0a-a97b-8d550456f67d" class=
"pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0"
cellpadding="0" width="100%" border="0">
<tr>
<td class="hpbhr">&nbsp;</td>
</tr>
<tr>
<td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center">
29</td>
</tr>
<tr>
<td>
<div style=
"WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div>
&nbsp;</td>
</tr>
<tr>
<td><i><a href="#TOC">Table of Contents</a></i></td>
</tr>
</table>
<p style="MARGIN: 0px">&nbsp;&nbsp;</p>
<p style="MARGIN: 0px" align="justify"><b>Limited Operating
History; Need for Additional Capital</b></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">There is very limited
historical financial information about us on which to base an
evaluation of our performance. We are a smaller reporting
biomedical company and have not generated revenues from operations.
We cannot guarantee we will be successful in our business
operations. Our business is subject to risks inherent in the
establishment of a new business enterprise, including limited
capital resources, and possible cost overruns due to increases in
the cost of services. To become profitable and competitive, we must
receive additional capital. We have no assurance that future
financing will materialize. If that financing is not available, we
may be unable to continue operations.</p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"><b>Overview</b></p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">The following management’s
discussion and analysis of financial condition and results of
operations (“MD&amp;A”) of Cerebain includes the following
sections:</p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px"></p>
<table style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN"
cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td width="4%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top" width="4%"><font style=
"FONT-FAMILY: Symbol">·</font></td>
<td valign="top">Results of Operations</td>
</tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top"><font style="FONT-FAMILY: Symbol">·</font></td>
<td valign="top">Liquidity and Capital Resources</td>
</tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top"><font style="FONT-FAMILY: Symbol">·</font></td>
<td valign="top">Capital Expenditures</td>
</tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top"><font style="FONT-FAMILY: Symbol">·</font></td>
<td valign="top">Fiscal Year End</td>
</tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top"><font style="FONT-FAMILY: Symbol">·</font></td>
<td valign="top">Going Concern</td>
</tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top"><font style="FONT-FAMILY: Symbol">·</font></td>
<td valign="top">Critical Accounting Policies</td>
</tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top"><font style="FONT-FAMILY: Symbol">·</font></td>
<td valign="top">Recent Accounting Pronouncements</td>
</tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top"><font style="FONT-FAMILY: Symbol">·</font></td>
<td valign="top">Off-Balance Sheet Arrangements</td>
</tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top"><font style="FONT-FAMILY: Symbol">·</font></td>
<td valign="top">Inflation</td>
</tr>
</table>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px"><b>Results of Operations</b></p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"><b>Three Months Ended March
31, 2018 Compared to Three Months Ended March 31, 2017</b></p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px"><b><i>Revenue</i></b></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">For the three-month periods
ended March 31, 2018 and 2017, we did not generate any
revenues.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"><b><i>Operating
expenses</i></b></p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">Operating expenses decreased
by approximately $103,000, or 19.64%, to approximately $422,000 in
the three-month period ended March 31, 2018 from approximately
$525,000 in the three-month period ended March 31, 2017 primarily
due to the following: decrease in consultant costs, including costs
related to fair value of stock and warrants issued for services and
amortization of compensation costs related to stock options as we
have fully amortized some of the expenses associated with these
costs; offset by an increase in research and development costs as
we continue to fund the development of the medical device; an
increase in compensation and employee expenses; increase in
professional fees due to an increase in legal fees and expenses;
and increase in travel and entertainment expenses due to increase
in required travel.</p>
<p style="MARGIN: 0px">&nbsp;</p>
<table id="pagebreak74792bb9-3a78-4d4d-9e40-e9308de3aaba" class=
"pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0"
cellpadding="0" width="100%" border="0">
<tr>
<td class="hpbhr">&nbsp;</td>
</tr>
<tr>
<td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center">
30</td>
</tr>
<tr>
<td>
<div style=
"WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div>
&nbsp;</td>
</tr>
<tr>
<td><i><a href="#TOC">Table of Contents</a></i></td>
</tr>
</table>
<p style="MARGIN: 0px">&nbsp;&nbsp;</p>
<p style="MARGIN: 0px" align="justify">Operating expenses for the
three-month period ended March 31, 2018 were primarily comprised of
(amounts approximate) marketing costs of $2,500, research and
development costs of $80,000, patent royalty expense of $25,000,
consulting services costs primarily paid through the issuance of
our common stock of $64,000, compensation expense of $84,000,
employee expense of $103,000; professional fees of $41,000, travel
and entertainment costs of $18,000, and other operating expenses of
$4,500.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">Operating expenses for the
three-months ended March 31, 2017 were primarily comprised of
(amounts approximate) marketing costs of $1,600, research and
development costs of $59,000, patent royalty expense of $25,000,
consulting services costs primarily paid through the issuance of
our common stock of $232,000, compensation expense of $77,500,
employee expense of $95,000, professional fees of $20,000, travel
and entertainment costs of $11,000, and other operating expenses of
$2,500.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"><b><i>Other income
(expenses)</i></b></p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">Other expense increased by
approximately $191,000, or 452.63%, to approximately $233,044 in
the three-month period ended March 31, 2018 from approximately
$42,000 in the three-month period ended March 31, 2017 primarily
due to a significant increase in interest expense due to the
recognition of derivative liabilities associated with the issuance
of convertible promissory notes and warrants; increase in accretion
of recorded debt discounts related to notes payable; and the
recognition in the change of fair value of warrant liability,
offset by a decrease in the change of fair value of derivative
liability.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"><b><i>Net loss before income
taxes</i></b></p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">Net loss before income taxes
for the three-month period ended March 31, 2018 totaled
approximately $655,000 compared to $567,000 for the three-month
period ended March 31, 2017. The increase in net loss before income
taxes was primarily due to the following: a significant increase in
interest expense due to the recognition of derivative liabilities
associated with the issuance of convertible promissory notes and
warrants; increase in accretion of recorded debt discounts related
to notes payable; the recognition in the change of fair value of
warrant liability; and increase in research and development costs
as we continue to fund the development of the medical device; an
increase in compensation and employee expenses; increase in
professional fees due to an increase in legal fees and expenses;
and increase in travel and entertainment expenses due to increase
in required travel, offset by a decrease in the change of fair
value of derivative liability and decrease in consultant costs,
including costs related to fair value of stock and warrants issued
for services and amortization of compensation costs related to
stock options as we have fully amortized some of the expenses
associated with these costs.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"><b>Nine Months Ended March
31, 2018 Compared to Nine Months Ended March 31, 2017</b></p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px"><b><i>Revenue</i></b></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">For the nine-month periods
ended March 31, 2018 and 2017, we did not generate any
revenues.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"><b><i>Operating
expenses</i></b></p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">Operating expenses decreased
by approximately $464,000, or 30.08%, to approximately $1,080,000
in the nine-month period ended March 31, 2018 from approximately
$1,540,000 in the nine-month period ended March 31, 2017 primarily
due to the following: decrease in marketing expense; decrease in
consultant costs, including costs related to fair value of stock
and warrants issued for services and amortization of compensation
costs related to stock options as we have fully amortized some of
the expenses associated with these costs; decrease in compensation
expense due to some of the expense having been fully amortized;
decrease in compensation expense as some of the expenses have been
fully amortized; decrease in professional fees due to the
settlement of the Miller litigation; and decrease in investor
relations; offset by increase in research and development cost as
we continue to fund the development of the medical device; increase
in employee expense; and increase in travel and entertainment
expenses due to increase in required travel.</p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">Operating expenses for the
nine-months ended March 31, 2018 were primarily comprised of
(amounts approximate) marketing costs of $8,700, research and
development costs of $205,000, patent royalty expense of $75,000,
consulting services costs primarily paid through the issuance of
our common stock of $249,000, compensation expense of $115,000,
employee expenses of $293,000, professional fees of $84,000,
investor relations expense of $1,000, travel and entertainment
costs of $37,000, and other operating expenses of $12,000.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<table id="pagebreak12b4d3a0-ca37-40ac-bb74-70483eada063" class=
"pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0"
cellpadding="0" width="100%" border="0">
<tr>
<td class="hpbhr">&nbsp;</td>
</tr>
<tr>
<td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center">
31</td>
</tr>
<tr>
<td>
<div style=
"WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div>
&nbsp;</td>
</tr>
<tr>
<td><i><a href="#TOC">Table of Contents</a></i></td>
</tr>
</table>
<p style="MARGIN: 0px">&nbsp;&nbsp;</p>
<p style="MARGIN: 0px" align="justify">Operating expenses for the
nine-months ended March 31, 2017 were primarily comprised of
(amounts approximate) marketing costs of $10,000, research and
development costs of $190,000, patent royalty expense of $75,000,
consulting services costs primarily paid through the issuance of
our common stock of $746,000, compensation expense of $264,000,
employee expense of $95,000, professional fees of $108,000,
investor relations expense of $10,000, travel and entertainment
costs of $33,000, and other operating expenses of $11,000.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"><b><i>Other income
(expenses)</i></b></p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">Other expense decreased by
approximately $10,486,000, or 75.41%, to approximately $3,420,000
in the nine-month period ended March 31, 2017 from approximately
$13,900,000 in the nine-month period ended March 31, 2017 primarily
due to a significant decrease in loss from extinguishment of debt
due to the embedded conversion feature meeting the criteria in ASC
470-50-40-10 or 470-20-25 and the issuance of the convertible
promissory note payable is considered an extinguishment that would
require the recognition of a loss and the decrease in accretion of
recorded debt discounts related to notes payable; and decrease in
the change of fair value of derivative liability, offset by an
increase in interest expense due to the recognition of derivative
liabilities associated with the issuance of convertible promissory
notes and warrants; increase in accretion of recorded debt
discounts related to notes payable; and the recognition in the
change of fair value of warrant liability.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"><b><i>Net loss before income
taxes</i></b></p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">Net loss before income taxes
for the nine-month period ended March 31, 2018 totaled
approximately $4,500,000 compared to $15,500,000 for the nine-month
period ended March 31, 2017. The decrease in net loss before income
taxes was primarily due to the following: a significant decrease in
loss from extinguishment of debt due to the embedded conversion
feature meeting the criteria in ASC 470-50-40-10 or 470-20-25 and
the issuance of the convertible promissory note payable is
considered an extinguishment that would require the recognition of
a loss; decrease in the change of fair value of derivative
liability; decrease in marketing expense; decrease in consultant
costs, including costs related to fair value of stock and warrants
issued for services and amortization of compensation costs related
to stock options as we have fully amortized some of the expenses
associated with these costs; decrease in compensation expense due
to some of the expense having been fully amortized; decrease in
compensation expense as some of the expenses have been fully
amortized; decrease in professional fees due to the settlement of
the Miller litigation; and decrease in investor relations offset by
an increase in interest expense due to the recognition of
derivative liabilities associated with the issuance of convertible
promissory notes and warrants; increase in accretion of recorded
debt discounts related to notes payable; and the recognition in the
change of fair value of warrant liability; increase in research and
development cost as we continue to fund the development of the
medical device; increase in employee expense; and increase in
travel and entertainment expenses due to increase in required
travel.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px"><b><i>Assets and Liabilities</i></b></p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">Assets were approximately
$125,000 as of March 31, 2018. Assets consisted of cash of
approximately $30,000 and prepaid expense of approximately $95,000.
Liabilities were approximately $5,320,000 as of March 31, 2018.
Liabilities primarily consisted of (amounts approximate) accounts
payable of $1,030,000, related party payables of $325,000, accrued
payroll of $161,000, payroll taxes payable of $70,000, short term
related party notes payable of $364,000, current portion of
convertible notes of $345,000, short term convertible notes
payable, net of debt discount, of $23,750, derivative liabilities
of $320,000, warrant liabilities of $97,000 and convertible notes
to stockholders, net of debt discount, of $2,584,000.</p>
<p style="MARGIN: 0px">&nbsp;</p>
<table id="pagebreak9402b01d-ba97-4429-bb0e-7c452d858ccd" class=
"pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0"
cellpadding="0" width="100%" border="0">
<tr>
<td class="hpbhr">&nbsp;</td>
</tr>
<tr>
<td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center">
32</td>
</tr>
<tr>
<td>
<div style=
"WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div>
&nbsp;</td>
</tr>
<tr>
<td><i><a href="#TOC">Table of Contents</a></i></td>
</tr>
</table>
<p style="MARGIN: 0px">&nbsp;&nbsp;</p>
<p style="MARGIN: 0px" align="justify"><b><i>Stockholders’
Deficit</i></b></p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">Stockholders’ deficit was
approximately $5,195,000 as of March 31, 2018. Stockholder’s
deficit consisted primarily of deficit accumulated of approximately
$32,000,000 at March 31, 2018, offset by shares issued to founders
and recorded as compensation in the amount of $13,900, shares
issued for fundraising totaling $1,781,000, net of issuance costs,
beneficial conversion feature associated with convertible note of
$18,361,000, shares issued in conversion of liabilities of
$758,000, shares associated with warrants, options and issuances
for services of $5,900,000 and shares issued for patent rights
totaling $6,600.</p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"><b>Liquidity and Capital
Resources</b></p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"><b><i>General</i></b> –
Overall, we had an increase in cash flows of approximately $19,000
in the nine-month period ended March 31, 2018 resulting from cash
used in operating activities of approximately $685,000, offset
partially by cash provided by financing activities of approximately
$703,000.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">The following is a summary
of our cash flows provided by (used in) operating and financing
activities during the periods indicated:</p>
<p style="MARGIN: 0px">&nbsp;</p>
<table style=
"WIDTH: 100%; TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN"
cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="hdcell" style="BORDER-BOTTOM: black 1px solid" valign=
"bottom" colspan="6" align="center">
<p style="MARGIN: 0px" align="center"><b>Nine Months Ended March
31,</b></p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px"><b>&nbsp;</b></p>
</td>
</tr>
<tr>
<td valign="bottom">
<p style="MARGIN: 0px"><b>&nbsp;</b></p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px"><b>&nbsp;</b></p>
</td>
<td id="hdcell" style="BORDER-BOTTOM: 1px solid" valign="bottom"
width="9%" colspan="2" align="center">
<p style="MARGIN: 0px" align="center"><b>2018</b></p>
</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom">
<p style="MARGIN: 0px"><b>&nbsp;</b></p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px"><b>&nbsp;</b></p>
</td>
<td id="hdcell" style="BORDER-BOTTOM: 1px solid" valign="bottom"
width="9%" colspan="2" align="center">
<p style="MARGIN: 0px" align="center"><b>2017</b></p>
</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" colspan="2" align=
"right">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" colspan="2" align=
"right">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#CCEEFF">
<td valign="top">
<p style="MARGIN: 0px" align="justify">Cash at beginning of
period</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">$</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
11,345</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">$</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
20,245</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#FFFFFF">
<td valign="top">
<p style="MARGIN: 0px" align="justify">Net cash used in operating
activities</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
(684,531</td>
<td valign="bottom" width="1%">)</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
(445,728</td>
<td valign="bottom" width="1%">)</td>
</tr>
<tr bgcolor="#CCEEFF">
<td valign="top">
<p style="MARGIN: 0px" align="justify">Net cash provided by
financing activities</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: 1px solid" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" style="BORDER-BOTTOM: 1px solid" valign="bottom"
width="9%" align="right">703,250</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: 1px solid" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" style="BORDER-BOTTOM: 1px solid" valign="bottom"
width="9%" align="right">426,000</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#FFFFFF">
<td valign="top">
<p style="MARGIN: 0px" align="justify">Cash at end of period</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: 3px double" valign="bottom" width="1%">
$</td>
<td id="ffcell" style="BORDER-BOTTOM: 3px double" valign="bottom"
width="9%" align="right">30,064</td>
<td style="PADDING-BOTTOM: 3px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: 3px double" valign="bottom" width="1%">
$</td>
<td id="ffcell" style="BORDER-BOTTOM: 3px double" valign="bottom"
width="9%" align="right">517</td>
<td style="PADDING-BOTTOM: 3px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
</table>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"><b><i>Cash Flows from
Operating Activities</i></b> – For the nine-month period ended
March 31, 2018, net cash used in operations was approximately
$685,000 compared to net cash used in operations of approximately
$446,000 for the nine-month period ended March 31, 2017. Net cash
used in operations for the nine-month period ended March 31, 2018
was primarily due to a net loss of approximately $4,500,000,
accretion of debt discount of approximately $29,000, initial fair
value of derivative liability included as interest expense of
approximately $173,000, decrease in the change in derivative
liabilities of approximately $10,000, change in warrant liabilities
of approximately $600, loss from extinguishment of debt of
approximately $3,102,000, stock-based compensation of approximately
$115,000, amortization of prepaid consulting compensation of
approximately $186,000, stock compensation for legal services of
approximately $15,000, and the changes in operating assets and
liabilities of approximately $203,000.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"><b><i>Cash Flows from
Financing Activities</i></b> – Net cash flows provided by financing
activities in the nine-month period ended March 31, 2018 was
approximately $703,000, compared to net cash provided of
approximately $426,000 in the same period in 2017. The cash
provided by financing activities for the nine-month period ended
March 31, 2018 was due to proceeds from promissory notes payable to
stockholders of approximately $175,000, proceeds from issuance of
stock of approximately $290,000 and proceeds from issuance of short
term convertible notes of approximately $253,000 offset by
repayment of promissory notes of approximately $15,000.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"><b><i>Financing</i></b> – We
expect that our current working capital position, together with our
expected future cash flows from operations will be insufficient to
fund our operations in the ordinary course of business, anticipated
capital expenditures, debt payment requirements and other
contractual obligations for at least the next twelve months.
However, this belief is based upon many assumptions and is subject
to numerous risks, and we will require additional funding in the
future.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">We have no present
agreements or commitments with respect to any material acquisitions
of other businesses, products, product rights or technologies or
any other material capital expenditures. However, we will continue
to evaluate acquisitions of and/or investments in products,
technologies, capital equipment or improvements or companies that
complement our business and may make such acquisitions and/or
investments in the future. Accordingly, we may need to obtain
additional sources of capital in the future to finance any such
acquisitions and/or investments. We may not be able to obtain such
financing on commercially reasonable terms, if at all. Even if we
are able to obtain additional financing, it may contain undue
restrictions on our operations, in the case of debt financing, or
cause substantial dilution for our stockholders, in the case of
equity financing.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<table id="pagebreakd72f8040-eb70-46f1-9f14-a9a183753fdc" class=
"pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0"
cellpadding="0" width="100%" border="0">
<tr>
<td class="hpbhr">&nbsp;</td>
</tr>
<tr>
<td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center">
33</td>
</tr>
<tr>
<td>
<div style=
"WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div>
&nbsp;</td>
</tr>
<tr>
<td><i><a href="#TOC">Table of Contents</a></i></td>
</tr>
</table>
<p style="MARGIN: 0px">&nbsp;&nbsp;</p>
<p style="MARGIN: 0px" align="justify"><b>Capital
Expenditures</b></p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"><i>Other Capital
Expenditures</i></p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">If we have the funds
available, we expect to purchase approximately $30,000 of equipment
in connection with the expansion of the business, primarily related
to office equipment and supplies.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"><b>Fiscal Year End</b></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">Cerebain and Cerebain
Biotech each has a June 30 fiscal year end.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"><b>Going Concern</b></p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">The accompanying unaudited
condensed consolidated financial statements have been prepared
assuming we will continue as a going concern, which contemplates,
among other things, the realization of assets and satisfaction of
liabilities in the normal course of business. We had an accumulated
deficit of approximately $32,000,000 and $27,500,000 at March 31,
2018 and June 30, 2017, respectively, and had a net loss of
approximately $4,500,000 and $15,500,000 for the nine-month periods
ended March 31, 2018 and 2017, respectively, net cash used in
operating activities of approximately $685,000 and $446,000 for the
nine-month periods ended March 31, 2018 and June 30, 2017,
respectively, with no revenue earned since inception, and limited
cash of $30,000 and $11,000 at March 31, 2018 and June 30, 2017,
respectively. These matters raise substantial doubt about our
ability to continue as a going concern.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">While we are attempting to
commence operations, and attempting to generate revenues, our cash
position will not be significant enough to support our daily
operations. Management intends to raise additional funds by way of
a public or private offering. Management believes that the actions
presently being taken to further implement its business plan and
generate revenues provide the opportunity for us to continue as a
going concern. While we believe in the viability of its strategy to
generate revenues and in its ability to raise additional funds,
there can be no assurances to that effect. Our ability to continue
as a going concern is dependent upon our ability to further
implement our business plan, generate revenues, and successfully
borrow money or sell our securities for cash.</p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">The financial statements do
not include any adjustments that might be necessary if we are
unable to continue as a going concern.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"><b>Critical Accounting
Policies</b></p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">The Commission has defined a
company’s critical accounting policies as the ones that are most
important to the portrayal of our financial condition and results
of operations and which require us to make its most difficult and
subjective judgments, often as a result of the need to make
estimates of matters that are inherently uncertain. Based on this
definition, we have identified the critical accounting policies and
judgments addressed below. We also have other key accounting
policies that are significant to understanding our results. For
additional information, see Note 3 - Summary of Significant
Accounting Policies on page 9.</p>
<p style="MARGIN: 0px; TEXT-INDENT: 19.8pt" align="justify">
&nbsp;</p>
<p style="MARGIN: 0px" align="justify">The following are deemed to
be the most significant accounting policies affecting us.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px"><i>Use of Estimates</i></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">The preparation of financial
statements in conformity with generally accepted accounting
principles in the United States requires us to make estimates and
assumptions that affect the reported amounts of assets and
liabilities and disclosure of contingent assets and liabilities at
the date of the financial statements, and the reported amounts of
revenue and expenses during the reporting periods. Measurement,
estimates and assumptions are used for, but not limited to, useful
lives and residual value of long-lived assets, and the valuation of
equity instruments. We make these estimates using the best
information available at the time the estimates are made; however
actual results when ultimately realized could differ from those
estimates. The more significant estimates and assumptions by
management include among others: useful lives and residual values
of long-lived assets, the valuation of equity instruments, the
valuation of warrants and options, the valuation of derivative
liabilities, and the valuation of warrant liabilities.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<table id="pagebreakd1ad9114-4787-48a5-9c85-6e2e13bf1948" class=
"pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0"
cellpadding="0" width="100%" border="0">
<tr>
<td class="hpbhr">&nbsp;</td>
</tr>
<tr>
<td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center">
34</td>
</tr>
<tr>
<td>
<div style=
"WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div>
&nbsp;</td>
</tr>
<tr>
<td><i><a href="#TOC">Table of Contents</a></i></td>
</tr>
</table>
<p style="MARGIN: 0px">&nbsp;&nbsp;</p>
<p style="MARGIN: 0px" align="justify"><i>Income Taxes</i></p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">We account for income taxes
under the Financial Accounting Standards Board (“FASB”) Accounting
Standards Codification (“ASC”) No. 740, Income Taxes (“ASC 740”).
Under ASC 740, deferred tax assets and liabilities are recognized
for the future tax consequences attributable to differences between
the financial statement carrying amounts of existing assets and
liabilities and their respective tax bases. Deferred tax assets and
liabilities are measured using enacted tax rates expected to apply
to taxable income in the years in which those temporary differences
are expected to be recovered or settled. Under ASC 740, the effect
on deferred tax assets and liabilities of a change in tax rates is
recognized in income in the period that includes the enactment
date.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"><i>Stock
Compensation</i></p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">We account for employee and
non-employee stock awards under ASC 718, Compensation – Stock
Compensation, whereby equity instruments issued to employees for
services are recorded based on the fair value of the instrument
issued and those issued to nonemployees are recorded based on the
fair value of the consideration received or the fair value of the
equity instrument, whichever is more reliably measurable.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"><i>Convertible debt –
derivative treatment</i></p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">When we issue debt with a
conversion feature, we must first assess whether the conversion
feature meets the requirements to be treated as a derivative, as
follows: a) one or more underlyings, typically the price of our
common stock; b) one or more notional amounts or payment provisions
or both, generally the number of shares upon conversion; c) no
initial net investment, which typically excludes the amount
borrowed; and d) net settlement provisions, which in the case of
convertible debt generally means the stock received upon conversion
can be readily sold for cash. An embedded equity-linked component
that meets the definition of a derivative does not have to be
separated from the host instrument if the component qualifies for
the scope exception for certain contracts involving an issuer’s own
equity. The scope exception applies if the contract is both a)
indexed to its own stock; and b) classified in shareholders’ equity
in its statement of financial position.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">If the conversion feature
within convertible debt meets the requirements to be treated as a
derivative, we estimate the fair value of the convertible debt
derivative using the Monte Carlo Method upon the date of issuance.
If the fair value of the convertible debt derivative is higher than
the face value of the convertible debt, the excess is immediately
recognized as interest expense. Otherwise, the fair value of the
convertible debt derivative is recorded as a liability with an
offsetting amount recorded as a debt discount, which offsets the
carrying amount of the debt. The convertible debt derivative is
revalued at the end of each reporting period and any change in fair
value is recorded as a gain or loss in the statement of operations.
The debt discount is amortized through interest expense over the
life of the debt.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"><i>Fair Value of Financial
Instruments</i></p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">We follow the provisions of
ASC 820. This Topic defines fair value, establishes a measurement
framework and expands disclosures about fair value
measurements.</p>
<p style="MARGIN: 0px">&nbsp;&nbsp;</p>
<p style="MARGIN: 0px" align="justify">We use fair value
measurements for determining the valuation of derivative financial
instruments payable in shares of its common stock. This primarily
involves option pricing models that incorporate certain assumptions
and projections to determine fair value. These require our
judgment.</p>
<p style="MARGIN: 0px">&nbsp;</p>
<table id="pagebreak1cd63f5e-9aa0-46b6-8628-23e285b25a39" class=
"pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0"
cellpadding="0" width="100%" border="0">
<tr>
<td class="hpbhr">&nbsp;</td>
</tr>
<tr>
<td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center">
35</td>
</tr>
<tr>
<td>
<div style=
"WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div>
&nbsp;</td>
</tr>
<tr>
<td><i><a href="#TOC">Table of Contents</a></i></td>
</tr>
</table>
<p style="MARGIN: 0px">&nbsp;&nbsp;</p>
<p style="MARGIN: 0px" align="justify"><b>Recent Accounting
Pronouncements</b></p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">We have evaluated new
accounting pronouncements that have been issued and are not yet
effective for us and determined that there are no such
pronouncements expected to have a significant impact on our future
financial statements.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px"><b>Off-Balance Sheet Arrangements</b></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px">We are a smaller reporting Company as
defined by Rule 12b-2 of the Securities Exchange Act of 1934 and
are not required to provide the information under this item.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"><b>Inflation</b></p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">Management believes that
inflation has not had a material effect on our results of
operations.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"><a name=
"ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK">
<b>ITEM 3.</b> <b>QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT
MARKET RISK</b></a></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px">We are a smaller reporting Company as
defined by Rule 12b-2 of the Securities Exchange Act of 1934 and
are not required to provide the information under this item.</p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px"><a name=
"ITEM 4. CONTROLS AND PROCEDURES"><b>ITEM 4.</b> <b>CONTROLS AND
PROCEDURES</b></a></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"><b>Evaluation of Disclosure
Controls and Procedures</b></p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">We maintain disclosure
controls and procedures (as defined in Rule 13a-l5(e) under the
Exchange Act) that are designed to ensure that information that
would be required to be disclosed in Exchange Act reports is
recorded, processed, summarized and reported within the time period
specified in the SEC’s rules and forms, and that such information
is accumulated and communicated to our management, including to our
Chief Executive Officer and Chief Financial Officer, as
appropriate, to allow timely decisions regarding required
disclosure.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">As required by Rule 13a-15
under the Exchange Act, our management, including our Chief
Executive Officer (our Principal Executive Officer) and Chief
Financial Officer (our Principal Financial Officer), evaluated the
effectiveness of the design and operation of our disclosure
controls and procedures as of March 31, 2018. Based on that
evaluation, our Chief Executive Officer and Chief Financial Officer
concluded that as of March 31, 2018, and as of the date that the
evaluation of the effectiveness of our disclosure controls and
procedures was completed, our disclosure controls and procedures
were not effective to satisfy the objectives for which they are
intended.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"><b>Management’s Report on
Internal Controls over Financial Reporting</b></p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">Our management is
responsible for establishing and maintaining effective internal
control over financial reporting (as defined in Rule 13a-l5(f) of
the Securities Exchange Act). Management assessed the effectiveness
of the Company’s internal control over financial reporting as of
March 31, 2018. In making this assessment, management used the
criteria set forth by the Committee of Sponsoring Organizations of
the Treadway Commission in the 2013 Internal Control – Integrated
Framework (“COSO”). Based on that assessment, management believes
that, as of March 31, 2018, our internal control over financial
reporting was ineffective, based on the COSO criteria, due to the
following material weaknesses listed below.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"></p>
<table style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN"
cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td width="4%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top" width="4%"><font style=
"FONT-FAMILY: Symbol">·</font></td>
<td valign="top">We have not performed a risk assessment and mapped
our processes to control objectives.</td>
</tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top"><font style="FONT-FAMILY: Symbol">·</font></td>
<td valign="top">We have not implemented comprehensive entity-level
internal controls.</td>
</tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top"><font style="FONT-FAMILY: Symbol">·</font></td>
<td valign="top">We have not implemented adequate system and manual
controls.</td>
</tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top"><font style="FONT-FAMILY: Symbol">·</font></td>
<td valign="top">We do not have sufficient segregation of
duties.</td>
</tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top"><font style="FONT-FAMILY: Symbol">·</font></td>
<td valign="top">We lack sufficient personnel with appropriate
training and expertise in accounting principles general accepted in
the United States.</td>
</tr>
</table>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">Despite the material
weaknesses reported above, our management believes that our
financial statements included in this report fairly present in all
material respects our financial condition, results of operations
and cash flows for the periods presented and that this report does
not contain any untrue statement of a material fact or omit to
state a material fact necessary to make the statements, in light of
the circumstances under which such statements were made, not
misleading with respect to the period covered by this report.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"><b>Changes in Internal
Control over Financial Reporting</b></p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">There was no change in our
internal control over financial reporting during the period ended
March 31, 2018, that has materially affected, or is reasonably
likely to materially affect, our internal control over financial
reporting.</p>
<p style="MARGIN: 0px">&nbsp;</p>
<table id="pagebreak163549a0-8eed-4b03-a88f-1f82493304c1" class=
"pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0"
cellpadding="0" width="100%" border="0">
<tr>
<td class="hpbhr">&nbsp;</td>
</tr>
<tr>
<td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center">
36</td>
</tr>
<tr>
<td>
<div style=
"WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div>
&nbsp;</td>
</tr>
<tr>
<td><i><a href="#TOC">Table of Contents</a></i></td>
</tr>
</table>
<p style="MARGIN: 0px">&nbsp;&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 0in" align="left"><b><a name=
"PART II. OTHER INFORMATION">PART II. OTHER INFORMATION</a></b></p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"><a name=
"ITEM 1. LEGAL PROCEEDINGS"><b>ITEM 1.</b> <b>LEGAL
PROCEEDINGS</b></a></p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">On July 21, 2016, we were
sued in the United States District Court for the Eastern District
of Pennsylvania (<i><u>Miriam Weber Miller v. Cerebain Biotech
Corp. and Eric Clemons</u></i>, Civil Action No. 16-3943) by Miriam
Weber Miller, with Mr. Clemons named as an individual defendant.
According to the Complaint, the Plaintiff alleged: (i) she was
hired by us to perform public relations, investor relations,
corporate growth strategies, and was to be an advisor to our Chief
Executive Officer, (ii) she performed services, and (iii) that she
was not fully compensated for those services. The Complaint claimed
causes of action for breach of contract, violation of the
Pennsylvania wage payment and collection law, and unjust
enrichment, and sought damages of approximately $400,000. On April
3, 2017, without admitting fault or liability, and still denying
the same, we made a business decision to resolve the lawsuit and it
is now settled, effectively ending the litigation. In consideration
for signing the agreement, we agreed to pay Ms. Miller as
follows:</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px 0px 0px 0in" align="justify">We paid Ms.
Miller the total gross amount of one hundred twenty thousand
dollars ($120,000) as follows:</p>
<p style="MARGIN: 0px; TEXT-INDENT: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 0px" align="justify"></p>
<table style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN"
cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td valign="top" width="3%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top" width="3%">a)</td>
<td valign="top">One payment of twenty thousand dollars ($20,000)
within thirty (30) days after March 29, 2017; and</td>
</tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr>
<td valign="top" width="3%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top" width="3%">b)</td>
<td valign="top">Beginning within ninety (90) days after March 29,
2017, we made monthly payments of fifteen thousand dollars
($15,000) to Ms. Miller’s representative until such time that Ms.
Miller and her representative has received the gross amount of
$120,000<u>.</u></td>
</tr>
</table>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">Upon all payments being made
pursuant to the terms set forth in the agreement, Ms. Miller has
agreed to knowingly and voluntarily release and discharge us of and
from all claims, demands, liabilities, obligations, promises,
controversies, compensation, wages, bonuses, commissions, damages,
rights, actions and causes of action known and unknown, at law or
in equity, which Ms. Miller has or may have against us as of the
date of execution of the settlement agreement.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">We had recognized an accrual
in Accounts Payable for payment of the agreed upon settlement, but
no accrual has been made for additional legal contingencies in the
consolidated financial statements as of March 31, 2018. For the
nine-month and three-month periods ended March 31, 2018, we paid
Ms. Miller $85,000 and $0, respectively, as agreed in the
settlement agreement. As of March 31, 2018, the terms of the
settlement agreement have been met and Ms. Miller has been paid in
full.</p>
<p style="MARGIN: 0px">&nbsp;</p>
<table id="pagebreak2d763637-12e7-40d9-8184-94a284d2dd12" class=
"pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0"
cellpadding="0" width="100%" border="0">
<tr>
<td class="hpbhr">&nbsp;</td>
</tr>
<tr>
<td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center">
37</td>
</tr>
<tr>
<td>
<div style=
"WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div>
&nbsp;</td>
</tr>
<tr>
<td><i><a href="#TOC">Table of Contents</a></i></td>
</tr>
</table>
<p style="MARGIN: 0px">&nbsp;&nbsp;</p>
<p style="MARGIN: 0px" align="justify">The following table
summarizes the dates and payments made to Ms. Miller:</p>
<p style="MARGIN: 0px">&nbsp;</p>
<table style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN"
cellspacing="0" cellpadding="0" width="85%" align="center" border=
"0">
<tr>
<td style="BORDER-BOTTOM: 1px solid" valign="bottom">
<p style="MARGIN: 0px" align="left"><b>Date of Payment</b></p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px"><b>&nbsp;</b></p>
</td>
<td id="hdcell" style="BORDER-BOTTOM: 1px solid" valign="bottom"
width="9%" colspan="2" align="center">
<p style="MARGIN: 0px" align="center"><b>Amount</b></p>
</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#CCEEFF">
<td valign="top">
<p style="MARGIN: 0px" align="justify">April 27, 2017</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">$</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
20,000</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#FFFFFF">
<td valign="top">
<p style="MARGIN: 0px" align="justify">June 29, 2017</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
15,000</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#CCEEFF">
<td valign="top">
<p style="MARGIN: 0px" align="justify">July 25, 2017</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
15,000</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#FFFFFF">
<td valign="top">
<p style="MARGIN: 0px" align="justify">September 5, 2017</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
15,000</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#CCEEFF">
<td valign="top">
<p style="MARGIN: 0px" align="justify">September 28, 2017</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
15,000</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#FFFFFF">
<td valign="top">
<p style="MARGIN: 0px" align="justify">October 27, 2017</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
15,000</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#CCEEFF">
<td valign="top">
<p style="MARGIN: 0px" align="justify">November 27, 2017</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
15,000</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#FFFFFF">
<td valign="top">
<p style="MARGIN: 0px" align="justify">December 28, 2017</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: 1px solid" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" style="BORDER-BOTTOM: 1px solid" valign="bottom"
width="9%" align="right">10,000</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#CCEEFF">
<td valign="top">
<p style="MARGIN: 0px" align="justify">Total</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: 3px double" valign="bottom" width="1%">
$</td>
<td id="ffcell" style="BORDER-BOTTOM: 3px double" valign="bottom"
width="9%" align="right">120,000</td>
<td style="PADDING-BOTTOM: 3px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
</table>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"><a name=
"ITEM 1A. RISK FACTORS"><b>ITEM 1A.</b> <b>RISK FACTORS</b></a></p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">There have been no changes
to our Risk Factors included in our Annual Report on Form 10-K
filed with the Securities and Exchange Commission on September 15,
2017.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px"><a name=
"ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS">
<b>ITEM 2.</b> <b>UNREGISTERED SALES OF EQUITY SECURITIES AND USE
OF PROCEEDS</b></a></p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">For the three-month period
ended March 31, 2018, we entered into a stock purchase agreement
with a non-affiliate stockholder, under which we issued 220,000
shares of our common stock, in exchange for $110,000. In connection
with the stock purchase agreement, we issued warrants to purchase
220,000 shares of our common stock at $1.00 per share. Based on the
representations of the stockholder in the stock purchase agreement,
the issuance of the shares and the warrant were exempt from
registration pursuant to Section 4(a)(2) of the Securities Act of
1933. The investor was accredited and sophisticated, familiar with
our operations, and there was no solicitation.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">For the three-month period
ended March 31, 2018, we issued 420,000 fully vested,
nonforfeitable shares of common stock to various individuals as
payment for legal services and employee stock awards per agreements
dated between January 2018 and March 2018. The aggregate fair
market value of these shares was approximately $73,000 as the fair
market value of the stock was between $0.15 and $0.18 per share. We
used recent sales of stock to determine the fair market value of
these transactions. Based on the information provided to us by the
individuals, the issuance of the shares were exempt from
registration pursuant to Section 4(a)(2) of the Securities Act of
1933. The investors were sophisticated, familiar with our
operations, and there was no solicitation.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"><u>Crown Bridge
Partners</u></p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">On March 2, 2018, we held an
initial closing under a Securities Purchase Agreement (the “Crown
SPA”) and corresponding Convertible Promissory Note (the “Crown
Note”) with Crown Bridge Partners, LLC (“Crown”), dated February
14, 2018. Under the Crown SPA and the Crown Note, Crown agreed to
loan us up to One Hundred Thirty Thousand Dollars ($130,000) in
tranches. The Crown Note has an original issuance discount of
$13,000, meaning the maximum amount we can borrow under the Crown
Note is $117,000. The initial tranche on March 2, 2018 was $65,000,
with us receiving $58,500 and the remaining $6,500 being retained
by Crown as the portion of the prorated original issuance discount.
The Crown Note bears interest at Ten Percent (10%) per annum and
matures twelve (12) months from the date of each tranche, with the
initial tranche of $65,000 maturing on March 2, 2019. Under the
terms of the Crown Note, Crown has the right, at any time to
convert all or part of the amounts due to it under the Crown Note
into shares of our common stock. The conversion price is 55% of the
lesser of (a) the lowest traded price or (b) the lowest closing bid
price, of our common stock on the twenty-five trading days prior to
the conversion date. However, Crown may not convert the amounts due
under the Note into shares of our common stock if such conversion
would cause it to own more than 4.99% of our then-outstanding
common stock, which limitation may be waived by Crown upon 61
days-notice. In the event we default under the terms of the Crown
Note, we owe 150% of the principal amount then due under the Note,
plus any unpaid interest, immediately. We may prepay the amounts
loaned to us under the Crown Note as follows: (i) during the
initial 60-day period after each tranche, at 125% multiplied by the
amount we are prepaying, (ii) during the 61st through 120 days
after each tranche, at 135% multiplied by the amount we are
prepaying, and (iii) during the 121st through 180th day after each
tranche, at 150% multiplied by the amount we are prepaying. Any
prepayments are subject to Crown’s written acceptance of such
prepayment. After 180 days from each tranche we cannot prepay that
tranche in cash.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<table id="pagebreakd5c18a36-3f80-4752-8117-13d4632fc5c6" class=
"pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0"
cellpadding="0" width="100%" border="0">
<tr>
<td class="hpbhr">&nbsp;</td>
</tr>
<tr>
<td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center">
38</td>
</tr>
<tr>
<td>
<div style=
"WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div>
&nbsp;</td>
</tr>
<tr>
<td><i><a href="#TOC">Table of Contents</a></i></td>
</tr>
</table>
<p style="MARGIN: 0px">&nbsp;&nbsp;</p>
<p style="MARGIN: 0px" align="justify">In addition to issuing the
Crown Note, we agreed to issue Crown a warrant with each funding
tranche. Each warrant will be for the purchase of shares of our
common stock equal to 75% of the face value of the tranche divided
by $0.50. For example, the first tranche of funding is for $65,000,
we issued a warrant to purchase 97,500 shares of our common stock
at an exercise price of $0.50 per share. The warrant contains an
anti-dilution provision. Subject to the anti-dilution provision, we
issued Crown a warrant to purchase 243,750 shares of our common
stock at an exercise price of $0.20 per share. The warrant contains
a cashless exercise provision. Each warrant expires five years
after the date of issuance.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">Based on the representations
of Crown in the Crown SPA, the issuance of the Crown Note and the
warrant issued to Crown were exempt from registration pursuant to
Section 4(a)(2) of the Securities Act of 1933. The investor was
accredited and sophisticated, familiar with our operations, and
there was no solicitation.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"><u>Auctus Fund</u></p>
<p style="MARGIN: 0px; TEXT-INDENT: 33.75pt" align="justify">
&nbsp;</p>
<p style="MARGIN: 0px" align="justify">On March 8, 2018, we closed
a Securities Purchase Agreement (the “Auctus SPA”) and
corresponding Convertible Promissory Note (the “Auctus Note”) with
Auctus Fund, LLC (“Auctus”), dated February 15, 2018. Under the
Auctus SPA and the Auctus Note, Auctus agreed to loan us One
Hundred Ten Thousand Dollars ($110,000). The Auctus Note bears
interest at Ten Percent (10%) per annum and matures on November 15,
2018. Under the terms of the Auctus Note, Auctus has the right, at
any time to convert all or part of the amounts due to it under the
Auctus Note into shares of our common stock. The conversion price
is 55% multiplied by the lowest Trading Price during the
twenty-five trading days prior to the conversion date. However,
Auctus may not convert the amounts due under the Note into shares
of our common stock if such conversion would cause it to own more
than 4.99% of our then-outstanding common stock, which limitation
may be waived by Auctus upon 61 days-notice. In the event we
default under the terms of the Auctus Note, we owe 150% of the
principal amount then due under the Note, plus any unpaid interest,
immediately. We may prepay the amounts loaned to us under the
Auctus Note as follows: (i) during the initial 90-day period after
the issue date, at 135% multiplied by the amount we are prepaying,
and (ii) from the 91st through the 180th day after the issue date,
at 150% multiplied by the amount we are prepaying. Any prepayments
are subject to Auctus’ written acceptance of such prepayment. After
180 days from the issue date we cannot prepay the Auctus Note.</p>
<p style="MARGIN: 0px; TEXT-INDENT: 33.75pt" align="justify">
&nbsp;</p>
<p style="MARGIN: 0px" align="justify">In addition to issuing the
Auctus Note, we agreed to issue Auctus a warrant to acquire 275,000
shares of our common stock at an exercise price of $0.20 per share.
The warrant contains an anti-dilution provision. The warrant
contains a cashless exercise provision and expires on the fifth
anniversary of the warrant.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">Based on the representations
of Auctus in the Auctus SPA, the issuance of the Auctus Note and
the warrant issued to Auctus were exempt from registration pursuant
to Section 4(a)(2) of the Securities Act of 1933. The investor was
accredited and sophisticated, familiar with our operations, and
there was no solicitation.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<table id="pagebreak7454881e-7798-4b41-9404-7624e28e3597" class=
"pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0"
cellpadding="0" width="100%" border="0">
<tr>
<td class="hpbhr">&nbsp;</td>
</tr>
<tr>
<td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center">
39</td>
</tr>
<tr>
<td>
<div style=
"WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div>
&nbsp;</td>
</tr>
<tr>
<td><i><a href="#TOC">Table of Contents</a></i></td>
</tr>
</table>
<p style="MARGIN: 0px">&nbsp;&nbsp;</p>
<p style="MARGIN: 0px" align="justify"><u>EMA Financial</u></p>
<p style="MARGIN: 0px; TEXT-INDENT: 33.75pt" align="justify">
&nbsp;</p>
<p style="MARGIN: 0px" align="justify">On March 8, 2018, we closed
a Securities Purchase Agreement (the “EMA SPA”) and corresponding
Convertible Promissory Note (the “EMA Note”) with EMA Financial,
LLC (“EMA”), dated February 12, 2018. Under the EMA SPA and the EMA
Note, EMA agreed to loan us One Hundred Ten Thousand Dollars
($110,000). The EMA Note has an original issuance discount of
$6,600, meaning the amount we received at funding was $103,400. The
EMA Note bears interest at Ten Percent (10%) per annum and matures
on February 12, 2019. Under the terms of the EMA Note, EMA has the
right, at any time to convert all or part of the amounts due to it
under the EMA Note into shares of our common stock. The conversion
price is 55% multiplied by the lowest Trading Price during the
twenty trading days prior to the conversion date. However, EMA may
not convert the amounts due under the Note into shares of our
common stock if such conversion would cause it to own more than
4.99% of our then-outstanding common stock, which limitation may be
waived by EMA upon 61 days-notice. In the event we default under
the terms of the EMA Note, we owe 150% of the principal amount then
due under the Note, plus any unpaid interest, immediately. We may
prepay the amounts loaned to us under the EMA Note as follows: (i)
during the initial 90-day period after the issue date, at 135%
multiplied by the amount we are prepaying, and (ii) from the 91st
through the 180th day after the issue date, at 150% multiplied by
the amount we are prepaying. Any prepayments are subject to EMA’s
written acceptance of such prepayment. After 180 days from the
issue date we cannot prepay the EMA Note.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;&nbsp;</p>
<p style="MARGIN: 0px" align="justify">In addition to issuing the
EMA Note, we agreed to issue EMA a warrant to acquire 137,500
shares of our common stock at an exercise price of $0.40 per share.
The warrant contains an anti-dilution provision. Subject to the
anti-dilution provision and as a result of the warrant issued to
Auctus detailed above, we issued EMA an amended and restated
warrant to purchase 275,000 shares of our common stock at an
exercise price of $0.20 per share, which replaced the original
warrant issued to EMA. The warrant contains a cashless exercise
provision and expires on the fifth anniversary of the warrant.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">Based on the representations
of EMA in the EMA SPA, the issuance of the EMA Note and the warrant
issued to EMA were exempt from registration pursuant to Section
4(a)(2) of the Securities Act of 1933. The investor was accredited
and sophisticated, familiar with our operations, and there was no
solicitation.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"><a name=
"ITEM 3. DEFAULTS UPON SENIOR SECURITIES"><b>ITEM 3.</b>
<b>DEFAULTS UPON SENIOR SECURITIES</b></a></p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">There have been no events
which are required to be reported under this Item.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"><b><a name=
"ITEM 4. MINING SAFETY DISCLOSURES">ITEM 4. MINING SAFETY
DISCLOSURES</a></b></p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">There have been no events
which are required to be reported under this Item.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"><a name=
"ITEM 5. OTHER INFORMATION"><b>ITEM 5.</b> <b>OTHER
INFORMATION</b></a></p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">There have been no events
which are required to be reported under this Item.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<table id="pagebreakb7b7009e-1e0c-46a2-be84-0810ac642fae" class=
"pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0"
cellpadding="0" width="100%" border="0">
<tr>
<td class="hpbhr">&nbsp;</td>
</tr>
<tr>
<td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center">
40</td>
</tr>
<tr>
<td>
<div style=
"WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div>
&nbsp;</td>
</tr>
<tr>
<td><i><a href="#TOC">Table of Contents</a></i></td>
</tr>
</table>
<p style="MARGIN: 0px">&nbsp;&nbsp;</p>
<p style="MARGIN: 0px" align="justify"><a name=
"ITEM 6. EXHIBITS"><b>ITEM 6.</b> <b>EXHIBITS</b></a></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px"></p>
<table style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN"
cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td style="BORDER-BOTTOM: 1px solid" valign="top" width="9%">
<p style="MARGIN: 0px" align="justify"><b>Item No.</b></p>
</td>
<td valign="top" width="2%">
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: 1px solid" valign="top">
<p style="MARGIN: 0px" align="justify"><b>Description</b></p>
</td>
</tr>
<tr bgcolor="#CCEEFF">
<td>
<p style="MARGIN: 0px" align="left"><a href=
"http://www.sec.gov/Archives/edgar/data/1453099/000107878209000070/ddms1ex31.htm">
3.1 (1)</a></p>
</td>
<td valign="top">
<p style="MARGIN: 0px" align="left">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px" align="left"><a href=
"http://www.sec.gov/Archives/edgar/data/1453099/000107878209000070/ddms1ex31.htm">
Articles of Incorporation of Cerebain Biotech Corp., a Nevada
corporation, filed with the Secretary of State for the State of
Nevada on December 18, 2007</a></p>
</td>
</tr>
<tr bgcolor="#FFFFFF">
<td>
<p align="left">&nbsp;</p>
</td>
<td valign="top">
<p align="left">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px" align="left">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#CCEEFF">
<td>
<p style="MARGIN: 0px" align="left"><a href=
"http://www.sec.gov/Archives/edgar/data/1453099/000107878209000070/ddms1ex32.htm">
3.2 (1)</a></p>
</td>
<td valign="top">
<p style="MARGIN: 0px" align="left">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px" align="left"><a href=
"http://www.sec.gov/Archives/edgar/data/1453099/000107878209000070/ddms1ex32.htm">
Bylaws of Cerebain Biotech Corp., a Nevada corporation</a></p>
</td>
</tr>
<tr bgcolor="#FFFFFF">
<td>
<p align="left">&nbsp;</p>
</td>
<td valign="top">
<p align="left">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px" align="left">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#CCEEFF">
<td>
<p style="MARGIN: 0px" align="left"><a href=
"http://www.sec.gov/Archives/edgar/data/1453099/000107878209000070/ddms1ex101.htm">
10.1 (1)</a></p>
</td>
<td valign="top">
<p style="MARGIN: 0px" align="left">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px" align="left"><a href=
"http://www.sec.gov/Archives/edgar/data/1453099/000107878209000070/ddms1ex101.htm">
Agreement by and between Cerebain Biotech Corp. and R. Douglas
Barton dated January 2, 2009</a></p>
</td>
</tr>
<tr bgcolor="#FFFFFF">
<td>
<p align="left">&nbsp;</p>
</td>
<td valign="top">
<p align="left">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px" align="left">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#CCEEFF">
<td>
<p style="MARGIN: 0px" align="left"><a href=
"http://www.sec.gov/Archives/edgar/data/1453099/000107878209000070/ddms1ex102.htm">
10.2 (1)</a></p>
</td>
<td valign="top">
<p style="MARGIN: 0px" align="left">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px" align="left"><a href=
"http://www.sec.gov/Archives/edgar/data/1453099/000107878209000070/ddms1ex102.htm">
Agreement by and between Cerebain Biotech Corp. and R. Douglas
Barton dated January 2, 2009</a></p>
</td>
</tr>
<tr bgcolor="#FFFFFF">
<td>
<p align="left">&nbsp;</p>
</td>
<td valign="top">
<p align="left">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px" align="left">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#CCEEFF">
<td>
<p style="MARGIN: 0px" align="left"><a href=
"http://www.sec.gov/Archives/edgar/data/1453099/000107878212000355/f8k020812_ex10z3.htm">
10.3 (2)</a></p>
</td>
<td valign="top">
<p style="MARGIN: 0px" align="left">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px" align="left"><a href=
"http://www.sec.gov/Archives/edgar/data/1453099/000107878212000355/f8k020812_ex10z3.htm">
Share Exchange Agreement by and between Cerebain Biotech Corp. and
the shareholders of Cerebain Operating, Inc. dated January 17,
2012</a></p>
</td>
</tr>
<tr bgcolor="#FFFFFF">
<td>
<p align="left">&nbsp;</p>
</td>
<td valign="top">
<p align="left">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px" align="left">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#CCEEFF">
<td>
<p style="MARGIN: 0px" align="left"><a href=
"http://www.sec.gov/Archives/edgar/data/1453099/000107878212000355/f8k020812_ex10z4.htm">
10.4 (2)</a></p>
</td>
<td valign="top">
<p style="MARGIN: 0px" align="left">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px" align="left"><a href=
"http://www.sec.gov/Archives/edgar/data/1453099/000107878212000355/f8k020812_ex10z4.htm">
Spinoff Agreement by and between Cerebain Biotech Corp. and R.
Douglas Barton dated January 17, 2012</a></p>
</td>
</tr>
<tr bgcolor="#FFFFFF">
<td>
<p align="left">&nbsp;</p>
</td>
<td valign="top">
<p align="left">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px" align="left">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#CCEEFF">
<td>
<p style="MARGIN: 0px" align="left"><a href=
"http://www.sec.gov/Archives/edgar/data/1453099/000107878212000355/f8k020812_ex10z5.htm">
10.5 (2)</a></p>
</td>
<td valign="top">
<p style="MARGIN: 0px" align="left">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px" align="left"><a href=
"http://www.sec.gov/Archives/edgar/data/1453099/000107878212000355/f8k020812_ex10z5.htm">
Stock Purchase Agreement by and between Cerebain Operating, Inc.
and certain shareholders of Cerebain Biotech Corp. dated January
17, 2012</a></p>
</td>
</tr>
<tr bgcolor="#FFFFFF">
<td>
<p align="left">&nbsp;</p>
</td>
<td valign="top">
<p align="left">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px" align="left">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#CCEEFF">
<td>
<p style="MARGIN: 0px" align="left"><a href=
"http://www.sec.gov/Archives/edgar/data/1453099/000107878212000355/f8k020812_ex10z6.htm">
10.6 (2)</a></p>
</td>
<td valign="top">
<p style="MARGIN: 0px" align="left">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px" align="left"><a href=
"http://www.sec.gov/Archives/edgar/data/1453099/000107878212000355/f8k020812_ex10z6.htm">
Patent License Agreement by and between Cerebain Operating, Inc.
and Dr. Surinder Singh Saini dated June 10, 2010</a></p>
</td>
</tr>
<tr bgcolor="#FFFFFF">
<td>
<p align="left">&nbsp;</p>
</td>
<td valign="top">
<p align="left">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px" align="left">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#CCEEFF">
<td>
<p style="MARGIN: 0px" align="left"><a href=
"http://www.sec.gov/Archives/edgar/data/1453099/000155475712000202/letter_agreement.htm">
10.7 (3)</a></p>
</td>
<td valign="top">
<p style="MARGIN: 0px" align="left">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px" align="left"><a href=
"http://www.sec.gov/Archives/edgar/data/1453099/000155475712000202/letter_agreement.htm">
Letter Agreement with Sonos Models, Inc. dated September 24,
2012</a></p>
</td>
</tr>
<tr bgcolor="#FFFFFF">
<td>
<p align="left">&nbsp;</p>
</td>
<td valign="top">
<p align="left">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px" align="left">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#CCEEFF">
<td>
<p style="MARGIN: 0px" align="left"><a href=
"http://www.sec.gov/Archives/edgar/data/1453099/000155475712000362/ex_10-8.htm">
10.8 (4)</a></p>
</td>
<td valign="top">
<p style="MARGIN: 0px" align="left">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px" align="left"><a href=
"http://www.sec.gov/Archives/edgar/data/1453099/000155475712000362/ex_10-8.htm">
$240,000 Principal Amount Convertible Promissory Note dated June
18, 2012</a></p>
</td>
</tr>
<tr bgcolor="#FFFFFF">
<td>
<p align="left">&nbsp;</p>
</td>
<td valign="top">
<p align="left">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px" align="left">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#CCEEFF">
<td>
<p style="MARGIN: 0px" align="left"><a href=
"http://www.sec.gov/Archives/edgar/data/1453099/000155475713000055/ex10_9.htm">
10.9 (6)</a></p>
</td>
<td valign="top">
<p style="MARGIN: 0px" align="left">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px" align="left"><a href=
"http://www.sec.gov/Archives/edgar/data/1453099/000155475713000055/ex10_9.htm">
$235,000 Amended and Consolidated Promissory Note dated November 1,
2012</a></p>
</td>
</tr>
<tr bgcolor="#FFFFFF">
<td>
<p align="left">&nbsp;</p>
</td>
<td valign="top">
<p align="left">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px" align="left">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#CCEEFF">
<td>
<p style="MARGIN: 0px" align="left"><a href=
"http://www.sec.gov/Archives/edgar/data/1453099/000147793213000350/ddoo_ex101.htm">
10.10 (5)</a></p>
</td>
<td valign="top">
<p style="MARGIN: 0px" align="left">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px" align="left"><a href=
"http://www.sec.gov/Archives/edgar/data/1453099/000147793213000350/ddoo_ex101.htm">
Termination Agreement and General Release with Gerald A. DeCiccio
dated January 18, 2013</a></p>
</td>
</tr>
<tr bgcolor="#FFFFFF">
<td>
<p align="left">&nbsp;</p>
</td>
<td valign="top">
<p align="left">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px" align="left">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#CCEEFF">
<td>
<p style="MARGIN: 0px" align="left"><a href=
"http://www.sec.gov/Archives/edgar/data/1453099/000147793213000350/ddoo_ex102.htm">
10.11 (5)</a></p>
</td>
<td valign="top">
<p style="MARGIN: 0px" align="left">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px" align="left"><a href=
"http://www.sec.gov/Archives/edgar/data/1453099/000147793213000350/ddoo_ex102.htm">
Termination Agreement and General Release with Eric Clemons dated
January 18, 2013</a></p>
</td>
</tr>
<tr bgcolor="#FFFFFF">
<td>
<p align="left">&nbsp;</p>
</td>
<td valign="top">
<p align="left">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px" align="left">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#CCEEFF">
<td>
<p style="MARGIN: 0px" align="left"><a href=
"http://www.sec.gov/Archives/edgar/data/1453099/000147793213000350/ddoo_ex103.htm">
10.12 (5)</a></p>
</td>
<td valign="top">
<p style="MARGIN: 0px" align="left">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px" align="left"><a href=
"http://www.sec.gov/Archives/edgar/data/1453099/000147793213000350/ddoo_ex103.htm">
Termination Agreement and General Release with Paul Sandhu dated
January 18, 2013</a></p>
</td>
</tr>
<tr bgcolor="#FFFFFF">
<td>
<p align="left">&nbsp;</p>
</td>
<td valign="top">
<p align="left">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px" align="left">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#CCEEFF">
<td>
<p style="MARGIN: 0px" align="left"><a href=
"http://www.sec.gov/Archives/edgar/data/1453099/000147793213000350/ddoo_ex104.htm">
10.13 (5)</a></p>
</td>
<td valign="top">
<p style="MARGIN: 0px" align="left">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px" align="left"><a href=
"http://www.sec.gov/Archives/edgar/data/1453099/000147793213000350/ddoo_ex104.htm">
Promissory Note Issued to Gerald A. DeCiccio dated January 18,
2013</a></p>
</td>
</tr>
<tr bgcolor="#FFFFFF">
<td>
<p align="left">&nbsp;</p>
</td>
<td valign="top">
<p align="left">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px" align="left">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#CCEEFF">
<td>
<p style="MARGIN: 0px" align="left"><a href=
"http://www.sec.gov/Archives/edgar/data/1453099/000147793213000350/ddoo_ex105.htm">
10.14 (5)</a></p>
</td>
<td valign="top">
<p style="MARGIN: 0px" align="left">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px" align="left"><a href=
"http://www.sec.gov/Archives/edgar/data/1453099/000147793213000350/ddoo_ex105.htm">
Promissory Note Issued to Eric Clemons dated January 18,
2013</a></p>
</td>
</tr>
<tr bgcolor="#FFFFFF">
<td>
<p align="left">&nbsp;</p>
</td>
<td valign="top">
<p align="left">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px" align="left">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#CCEEFF">
<td>
<p style="MARGIN: 0px" align="left"><a href=
"http://www.sec.gov/Archives/edgar/data/1453099/000147793213000350/ddoo_ex106.htm">
10.15 (5)</a></p>
</td>
<td valign="top">
<p style="MARGIN: 0px" align="left">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px" align="left"><a href=
"http://www.sec.gov/Archives/edgar/data/1453099/000147793213000350/ddoo_ex106.htm">
Promissory Note Issued to Paul Sandhu dated January 18,
2013</a></p>
</td>
</tr>
<tr bgcolor="#FFFFFF">
<td>
<p align="left">&nbsp;</p>
</td>
<td valign="top">
<p align="left">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px" align="left">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#CCEEFF">
<td>
<p style="MARGIN: 0px" align="left"><a href=
"http://www.sec.gov/Archives/edgar/data/1453099/000155475713000259/ex_10-16.htm">
10.16 (7)</a></p>
</td>
<td valign="top">
<p style="MARGIN: 0px" align="left">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px" align="left"><a href=
"http://www.sec.gov/Archives/edgar/data/1453099/000155475713000259/ex_10-16.htm">
$600,000 Amended and Consolidated Promissory Note dated March 14,
2013</a></p>
</td>
</tr>
</table>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px"></p>
<table id="pagebreakc5ece686-be21-42d7-a88a-7109ebd1cc38" class=
"pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0"
cellpadding="0" width="100%" border="0">
<tr>
<td class="hpbhr">&nbsp;</td>
</tr>
<tr>
<td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center">
41</td>
</tr>
<tr>
<td>
<div style=
"WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div>
&nbsp;</td>
</tr>
<tr>
<td><i><a href="#TOC">Table of Contents</a></i></td>
</tr>
</table>
<p style="MARGIN: 0px">&nbsp;</p>
<table style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN"
cellspacing="0" cellpadding="0" width="100%" border="0">
<tr bgcolor="#CCEEFF">
<td width="9%">
<p style="MARGIN: 0px" align="left"><a href=
"http://www.sec.gov/Archives/edgar/data/1453099/000152482913000175/ex10_17.htm">
10.17 (8)</a></p>
</td>
<td valign="top" width="2%">
<p style="MARGIN: 0px" align="left">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px" align="left"><a href=
"http://www.sec.gov/Archives/edgar/data/1453099/000152482913000175/ex10_17.htm">
Employment Agreement with Eric Clemons dated June 15, 2013</a></p>
</td>
</tr>
<tr bgcolor="#FFFFFF">
<td>
<p align="left">&nbsp;</p>
</td>
<td valign="top">
<p align="left">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px" align="left">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#CCEEFF">
<td>
<p style="MARGIN: 0px" align="left"><a href=
"http://www.sec.gov/Archives/edgar/data/1453099/000152482913000175/ex10_18.htm">
10.18 (8)</a></p>
</td>
<td valign="top">
<p style="MARGIN: 0px" align="left">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px" align="left"><a href=
"http://www.sec.gov/Archives/edgar/data/1453099/000152482913000175/ex10_18.htm">
Employment Agreement with Wesley Tate dated June 15, 2013</a></p>
</td>
</tr>
<tr bgcolor="#FFFFFF">
<td>
<p align="left">&nbsp;</p>
</td>
<td valign="top">
<p align="left">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px" align="left">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#CCEEFF">
<td>
<p style="MARGIN: 0px" align="left"><a href=
"http://www.sec.gov/Archives/edgar/data/1453099/000152482913000175/ex10_19.htm">
10.19 (8)</a></p>
</td>
<td valign="top">
<p style="MARGIN: 0px" align="left">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px" align="left"><a href=
"http://www.sec.gov/Archives/edgar/data/1453099/000152482913000175/ex10_19.htm">
Consulting Agreement with Gerald DeCiccio dated June 15,
2013</a></p>
</td>
</tr>
<tr bgcolor="#FFFFFF">
<td>
<p align="left">&nbsp;</p>
</td>
<td valign="top">
<p align="left">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px" align="left">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#CCEEFF">
<td>
<p style="MARGIN: 0px" align="left"><a href=
"http://www.sec.gov/Archives/edgar/data/1453099/000152482913000175/ex10_20.htm">
10.20 (8)</a></p>
</td>
<td valign="top">
<p style="MARGIN: 0px" align="left">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px" align="left"><a href=
"http://www.sec.gov/Archives/edgar/data/1453099/000152482913000175/ex10_20.htm">
Consulting Agreement with IDC Consulting &amp; Investors LLC dated
April 15, 2013</a></p>
</td>
</tr>
<tr bgcolor="#FFFFFF">
<td>
<p align="left">&nbsp;</p>
</td>
<td valign="top">
<p align="left">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px" align="left">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#CCEEFF">
<td>
<p style="MARGIN: 0px" align="left"><a href=
"http://www.sec.gov/Archives/edgar/data/1453099/000147793214000591/ddoo_ex1021.htm">
10.21 (10)</a></p>
</td>
<td valign="top">
<p style="MARGIN: 0px" align="left">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px" align="left"><a href=
"http://www.sec.gov/Archives/edgar/data/1453099/000147793214000591/ddoo_ex1021.htm">
Consulting Agreement with Superior Inc. dated October 15,
2013</a></p>
</td>
</tr>
<tr bgcolor="#FFFFFF">
<td>
<p align="left">&nbsp;</p>
</td>
<td valign="top">
<p align="left">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px" align="left">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#CCEEFF">
<td>
<p style="MARGIN: 0px" align="left"><a href=
"http://www.sec.gov/Archives/edgar/data/1453099/000147793214000591/ddoo_ex1022.htm">
10.22 (10)</a></p>
</td>
<td valign="top">
<p style="MARGIN: 0px" align="left">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px" align="left"><a href=
"http://www.sec.gov/Archives/edgar/data/1453099/000147793214000591/ddoo_ex1022.htm">
$970,000 Amended and Consolidated Promissory Note dated October 15,
2013</a></p>
</td>
</tr>
<tr bgcolor="#FFFFFF">
<td>
<p align="left">&nbsp;</p>
</td>
<td valign="top">
<p align="left">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px" align="left">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#CCEEFF">
<td>
<p style="MARGIN: 0px" align="left"><a href=
"http://www.sec.gov/Archives/edgar/data/1453099/000147793214000049/ddoo_ex101.htm">
10.23 (9)</a></p>
</td>
<td valign="top">
<p style="MARGIN: 0px" align="left">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px" align="left"><a href=
"http://www.sec.gov/Archives/edgar/data/1453099/000147793214000049/ddoo_ex101.htm">
Stock Purchase Agreement with Eric Clemons from Conversion of Debt
dated December 30, 2013</a></p>
</td>
</tr>
<tr bgcolor="#FFFFFF">
<td>
<p align="left">&nbsp;</p>
</td>
<td valign="top">
<p align="left">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px" align="left">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#CCEEFF">
<td>
<p style="MARGIN: 0px" align="left"><a href=
"http://www.sec.gov/Archives/edgar/data/1453099/000147793214000049/ddoo_ex102.htm">
10.24 (9)</a></p>
</td>
<td valign="top">
<p style="MARGIN: 0px" align="left">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px" align="left"><a href=
"http://www.sec.gov/Archives/edgar/data/1453099/000147793214000049/ddoo_ex102.htm">
Stock Purchase Agreement with Gerald DeCiccio from Conversion of
Debt dated December 30, 2013</a></p>
</td>
</tr>
<tr bgcolor="#FFFFFF">
<td>
<p align="left">&nbsp;</p>
</td>
<td valign="top">
<p align="left">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px" align="left">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#CCEEFF">
<td>
<p style="MARGIN: 0px" align="left"><a href=
"http://www.sec.gov/Archives/edgar/data/1453099/000147793214002515/ddoo_ex1025.htm">
10.25 (11)</a></p>
</td>
<td valign="top">
<p style="MARGIN: 0px" align="left">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px" align="left"><a href=
"http://www.sec.gov/Archives/edgar/data/1453099/000147793214002515/ddoo_ex1025.htm">
$1,245,000 Amended and Consolidated Promissory Note dated February
25, 2014</a></p>
</td>
</tr>
<tr bgcolor="#FFFFFF">
<td>
<p align="left">&nbsp;</p>
</td>
<td valign="top">
<p align="left">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px" align="left">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#CCEEFF">
<td>
<p style="MARGIN: 0px" align="left"><a href=
"http://www.sec.gov/Archives/edgar/data/1453099/000147793214004172/ddoo_ex1027.htm">
10.27(13)</a></p>
</td>
<td valign="top">
<p style="MARGIN: 0px" align="left">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px" align="left"><a href=
"http://www.sec.gov/Archives/edgar/data/1453099/000147793214004172/ddoo_ex1027.htm">
$1,345,000 Amended and Consolidated Promissory Note dated May 29,
2014</a></p>
</td>
</tr>
<tr bgcolor="#FFFFFF">
<td>
<p align="left">&nbsp;</p>
</td>
<td valign="top">
<p align="left">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px" align="left">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#CCEEFF">
<td>
<p style="MARGIN: 0px" align="left"><a href=
"http://www.sec.gov/Archives/edgar/data/1453099/000147793214004172/ddoo_ex1028.htm">
10.28(13)</a></p>
</td>
<td valign="top">
<p style="MARGIN: 0px" align="left">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px" align="left"><a href=
"http://www.sec.gov/Archives/edgar/data/1453099/000147793214004172/ddoo_ex1028.htm">
Stock Purchase Agreement with Wesley Tate from Conversion of Debt
dated June 16, 2014</a></p>
</td>
</tr>
<tr bgcolor="#FFFFFF">
<td>
<p align="left">&nbsp;</p>
</td>
<td valign="top">
<p align="left">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px" align="left">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#CCEEFF">
<td>
<p style="MARGIN: 0px" align="left">10.29 (12)</p>
</td>
<td valign="top">
<p style="MARGIN: 0px" align="left">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px" align="left">2014 Cerebain Biotech Corp.
Omnibus Stock Grant and Option Plan</p>
</td>
</tr>
<tr bgcolor="#FFFFFF">
<td>
<p align="left">&nbsp;</p>
</td>
<td valign="top">
<p align="left">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px" align="left">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#CCEEFF">
<td>
<p style="MARGIN: 0px" align="left"><a href=
"http://www.sec.gov/Archives/edgar/data/1453099/000147793215007042/cbbt_ex1030.htm">
10.30(14)</a></p>
</td>
<td valign="top">
<p style="MARGIN: 0px" align="left">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px" align="left"><a href=
"http://www.sec.gov/Archives/edgar/data/1453099/000147793215007042/cbbt_ex1030.htm">
Employment Agreement with Wesley Tate dated October 1, 2015</a></p>
</td>
</tr>
<tr bgcolor="#FFFFFF">
<td>
<p align="left">&nbsp;</p>
</td>
<td valign="top">
<p align="left">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px" align="left">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#CCEEFF">
<td>
<p style="MARGIN: 0px" align="left"><a href=
"http://www.sec.gov/Archives/edgar/data/1453099/000147793216013450/cbbt_ex1031.htm">
10.31 (15)</a></p>
</td>
<td valign="top">
<p style="MARGIN: 0px" align="left">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px" align="left"><a href=
"http://www.sec.gov/Archives/edgar/data/1453099/000147793216013450/cbbt_ex1031.htm">
$2,285,000 Amended and Consolidated Promissory Note dated August 1,
2016</a></p>
</td>
</tr>
<tr bgcolor="#FFFFFF">
<td>
<p align="left">&nbsp;</p>
</td>
<td valign="top">
<p align="left">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px" align="left">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#CCEEFF">
<td>
<p style="MARGIN: 0px" align="left"><a href=
"http://www.sec.gov/Archives/edgar/data/1453099/000147793217000675/cbbt_ex1032.htm">
10.32(16)</a></p>
</td>
<td valign="top">
<p style="MARGIN: 0px" align="left">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px" align="left"><a href=
"http://www.sec.gov/Archives/edgar/data/1453099/000147793217000675/cbbt_ex1032.htm">
$2,410,000 Amended and Consolidated Promissory Note dated November
22, 2016</a></p>
</td>
</tr>
<tr bgcolor="#FFFFFF">
<td>
<p align="left">&nbsp;</p>
</td>
<td valign="top">
<p align="left">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px" align="left">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#CCEEFF">
<td>
<p style="MARGIN: 0px" align="left"><a href=
"http://www.sec.gov/Archives/edgar/data/1453099/000147793217002177/cbbt_ex1033.htm">
10.33(17)</a></p>
</td>
<td valign="top">
<p style="MARGIN: 0px" align="left">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px" align="left"><a href=
"http://www.sec.gov/Archives/edgar/data/1453099/000147793217002177/cbbt_ex1033.htm">
$2,460,000 Amended and Consolidated Promissory Note date January
24, 2017</a></p>
</td>
</tr>
<tr bgcolor="#FFFFFF">
<td>
<p align="left">&nbsp;</p>
</td>
<td valign="top">
<p align="left">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px" align="left">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#CCEEFF">
<td>
<p style="MARGIN: 0px" align="left"><a href=
"http://www.sec.gov/Archives/edgar/data/1453099/000147793218000653/cbbt_ex1034.htm">
10.34(18)</a></p>
</td>
<td valign="top">
<p style="MARGIN: 0px" align="left">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px" align="left"><a href=
"http://www.sec.gov/Archives/edgar/data/1453099/000147793218000653/cbbt_ex1034.htm">
Stock Purchase Agreement with Stockholder dated February 1,
2018</a></p>
</td>
</tr>
<tr bgcolor="#FFFFFF">
<td>
<p align="left">&nbsp;</p>
</td>
<td valign="top">
<p align="left">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px" align="left">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#CCEEFF">
<td>
<p style="MARGIN: 0px" align="left"><a href=
"http://www.sec.gov/Archives/edgar/data/1453099/000147793218000653/cbbt_ex1035.htm">
10.35(18)</a></p>
</td>
<td valign="top">
<p style="MARGIN: 0px" align="left">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px" align="left"><a href=
"http://www.sec.gov/Archives/edgar/data/1453099/000147793218000653/cbbt_ex1035.htm">
Employment Agreement with Eric Clemons dated February 1,
2018</a></p>
</td>
</tr>
<tr bgcolor="#FFFFFF">
<td>
<p align="left">&nbsp;</p>
</td>
<td valign="top">
<p align="left">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px" align="left">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#CCEEFF">
<td>
<p style="MARGIN: 0px" align="left"><a href=
"http://www.sec.gov/Archives/edgar/data/1453099/000147793218000653/cbbt_ex1036.htm">
10.36(18)</a></p>
</td>
<td valign="top">
<p style="MARGIN: 0px" align="left">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px" align="left"><a href=
"http://www.sec.gov/Archives/edgar/data/1453099/000147793218000653/cbbt_ex1036.htm">
Employment Agreement with Wesley Tate dated February 1,
2018</a></p>
</td>
</tr>
<tr bgcolor="#FFFFFF">
<td>
<p align="left">&nbsp;</p>
</td>
<td valign="top">
<p align="left">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px" align="left">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#CCEEFF">
<td>
<p style="MARGIN: 0px" align="left"><a href=
"http://www.sec.gov/Archives/edgar/data/1453099/000147793218001232/cbbt_ex102.htm">
10.37(19)</a></p>
</td>
<td valign="top">
<p style="MARGIN: 0px" align="left">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px" align="left"><a href=
"http://www.sec.gov/Archives/edgar/data/1453099/000147793218001232/cbbt_ex102.htm">
Convertible Promissory Note, Warrant Agreement and Stock Purchase
Agreement with Crown Bridge Partners dated March 2, 2018</a></p>
</td>
</tr>
<tr bgcolor="#FFFFFF">
<td>
<p align="left">&nbsp;</p>
</td>
<td valign="top">
<p align="left">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px" align="left">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#CCEEFF">
<td>
<p style="MARGIN: 0px" align="left"><a href=
"http://www.sec.gov/Archives/edgar/data/1453099/000147793218001232/cbbt_ex105.htm">
10.38(19)</a></p>
</td>
<td valign="top">
<p style="MARGIN: 0px" align="left">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px" align="left"><a href=
"http://www.sec.gov/Archives/edgar/data/1453099/000147793218001232/cbbt_ex105.htm">
Convertible Promissory Note, Warrant Agreement and Stock Purchase
Agreement with Auctus Fund dated March 8, 2018</a></p>
</td>
</tr>
<tr bgcolor="#FFFFFF">
<td>
<p align="left">&nbsp;</p>
</td>
<td valign="top">
<p align="left">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px" align="left">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#CCEEFF">
<td>
<p style="MARGIN: 0px" align="left"><a href=
"http://www.sec.gov/Archives/edgar/data/1453099/000147793218001232/cbbt_ex108.htm">
10.39(19)</a></p>
</td>
<td valign="top">
<p style="MARGIN: 0px" align="left">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px" align="left"><a href=
"http://www.sec.gov/Archives/edgar/data/1453099/000147793218001232/cbbt_ex108.htm">
Convertible Promissory Note, Warrant Agreement and Stock Purchase
Agreement with EMA Financial dated March 8, 2018</a></p>
</td>
</tr>
<tr bgcolor="#FFFFFF">
<td>
<p align="left">&nbsp;</p>
</td>
<td valign="top">
<p align="left">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px" align="left">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#CCEEFF">
<td>
<p style="MARGIN: 0px" align="left"><a href=
"cbbt_ex1040.htm">10.40*</a></p>
</td>
<td valign="top">
<p style="MARGIN: 0px" align="left">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px" align="left"><a href=
"cbbt_ex1040.htm">Amended and Restated Warrant Agreement with EMA
Financial dated February 15, 2018</a></p>
</td>
</tr>
<tr bgcolor="#FFFFFF">
<td>
<p align="left">&nbsp;</p>
</td>
<td valign="top">
<p align="left">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px" align="left">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#CCEEFF">
<td>
<p style="MARGIN: 0px" align="left">14 (1)</p>
</td>
<td valign="top">
<p style="MARGIN: 0px" align="left">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px" align="left">Code of Ethics of Cerebain
Biotech Corp.</p>
</td>
</tr>
<tr bgcolor="#FFFFFF">
<td>
<p align="left">&nbsp;</p>
</td>
<td valign="top">
<p align="left">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px" align="left">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#CCEEFF">
<td>
<p style="MARGIN: 0px" align="left">21(13)</p>
</td>
<td valign="top">
<p style="MARGIN: 0px" align="left">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px" align="left">Cerebain Biotech Corps.
Domestic and International Subsidiaries</p>
</td>
</tr>
<tr bgcolor="#FFFFFF">
<td>
<p align="left">&nbsp;</p>
</td>
<td valign="top">
<p align="left">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px" align="left">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#CCEEFF">
<td>
<p style="MARGIN: 0px" align="left"><a href=
"cbbt_ex311.htm">31.1</a></p>
</td>
<td valign="top">
<p style="MARGIN: 0px" align="left">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px" align="left"><a href=
"cbbt_ex311.htm">Certification of the Chief Executive Officer
pursuant to Rule 13a-14 of the Securities Exchange Act of 1934 as
amended, as adopted pursuant to Section 302 of the Sarbanes-Oxley
Act of 2003. *</a></p>
</td>
</tr>
<tr bgcolor="#FFFFFF">
<td>
<p style="MARGIN: 0px" align="left"><a href=
"cbbt_ex312.htm">31.2</a></p>
</td>
<td valign="top">
<p style="MARGIN: 0px" align="left">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px" align="left"><a href=
"cbbt_ex312.htm">Certification of the Chief Financial Officer
pursuant to Rule 13a-14 of the Securities Exchange Act of 1934 as
amended, as adopted pursuant to Section 302 of the Sarbanes-Oxley
Act of 2003. *</a></p>
</td>
</tr>
<tr bgcolor="#CCEEFF">
<td>
<p style="MARGIN: 0px" align="left"><a href=
"cbbt_ex321.htm">32.1</a></p>
</td>
<td valign="top">
<p style="MARGIN: 0px" align="left">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px" align="left"><a href=
"cbbt_ex321.htm">Certification of the Chief Executive Officer
pursuant to 18 U.S.C. Section 1350 as adopted pursuant to Section
906 of the Sarbanes-Oxley Act of 2003. *</a></p>
</td>
</tr>
<tr bgcolor="#FFFFFF">
<td>
<p style="MARGIN: 0px" align="left"><a href=
"cbbt_ex322.htm">32.2</a></p>
</td>
<td valign="top">
<p style="MARGIN: 0px" align="left">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px" align="left"><a href=
"cbbt_ex322.htm">Certification of the Chief Financial Officer
pursuant to 18 U.S.C. Section 1350 as adopted pursuant to Section
906 of the Sarbanes-Oxley Act of 2003. *</a></p>
</td>
</tr>
</table>
<br />
<table id="pagebreak1c628888-a9ac-40b2-9398-a85e5a40e0b1" class=
"pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0"
cellpadding="0" width="100%" border="0">
<tr>
<td class="hpbhr">&nbsp;</td>
</tr>
<tr>
<td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center">
42</td>
</tr>
<tr>
<td>
<div style=
"WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div>
&nbsp;</td>
</tr>
<tr>
<td><i><a href="#TOC">Table of Contents</a></i></td>
</tr>
</table>
<p style="MARGIN: 0px">&nbsp;</p>
<table style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN"
cellspacing="0" cellpadding="0" width="100%" border="0">
<tr bgcolor="#CCEEFF">
<td width="9%">
<p style="MARGIN: 0px" align="left">101**</p>
</td>
<td valign="top" width="2%">
<p style="MARGIN: 0px" align="left">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px" align="left">Interactive Data File (Form
10-Q for the three-month periods ended March 31, 2018 furnished in
XBRL).</p>
</td>
</tr>
<tr bgcolor="#FFFFFF">
<td>
<p style="MARGIN: 0px" align="left">101.INS</p>
</td>
<td valign="top">
<p style="MARGIN: 0px" align="left">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px" align="left">Interactive Data File (Form
10-Q for the three-month periods ended March 31, 2018 furnished in
XBRL).</p>
</td>
</tr>
<tr bgcolor="#CCEEFF">
<td>
<p style="MARGIN: 0px" align="left">101.SCH</p>
</td>
<td valign="top">
<p style="MARGIN: 0px" align="left">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px" align="left">XBRL Taxonomy Extension Schema
Document</p>
</td>
</tr>
<tr bgcolor="#FFFFFF">
<td>
<p style="MARGIN: 0px" align="left">101.CAL</p>
</td>
<td valign="top">
<p style="MARGIN: 0px" align="left">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px" align="left">XBRL Taxonomy Extension
Calculation Linkbase Document</p>
</td>
</tr>
<tr bgcolor="#CCEEFF">
<td>
<p style="MARGIN: 0px" align="left">101.DEF</p>
</td>
<td valign="top">
<p style="MARGIN: 0px" align="left">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px" align="left">XBRL Taxonomy Extension
Definition Linkbase Document</p>
</td>
</tr>
<tr bgcolor="#FFFFFF">
<td>
<p style="MARGIN: 0px" align="left">101.LAB</p>
</td>
<td valign="top">
<p style="MARGIN: 0px" align="left">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px" align="left">XBRL Taxonomy Extension Label
Linkbase Document</p>
</td>
</tr>
<tr bgcolor="#CCEEFF">
<td>
<p style="MARGIN: 0px" align="left">101.PRE</p>
</td>
<td valign="top">
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">XBRL Taxonomy Extension Presentation
Linkbase Document</p>
</td>
</tr>
</table>
___________&nbsp;
<p style="MARGIN: 0px">* filed herewith</p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px">** Furnished herewith. Pursuant to Rule 406T
of Regulation S-T, the Interactive Data Files on Exhibit 101 hereto
are deemed not filed or part of any registration statement or
prospectus for purposes of Sections 11 or 12 of the Securities Act
of 1933, are deemed not filed for purposes of Section 18 of the
Securities and Exchange Act of 1934, and otherwise are not subject
to liability under those sections</p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"></p>
<table style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN"
cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td valign="top" width="3%">(1)</td>
<td valign="top">Incorporated by reference from our Registration
Statement on Form S-1 filed with the Commission on January 27,
2009.</td>
</tr>
<tr>
<td valign="top" width="3%">(2)</td>
<td valign="top">Incorporated by reference from our Form 8-K filed
with the Commission on February 10, 2012.</td>
</tr>
<tr>
<td valign="top" width="3%">(3)</td>
<td valign="top">Incorporated by reference from our Form 8-K filed
with the Commission on September 28, 2012.</td>
</tr>
<tr>
<td valign="top" width="3%">(4)</td>
<td valign="top">Incorporated by reference from our Form 10-Q filed
with the Commission on November 14, 2012.</td>
</tr>
<tr>
<td valign="top" width="3%">(5)</td>
<td valign="top">Incorporated by reference from our Form 8-K filed
with the Commission on January 24, 2013.</td>
</tr>
<tr>
<td valign="top" width="3%">(6)</td>
<td valign="top">Incorporated by reference from our Form 10Q filed
with the Commission on February 12, 2013.</td>
</tr>
<tr>
<td valign="top" width="3%">(7)</td>
<td valign="top">Incorporated by reference from our Form 10-Q filed
with the Commission on May 3, 2013.</td>
</tr>
<tr>
<td valign="top" width="3%">(8)</td>
<td valign="top">Incorporated by reference from our Form 10K/A
filed with the Commission on October 4, 2013.</td>
</tr>
<tr>
<td valign="top" width="3%">(9)</td>
<td valign="top">Incorporated by reference from our Form 8-K filed
with the Commission on January 6, 2014.</td>
</tr>
<tr>
<td valign="top" width="3%">(10)</td>
<td valign="top">Incorporated by reference from our Form 10-Q filed
with the Commission on February 10, 2014.</td>
</tr>
<tr>
<td valign="top" width="3%">(11)</td>
<td valign="top">Incorporated by reference from our Form 10-Q filed
with the Commission on May 14, 2014.</td>
</tr>
<tr>
<td valign="top" width="3%">(12)</td>
<td valign="top">Incorporated by reference from our Form DEF 14A
filed with the Commission on March 14, 2014.</td>
</tr>
<tr>
<td valign="top" width="3%">(13)</td>
<td valign="top">Incorporated by reference from our Form 10K filed
with the Commission on August 11, 2014.</td>
</tr>
<tr>
<td valign="top" width="3%">(14)</td>
<td valign="top">Incorporated by reference from our Form 10Q filed
with the Commission on November 16, 2015.</td>
</tr>
<tr>
<td valign="top" width="3%">(15)</td>
<td valign="top">Incorporated by reference from our Form 10Q filed
with the Commission on November 14, 2016.</td>
</tr>
<tr>
<td valign="top" width="3%">(16)</td>
<td valign="top">Incorporated by reference from our Form 10Q filed
with the Commission on February 10, 2017.</td>
</tr>
<tr>
<td valign="top" width="3%">(17)</td>
<td valign="top">Incorporated by reference from our Form 10Q filed
with the Commission on May 11, 2017.</td>
</tr>
<tr>
<td valign="top" width="3%">(18)</td>
<td valign="top">Incorporated by reference from our Form 10Q filed
with the Commission on February 6, 2018.</td>
</tr>
<tr>
<td valign="top" width="3%">(19)</td>
<td valign="top">Incorporated by reference from our Form 8-K filed
with the Commission on March 13, 2018.</td>
</tr>
</table>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"></p>
<table id="pagebreaka8dbbde0-54f6-429a-ba17-27770e7f74bc" class=
"pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0"
cellpadding="0" width="100%" border="0">
<tr>
<td class="hpbhr">&nbsp;</td>
</tr>
<tr>
<td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center">
43</td>
</tr>
<tr>
<td>
<div style=
"WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div>
&nbsp;</td>
</tr>
<tr>
<td><i><a href="#TOC">Table of Contents</a></i></td>
</tr>
</table>
<p style="MARGIN: 0px">&nbsp;&nbsp;</p>
<p style="MARGIN: 0px 0px 0px 0in" align="center"><b><a name=
"SIGNATURES" id="SIGNATURES">SIGNATURES</a></b></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly
caused this report to be signed on its behalf by the undersigned
thereunto duly authorized.</p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px"></p>
<table style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0"
cellpadding="0" width="100%" border="0">
<tr>
<td colspan="2"><b>Cerebain Biotech Corp.</b>
<p style="MARGIN: 0px"><b>A Nevada corporation</b></p>
</td>
<td></td>
</tr>
<tr>
<td width="3%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</td>
<td width="35%">&nbsp;</td>
<td>&nbsp;</td>
</tr>
<tr>
<td>By:</td>
<td style="BORDER-BOTTOM: black 1px solid"><em>/s/ ERIC
CLEMONS</em></td>
<td></td>
</tr>
<tr>
<td>&nbsp;</td>
<td>
<p style="MARGIN: 0px" align="left">Eric Clemons, President
(Principal Executive Officer)</p>
</td>
<td>&nbsp;</td>
</tr>
<tr height="15">
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr height="15">
<td>
<p style="MARGIN: 0px">By:</p>
</td>
<td style="BORDER-BOTTOM: black 1px solid">
<p style="MARGIN: 0px"><em>/s/ WESLEY TATE</em></p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr height="15">
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px" align="left">Wesley Tate, Chief Financial
Officer (Principal Financial and Accounting Officer)</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr height="15">
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr height="15">
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">Date: May 15, 2018</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
</table>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px">&nbsp;&nbsp;</p>
<p style="MARGIN: 0px"></p>
<table class="pagebreak" style="FONT: 10pt TIMES NEW ROMAN"
cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center">
44</td>
</tr>
</table>
<p style="MARGIN: 0px">&nbsp;</p>
<!--Document Created by EDGARMaster-->
</body>
</html>

